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 Methylation is the only known modification of DNA and in animals it mainly 
occurs at cytosines in a CpG context. The pattern of DNA methylation varies among 
organisms; some invertebrates are totally devoid of it, while others have densely 
methylated regions embedded in an otherwise unmethylated genome. The genome of 
mammals on the other hand, is very rich in DNA methylation with the exception of 
regions with high CpG frequency, known as CpG islands, that are often found devoid 
of methylation. Little is known about the factors that determine the genome-wide 
pattern of DNA methylation. Moreover, although there appears to be a specific 
developmental program for the establishment of methylation in specific genomic 
regions, the molecular events that lead to methylation establishment remain 
unknown. The establishment of methylation in the regulatory region of the murine 
Oct4 gene as well as the occurrence and establishment of methylation in mouse CpG 
islands are investigated in this study. 
 The promoter of Oct4, which encodes an important developmental regulator, 
is known to gain methylation as the gene becomes silenced during early 
development. An in vitro model of murine early development has been used to 
recapitulate the events that lead to the gene’s silencing. In accordance to other 
reports, detailed methylation analysis of the gene’s entire upstream region and 
expression analysis showed that DNA methylation establishment follows the gene’s 
downregulation. Moreover, establishment of methylation at the Oct4 locus seems to 
start from the gene’s proximal enhancer and then spread towards the distal enhancer 
and the promoter. Although the initial establishment of methylation in the distal 
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enhancer was not impaired in G9a -/- cells, methylation in these cells was unable to 
spread and accumulate. These findings demonstrate that the promoter of the gene is 
not the primary target for methylation as previously assumed and give rise to two 
possible mechanisms for DNA methylation establishment at this gene; one 
possibility is that methylation is actively targeted to the proximal enhancer, while the 
other is that the promoter and the distal enhancer are resistant to methylation, 
perhaps because of transcription factors bound to them. Moreover, the finding that 
G9a is not necessary for DNA methylation establishment but appears to have a role 
in methylation spreading, together with observations on the kinetics of the 
downregulation and the timing of methylation establishment, allowed the formation 
of a possible model for the role of DNA methylation in this gene’s downregulation. 
According to this model, DNA methylation acts to accelerate the gene’s 
downregulation ensuring its coordinated repression in the developing organism. 
  For the study of methylation in CpG islands, first a novel algorithm was 
applied for the identification of CpG islands in the mouse genome. Approximately 
21,000 CpG islands were identified in the mouse genome, half of which localised at 
the 5’ of genes, while the majority of the remaining was equally distributed in 
intragenic and intergenic regions. Only a very small proportion of the CpG islands 
localised at the 3’ of genes. When the gene ontology terms related with the CpG 
island-associated genes where interrogated, two main gene functions emerged as 
being preferentially associated with CpG islands, development and cell maintenance. 
Then, an affinity purification method, together with microarray hybridisation was 
applied for the identification of methylated CpG islands from mouse brain. 
Approximately 18% of all CpG islands were methylated in brain, with the big 
majority localised at 5’ and intragenic regions. When the gene ontology of the 
methylated CpG island-associated genes was analysed, developmental but not 
housekeeping genes were overrepresented in the methylated fraction. In order to 
further investigate the relationship of CpG islands with developmental genes, the 
same methodology was applied for the identification of CpG islands that become 
methylated after the in vitro induction of differentiation of ES cells. Although this 
approach failed to produce genome-wide data, it enforced the idea of a 
developmental program for CpG island methylation. 
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Abbreviations 
Ax absorbance at x nm 
BSA  bovine serum albumin 
cDNA complementary DNA 
CGBP CpG-binding protein 
ChIP chromatin immunoprecipitation 
CIP calf intestinal phosphatase 
CO carbon monoxide 
CpG cytosine ‒phosphate diester‒ guanine 
dATP deoxyadenosine triphosphate 
dCTP deoxycytosine triphosphate 
DE distal enhancer 
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DTT dithiothreitol 
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E embryonic day 
EB embryoid bodies 
EC embryonic carcinoma cells 
EDTA ethylenediamine tetraacetic acid 
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e.g. (exempla grata) for examble 
EMSA electrophoretic mobility shift assay 
ES cells embryonic stem cells 
EST expressed sequence tag 
et al. (et alii) and others 
FPLC fast performance liquid chromatography 
FRAP fluorescence recovery after photobleaching 
g gram/ acceleration of gravity 
GO gene ontology 
h hours 
HAT histone acetyltransferase 
HDAC  histone deacetylase 
J joules 
ICF immunodeficiency, centromeric instability and facial anomalies syndrome 
ICM inner cell mass 










MAP MBD affinity purification 
MBD methyl-CpG binding domain 
min minutes 
MLL mixed lineage leukaemia 
MOPS 3-[N-morpholino]propanesulfonic acid 
NMR nuclear magnetic resonance 
NOR nucleolus organising region 
nt nucleotides 
o/e observed versus expected CpG ratio 
ODx optical density at x nm 
P promoter 
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
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PE proximal enhancer 
PGC primordial germ cells 
qPCR real-time quantitative PCR 
RA all-trans retinoic acid/ RA-induced embryoid bodies 
RARE retinoic acid response element 
RdDM RNA-directed DNA methylation  
RIP repeat-induced point mutation 
RLGS  restriction landmark genome scanning 
RNA ribonucleic acid 
RNAi RNA interference 
RNase ribonuclease 
rpm revolutions per minute 
rRNA ribosomal RNA 
RT-qPCR reverse-transcription real-time quantitative PCR 
SAM S-adenosyl-L-methionine 
SDS sodium doedecyl sulfate 
sec second 
siRNA small interfering RNA 
SRA  SET- and RING- associated 
Tan annealing temperature 
TEMED N,N,N,N',N'- tetramethylethylenediamine 
tRNA transfer RNA 
TSA  trichostatin A 
U unit 





Xa active X chromosome 
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1.1.  DNA sequence in a biological context 
 Since the classical work of Watson and Crick  in 1953 and the experiments of 
Marshall Nirenberg in the early 60s, the most celebrated function of DNA sequence, 
is containing the genetic information encoded in triplets of nucleotides. Despite the 
suitability of DNA’s design for encoding genetic information, only approximately 
1.2-21 % of the genome is dedicated to this function in higher organisms 
(Arabidopsis Genome Initiative 2000; Mouse Genome Sequencing Consortium 2002; 
Human Genome Sequencing International Consortium 2004). These numbers make it 
obvious that the function of DNA in an organism extends beyond being translated to 
protein. In fact, it is long known that the genome also encodes RNA that has either a 
structural, e.g. ribosomal RNA, or functional role, e.g. ribozymes. Other DNA 
functions include chromosome organisation, e.g centromeres and telomeres, and 
regulation of transcription, e.g. promoters and enhancers. However, the exact 
function of every genomic region is far from understood. 
 One way of investigating the genome function is by identifying signature 
nucleotide sequences. For example it is possible to test for the presence of specific 
transcription factor binding sites in the promoter of a gene, calculate the nucleosome 
positioning potential of a given sequence or identify satellite DNA sequences that 
comprise the mammalian centromeres. It is nevertheless still not possible to draw any 
certain conclusions about the function of those recognisable sequences without 
experimentally testing them.  
  There are two main reasons for the disagreement between our theoretical 
expectation and the actual biological role of a DNA sequence in the genome. The 
first reason is that, despite the extensive current proteomics studies, we are still far 
from knowing the exact protein composition of every cell type under every 
environmental influence. Since any biological function of the DNA sequence is 
traditionally expected to be mediated and modified by proteins, it is important to 
know what mediators are present in the system we investigate. In a simplistic 
example, a DNA sequence might carry a strong nucleosome positioning signal but if 
transcription factors that can displace the nucleosome are present, then the theoretical 
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prediction would be wrong. On the same note, we are still far from knowing the 
chemical equilibrium values of all the biological interactions. In the previous 
example this would mean that the transcription factor that can displace nucleosomes 
should also have a lower dissociation constant for binding to that particular DNA 
sequence than the nucleosome. If there is no information about these values there is 
no way of predicting how the system will behave. The study of these phenomena is 
the subject of “Systems Biology”. 
 The other main reason we can not predict the biological role of DNA 
sequences, especially regarding transcription, is the influence of the chromatin 
environment in which these regulatory elements are embedded. In the 
promoter/enhancer regions for example it is generally agreed that the sequence is the 
principal regulator that provides the recognition and binding template for 
transcription factors. But as position effect variegation and transgene silencing 
phenomena suggest, the influence of these regulatory elements can be overridden if 
the surrounding chromosomal region dictates so. This happens even in the presence 
of all the protein components that are necessary for expression. Contemporary 
research of this all-important “chromatin environment” focuses on histones and their 
post-translational modifications and DNA methylation. It is the area of study of the 
field of epigenetics. 
1.2. Histone modifications 
 The eukaryotic genomic DNA is found as a complex with histone proteins. 
Histones H2A, H2B H3 and H4 are the core histones around which the double strand 
of DNA is wrapped, while histones H1 and H5 are the linker histones. Two sets of 
the core histones whith the DNA around them form a nucleosome. The core histones 
are post-translationally modified at their amino-terminal end that protrudes from the 
nucleosome. The histone modifications involve methylation, acetylation, 
phosphorylation, glycosylation, ADP-ribosylation and ubiquitylation and happen at 
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specific amino acids. The modifications that are the most relevant to the work 
presented here are going to be outlined here. 
  Acetylation and de-acetylation of histones H3 and H4 are catalysed by 
histone acetyltransferases (HATs) and deacetylases (HDACs) respectively. 
Acetylation and de-acetylation is a very dynamic process, important for the 
determination of the transcriptional status of the genes they are associated with; 
acetylation is associated with transcription activation and de-acetylation with 
repression (Spencer and Davie 1999). In the majority of cases, methylation at the 
aminoterminal domains of H3 and H4 is catalysed by members of the SET-domain 
family (Dillon et al. 2005). Methylation at H3K4 and H3K36 is indicative of active 
genes (Bernstein et al. 2002; Santos-Rosa et al. 2002; Xiao et al. 2003; Krogan et al. 
2003; Ng et al. 2003; Bernstein et al. 2005), while methylation at H3K9 and H3K20 
is associated with gene repression (Aagaard et al. 1999; Guanchao Jiang 2004). 
Another study has shown that H3K9 methylation is also associated with the 
transcribed region of active genes (Vakoc et al. 2005). A special case of histone 
methylation is H3K27 that is catalysed by polycomb-group proteins and is related 
with transcriptional repression (Muller et al. 2002; Czermin et al. 2002; Kunert et al. 
2003). 
1.3. DNA methylat ion 
 Histone modifications vary in different chromatin regions and often reflect 
the methylation status of the DNA in these regions. However, DNA methylation is 
the only epigenetic modification that directly affects the DNA chain and this raises 
the possibility that DNA methylation could be an important link between DNA 
sequence and chromatin function. However, its importance in higher organisms is 
disputed, as many eukaryotes are virtually devoid of it. The fact that inhibition of 
DNA methylation in the organisms that normally have it is embryonic lethal, shows 
that, in the species in which it is present, it plays a vital role for the survival of the 
individual.   
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1.3.1. DNA methylation across organisms 
 DNA in nature can be found methylated at the C-5 or N-4 positions of 
cytosine and at the N-6 position of adenine (Figure 1-1). In multicellular eukaryotes  
only C-5 methylcytosine exists. The methyl group of 5’-methylcytosine in the double 
stranded helix has been shown to protrude to the major groove (Mayer-Jung et al. 
1997). Methylation of cytosines in the genome is highly dependent on the sequence 
context. In Arabidopsis thaliana and other plant species, methylcytosines can be 
found in a CpG, CpNpG, or Cp(A/T)p(A/T) context. In mammals, methylcytosine is 
mainly found in a CpG context, although there is evidence of limited CpA, CpT and 
CpC methylation at specific developmental stages (Ramsahoye et al. 2000; Haines et 
al. 2001; Dodge et al. 2002; White et al. 2002). Finally, it has been shown that the 
genome of Drosophila melanogaster contains traces of methylcytosine in every 
dinucleotide (CpN) context (Lyko et al. 2000).  
 
 
Figure 1-1. Chemical structure of deoxycitidine and deoxyadenosine. R, deoxyribose 
sugar. 
 
 The proportion of the methylcytosines versus all cytosines in a CpG context 
in the eukaryotic genomes varies considerably from ~0 to 90%. It is interesting that 
invertebrates seem to be at the lower end of methylation levels, while vertebrates 
have a high proportion of methylcytosines in their genome. A divide between 
vertebrates and invertebrates seems to exist also in the way methylcytosines are 
distributed in the genome. In mammals, methylation is dispersed throughout the 
genome with the exception of CpG-rich regions, called CpG islands, that are 
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generally methylation-free and roughly correlate with the promoters of genes. The 
unusual CpG frequency of CpG islands most likely reflects the AT-rich character of 
the bulk of the genome due to the hypermutability of methylcytosine to thymine 
(Bird 1980; Duncan and Miller 1980). On the other hand, the genomes of 
invertebrates have patchy methylation, with regions that are rich in methylation 
interspersed in methylation-free DNA (Tweedie et al. 1997; Suzuki et al. 2007). 
 There have been several hypotheses that try to explain the differences 
regarding methylation levels among eukaryotes. One model suggests that 
methylation is primarily a defence mechanism against repetitive sequences, a 
function inherited from the bacterial exogenous DNA defence mechanism (Bestor 
1990). According to this hypothesis, the differences in methylation levels reflect the 
genomic content of repetitive sequences. This hypothesis is supported by the 
observations that some transposable elements are usually found heavily methylated 
in the genome (Yoder et al. 1997) and that lack of methylation causes increased 
levels of IAP transcription (Walsh et al. 1998). Nevertheless, Simmen et al. (1999) 
and Suzuki et al. (2007) have shown that the methylated regions of the invertebrate, 
Ciona intestinalis genome, do not show any preference for repetitive sequences. 
Recent large-scale projects have finally shown that the proportion of the repetitive 
sequences in the genomes of different organisms does not agree with this being the 
reason for the differences in methylation levels. In their review on repetitive 
elements Shapiro and Von Sternberg  (2005) show that in Caenorhabditis elegans  
and Arabidopsis thaliana, 16.6% and 13-14% of the genome respectively consists of 
repetitive elements, nevertheless methylation has never been detected in the first. 
Similarily, in Mus musculus and Drosophila melanogaster approximately 40% of the 
genome is non-coding repetitive elements but only traces of methylcytosine have 
been found in the latter.  
 An alternative to the genome defence idea is that methylation has evolved to 
suppress general background transcription (Bird 1995). Although this hypothesis had 
been initially based on an overestimation of the gene number in vertebrates before 
the genome projects, recent information has come to light that provides support to 
this idea. Extensive methylation analysis of Ciona intestinalis genomic DNA (Suzuki 
et al. 2007) has showed that methylation coincides with the body of housekeeping 
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genes. Gene body methylation has also been reported for Arabidopsis thaliana (Tran 
et al. 2005; Zhang et al. 2006; Zilberman et al. 2007) and the insects Apis melifera 
(Wang 2006) and  Myzus persicae (Field 2000). According to this hypothesis, genes 
that need to be constitutively expressed at low levels can not afford to allow cryptic 
promoters in the gene body to interfere with transcription, and methylation is in place 
to suppress such elements. On the other hand, genes that have strong promoters and 
are expressed at high levels do not have a need for such a mechanism and remain 
methylation-free. The model relies on the fitness trade-off between having tight 
regulation of transcription and a hypermutable methylcytosine-rich genome. 
Nevertheless, the different levels and patterns of methylation between organisms are 
not yet explained by this model. 
 Another theory proposes that the presence of DNA methylation in a 
multicellular organism depends on its developmental strategy (Jablonka and Lamb 
1995). For organisms like C. elegans and D. melanogaster that have a short life span 
and little cell turnover it is beneficial to avoid methylation and the high mutation 
rates that are associated with it. Organisms that go through many cell duplications 
and an extended life span on the other hand, cannot afford to loose the benefit of a 
cellular memory that can persist through cell divisions. It is an interesting idea that 
has been tested for a variety of invertebrates with different developmental strategies 
and different degrees of methylation (Regev et al. 1998). In the study, invertebrate 
organisms were grouped into categories according to their cell turnover and their 
methylcytosine content was plotted. This approach showed a very good correlation 
between low methylation and high cell turnover. 
 A last model proposes a correlation between body temperature and 
methylation levels (Jabbari et al. 1997). In more detail, this hypothesis sees DNA 
methylation levels as being inversely proportional with the body temperature of the 
animal. GC and CpG content follow the same pattern. The authors argue that an 
increase in temperature causes the methylcytosine to thymidine transition to 
accelerate, thus selecting for the minimum amount of methylcytosines that are 
necessary for the proper function of the organism. Further support to this idea comes 
from studies in fish and reptiles that have different strategies for maintaining their 
body temperature (Varriale and Bernardi 2006a; 2006b). 
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1.3.2. DNA methyltransferases 
 The class of enzymes that is responsible for the methylation of cytosines at 
the 5’ position are cytosine methyltransferases that catalyse the transfer of the  
methyl-group from S-adenosyl-L-methionine (SAM) to the DNA. Cytosine 
methyltransferases are present in most eukaryotes (Figure 1-2). 
 
  
Figure 1-2. Distribution of the various DNA methyltransferases in different eukaryotes. 
The organisms are classified according to the sequence of 18S rDNA. S. cerevisae and C. 
elegans that do not appear to contain DNA methyltransferases are shown in red. (Adapted 
from Goll and Bestor 2005) 
 
 There are four families of DNA methyltransferases, the DNA 
methyltransferase 1 (DNMT1), DNA methyltransferase 2 (DNMT2), DNA 
methyltransferase 3 (DNMT3) and chromomethylase families. Chromomethylases 
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are only found in flowering plants. Mice and humans have one DNMT1, one 
DNMT2 and three DNMT3 genes (Figure 1-3). They all share some homology at 
their carboxyterminal catalytic domain although their specificities, and in some cases 
even their functions, differ. The aminoterminal domain contains sequences that are 
responsible for protein-protein interactions. Knock-out of the catalytic domain of 
DNMT1, DNMT3a and DNMT3b in mouse embryonic stem (ES) cells, completely 
abolished CpG methylation (Tsumura et al. 2006). This shows that CpG methylation 
is exclusively dependent on these enzymes. 
 
 
Figure 1-3. Cytosine methyltransferases of mammals. NLS, nuclear localisation signal; 
PWWP, conserved PWWP tetrapeptide; ATRX, cysteine-rich zinc-finger DNA-binding motif; PHD, 




 DNMT1 catalyses the transfer of methyl-groups in a  processive manner 
(Hermann et al. 2004). This means that it transfers many methyl-groups without the 
release of DNA, something that can be demonstrated experimentally as a lack of 
intermediate products. DNMT1 is considered to be the maintenance 
methyltransferase in the cell, as it has been shown that in vitro it prefers DNA with 
hemimethylated 5’-CpG-3’:3’-GpC-5’  (Fatemi et al. 2001). The maintenance 
activity implies that it is the enzyme responsible for methylating the hemimethylated 
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CpGs that are present in the double strand of DNA after replication. Indeed, it has 
been shown to localise at the replication foci during S phase (Leonhardt et al. 1992). 
Its action however is not restricted there, as deletion of the domain that is responsible 
for the interaction with the replication machinery (charge-rich region, Figure 1-3) 
showed that DNMT1 activity is independent of this interaction (Spada et al. 2007). 
According to a report by Robertson et al. (2000), DNMT1 associates with the E2F-
Rb complex  that acts to silence genes de novo. DNMT1 also interacts with the 
histone deacetylases 1 and 2 (HDAC1 and 2), the H3K9 methyltransferase 
SUV39H1, heterochromatin protein 1 (HP1) and the chromatin remodeler SNF2 
(Robertson et al. 2000; Fuks et al. 2000; Rountree et al. 2000; Fuks et al. 2003a). In 
summary, the experiments suggest that DNMT1 has a role in both maintenance of 
the methylation patterns and de novo epigenetic modifications in the genome. 
 There are three DNMT1 isoforms, DNMT1s, DNMT1o and DNMT1p that 
are found in somatic tissues, oocytes and pachytene-stage spermatocytes respectively 
(Mertineit et al. 1998). They are all products of alternative splicing that causes either 
an increase of the size of the first exon of the DNMT1p transcript or a small decrease 
of that of DNMT1o. DNMT1o is present throughout oogenesis and during early 
embryogenesis until the blastocyst stage and is actively retained in the cytoplasm 
despite its strong nuclear localisation signal. It enters the nucleus at a specific 
developmental stage that appears to be determined by the embryo’s molecular clock 
(Cardoso and Leonhardt 1999). Post-translation modifications that have been 
observed to alter the electrophoretic mobility of DNMT1o in comparison to 
DNMT1s could be playing a role in the timely entry to the nucleus (Carlson et al. 
1992). The transition from the DNMT1s to the DNMT1p transcript happens at the 
early pachytene stage of spermatogenesis and results in repression of DNMT1p 
translation (Mertineit et al. 1998). It seems that a common mechanism involving 
elimination of DNMT1 from the nucleus via alternative splicing is employed during 
gametogenesis and early developmental stages. The implications of this will be 
discussed later.  
DNMT2 
 Until recently, DNMT2 posed a mystery because it is in many cases the only 
cytosine methyltransferase present in organisms that are virtually free of methylation, 
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such as D. melanogaster and S. pombe (Figure 1-2). Furthermore, the cytosine 
methyltransferase activity of DNMT2 in vitro is very low and it localises to the 
cytoplasm. DNMT2 overexpression in Drosophila, caused a significant increase in 
cytosine methylation in a Cp(A/T) context (Kunert et al. 2003). This indicated that 
DNMT2 might have a role for DNA methylation establishment in Drosophila. 
However, only trace amounts of Cp(A/T) methylation exist in this organism. A 
satisfactory explanation for the role of DNMT2 has been recently provided by Goll et 
al. (2006). These researchers showed that DNMT2 in mouse, Drosophila and A. 
thaliana is actually an aspartic acid transfer-RNA (tRNA
Asp
) methyltransferase. 
Apparently, in this case, evolution employed the methyl-transferring activity of the 
enzyme in another biological function. 
DNMT3 
 Mammals have three DNMT3 enzymes, DNMT3a and DNMT3b have de 
novo  methyltransferase activity, while DNMT3L lacks methyltransferase activity 
and is a co-factor of DNMT3a and b, expressed during gametogenesis (Hata et al. 
2002). DNMT3L probably acts by facilitating SAM loading onto the DNMT3 
enzymes (Kareta et al. 2006) and, as it will be discussed later, it has a role in the 
establishment of parental imprints. The de novo methyltransferase activity of the 
other two enzymes means that they can methylate unmethylated substrates. In vitro, 
DNMT3a has been shown to prefer the DNA strand in which the CpG site is flanked 
by pyrimidines leading to hemimethylated products (Lin et al. 2002). This, together 
with the observation that the DNMT3 proteins co-immunoprecipitate with DNMT1 
(Kim et al. 2002; Rhee et al. 2002), gives rise to the possibility that DNMT3s act by 
hemimethylating their substrate and DNMT1 is responsible for completing the 
reaction. However, verification of this begs further experimental evidence. The 
biochemical characteristics of the two enzymes differ; DNMT3b is processive (i.e. 
methylates more than one cytosines without releasing the DNA), while DNMT3a is 
distributive (i.e. methylates one cytosine at a time) (Gowher and Jeltsch 2002). The 
activity of DNMT3a on nucleosomal DNA is much lower that that of DNMT3b 
(Takeshima et al. 2006) and the opposite is true for naked DNA (Suetake et al. 
2003). This could mean that DNMT3a and DNMT3b in vivo act on naked and 
nucleosomal DNA respectively.  
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 Despite their distinct biochemical properties, the particular roles of the two 
enzymes in vivo are not very well understood. Deletion of the catalytic activities of 
one or the other enzyme showed that, at the majority of the studied loci, methylation 
was not affected (Okano et al. 1999). When both the enzymes were knocked out, and 
only then, could the methylation be erased in these loci. This means that, in most 
cases, the two enzymes probably complement each other. This is further supported 
by the fact that DNMT3a and b co-immunoprecipitate both in vivo and in vitro (Kim 
et al. 2002). In the study of  Okano et al. (1999) DNMT3b alone was shown to be 
responsible for the methylation of centromeric minor satellite repeats. DNMT3a and 
not DNMT3b on the other hand appears to be able to restore the methylation of the 
Xist and H19 genes in DNMT3a/b -/- cells (Chen et al. 2003). It is still unknown if 
the two enzymes have different specificities in the case of other genes.  
  Like DNMT1, DNMT3a and DNMT3b interact with other proteins. In more 
detail, DNMT3L has been shown to associate with histone H3 tails that are not 
methylated at lysine 4 and to induce methylation of the associated DNA (Ooi et al. 
2007). In addition, DNMT3L forms a symmetric heterotetramer with DNMT3a, 
altering its structure and puting constraints on the distance of CpGs that can be 
methylated by the complex (Jia et al. 2007). DNMT3a also reportedly associates 
with HDAC1 (Fuks et al. 2001; Bai et al. 2005), the H3K9 methyltransferases G9a 
(Feldman et al. 2006), SUV39H1 (Fuks et al. 2003a) and SETDB1 (Li et al. 2006a) 
and with HP1 (Fuks et al. 2003a), while DNMT3b has been shown to interact with 
HDAC2 (Bai et al. 2005). Additionally, both DNMT3a and DNMT3b have been 
shown to associate with the EZH2 polycomb-group protein at repressed genes (Vire 
et al. 2006) while another polycomb-group protein, Cbx4, might regulate DNMT3a 
activity through SUMOylation (Li et al. 2007). All these interactions provide a 
mechanistic explanation for the observed relationship between heterochromatin and 
methylated DNA. Functionally, the most important interaction seems to be that with 
HDACs since HDAC association alone has been shown to be enough for trichostatin 
A (TSA)-sensitive repression of a reporter gene by DNMT3a (Fuks et al. 2001). 
Moreover, DNMT3b-associated HDAC activity regulates  differentiation of 
pheochromocytoma cells (Bai et al. 2005).  
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 DNMT3a has three isoforms that are all enzymatically active. Isoforms 
DNMT3a-α and-β (Weisenberger et al. 2002) are products of alternative splicing at 
exon 1 and they are often considered together as DNMT3a. DNMT3a-α is the most 
abundantly expressed of the two in all tissues except testes, where DNMT3a-β seems 
to take over. The third isoform, DNMT3a2  is the product of an alternative promoter 
that is active in ES but not fibroblast cells (3T3) (Chen et al. 2002). DNMT3a2 
misses regions of the aminoterminal domain and this appears to cause a more diffuse 
localisation at the nucleus. DNMT3a2 is ubiquitously present in all examined tissues 
with the exception of brain, in which it can not be detected.  
 There are six isoforms of DNMT3b (DNMT3b1 to b6), all produced by 
alternative splicing (Robertson et al. 1999). Of all the isoforms, only DNMT3b1 and 
2 appear to be catalytically active (Aoki et al. 2001; Chen et al. 2003). The other four 
isoforms are missing parts of the catalytic carboxyterminal domain. They are 
nevertheless all expressed in different combinations in the tissues tested (Robertson 
et al. 1999). Regarding the DNA binding capacity of the inactive isoforms, the 
subnuclear localisation to heterochromatin is lost in DNMT3b3 (Ueda et al. 2006). 
Additionally, DNMT3b3 and b6 can be depleted after 5’-azacytidine treatment which 
indicates they can interact with DNA (Weisenberger et al. 2002). This method relies 
on the covalent trapping of the enzyme to the DNA where the nucleotide analogue 
has been incorporated. It is a not immediately clear why the cell would invest 
resources on transcribing the inactive forms of DNMT3b. A possibility is that they 
could be active through their aminoterminal domain or perhaps their transcription is 
a means to regulate DNMT3b levels without altering the transcription rate.  
 Finally, DNMT3L was recently found to exist in three isoforms produced 
from alternative promoters (Shovlin et al. 2007). The typical promoter seems to be 
active in stem cells and early spermatogenesis, while at late pachytene spermatocytes 
a second promoter is activated that causes the transcription of a truncated, non-
coding mRNA. Finally, a third promoter is active in the oocytes and causes 
transcription of a longer, active form of DNMT3L. The implications that these 
discoveries might have during differentiation is discussed later. 
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1.3.3. Establishment of DNA methylation patterns 
 As already discussed (section 1.3.1), the DNA methylation profile is very 
different between vertebrates and invertebrates genomes. In the first, the entire 
genome is globally methylated with the exception of CpG islands. In the second, 
there are methylated regions that are interrupted by long unmethylated regions. 
Furthermore, methylation in vertebrates can be found at inactive promoters but 
transcriptional activity cannot predict the methylation status of the 5’ upstream 
region of a gene. What determines these methylation patterns? What’s more, is there 
an active targeting mechanism that selects some regions and not others for 
methylation?  
 In vitro experiments have not revealed any intrinsic sequence specificity of 
the DNMT enzymes. Specificity however, could be conferred indirectly through 
interactions with transcription factors. Transcription factors are known to display 
sequence specificity and DNMTs have been shown to associate with E2F-Rb 
(Robertson et al. 2000), GCNF (Sato et al. 2006), COUP-TF1(Gallais et al. 2007), 
PML-RAR (Di Croce et al. 2002) and RP58 (Fuks et al. 2001). Most probably the 
list is still incomplete and this is potentially an effective way for the determination of 
the methylation patterns of the regulatory elements of genes.  
 Another mechanism for determining the methylation pattern through a 
transcription factor has been reported for the aprt gene (Brandeis et al. 1994; 
Macleod et al. 1994; Mummaneni et al. 1998). In the promoter of the active gene, 
Sp1 binding to its response element protects the region from methylation. Evidence 
for a similar mechanism for the prevention of DNA methylation has been recently 
uncovered for the imprinted H19/Igfr2r locus (Engel et al. 2006). In this study, 
binding of the CTCF factor to the differentially methylated region (DMR) of the 
maternal allele seems to prevent methylation and regulate enhancer activity in cis. 
 The examples examined above concern establishment of DNA methylation 
patterns at the regulatory elements of genes but there is no easy way to explain the 
genome-wide methylation observed in vertebrates through the mediation of 
transcription factors. A mechanism that seems to satisfactorily explain the 
methylation at the repetitive elements of flowering plants is RNA-directed DNA 
methylation (RdDM) (Wassenegger et al. 1994; Mette et al. 2000). In this case, 
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double-stranded antisense RNA transcripts are recognised by the RNAi core enzyme 
Dicer and cleaved to 21-24mers. Through a less well understood mechanism, these 
small interfering RNAs (siRNAs) cause methylation of the DNA that is homologous 
to them. It is an elegant mechanism that takes advantage of the RNA:DNA 
complementarity. An RNAi-related mechanism has also been implicated in the 
heterochromatinisation of centromeric and other repeats in many organisms that do 
not have DNA methylation. 
 The existence of an RdDM mechanism in mammals that is analogous to that 
of plants is controversial. On one hand, RNA polymerase VI (Wassenegger and 
Krczal 2006) and chromomethylases (Cao et al. 2003) are central to RdDM in plants 
but neither of these enzymes has homologues in animals. Similarily, CpNpG 
methylation is typical of RdDM but only traces of non-CpG methylation can be 
detected in animals (Ramsahoye et al. 2000; Haines et al. 2001; Dodge et al. 2002; 
White et al. 2002). In an older study however, CpNpG methylation occurred quite 
frequently in a stably transfected plasmid (Clark et al. 1995). In this case methylation 
levels reached 20-40% for the CpA/TpG trinucleotide. It would be interesting to 
confirm this result. 
 Importantly, in human, Tufarelli et al. (2003) showed that a chromosomal 
deletion in a patient of α-thalassemia caused transcription of an antisense RNA of the 
α2-globin gene. This antisense RNA was responsible for dense methylation and 
repression of the α2-globin gene. This phenomenon is reminiscent of the Xist and Air 
genes, in which regulated transcription from an antisense promoter causes allele-
specific methylation. In all the cases however, antisense transcripts are several Kb 
long and the RNAi machinery does not seem to be involved. The best indication that 
RdDM might be acting in mammals are the experiments by Kanellopoulou et al.  
(2005), in which conditional knock-out of the Dicer gene resulted in reduced 
methylation in centromeric and pericentromeric repeats. Unfortunately, until more 
specific examples have been discovered, evidence for RdDM in mammals remains 
elusive. 
 A methylation pattern that seems to be shared between animals and plants is 
gene body methylation (Field 2000; Tran et al. 2005; Zhang et al. 2006; Zilberman et 
al. 2007; Suzuki et al. 2007). In more detail, in invertebrates DNA methylation 
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seems to be confined in the gene body of housekeeping genes (Suzuki et al. 2007), 
while in plants high gene body methylation levels appear to correlate with 
transcription  (Zilberman et al. 2007). 
 There is no experimental evidence to my knowledge that sheds light on the 
mechanism that is responsible for this methylation pattern. It is difficult however to 
ignore the similarity with methylation at lysine 36 of histone 3 (metH3K36), that has 
also been shown to localise at the gene-body of actively transcribed genes. In these 
cases, at least in yeast, metH3K36 is brought about because its specific 
methyltransferase, Set2, associates with the elongating form of RNA polymerase II 
(Krogan et al. 2003; Xiao et al. 2003). Set2 also recruits histone deacetylases that are 
deacetylating the gene body (Krogan et al. 2003; Joshi and Struhl 2005). Given the 
strong evidence for the association of DNMTs with histone deacetylases (section 
1.3.2), it is not unreasonable to imagine that DNMTs are recruited to the gene body 
through their association with HDACs. Unfortunately the genome of S. cerevisiae is 
not methylated. It would be interesting to show if the same H3K36 methylation 
mechanism exists in other organisms that have methylation. If this is the case, then 
gene-body methylation should be happening downstream of H3K36 methylation. 
1.4. Proteins that read the methylation signal 
 The identification of proteins that can read the methylation signal is 
imperative for our understanding of both how DNA methylation has evolved in 
eukaryotes and what its function is.  Our current knowledge about this first step of 
how the DNA methylation pattern communicates information to the cell is outlined 
here. A comparison of the domains of the proteins described here with regard to their 
function is shown in Figure 1-4.  
1.4.1. The methyl CpG-binding domain (MBD) family 
 The best characterised methylcytosine-binding protein family is the MBD 
family. It consists of five members, namely MeCP2, MBD1, MBD2, MBD3 and 
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Figure 1-4. Proteins that read the methylation signal. Graphical representation of the 
domains in the proteins that recognise and bind specifically methylcytosines (A,B and C) and 
cytosines (D). MBD 1 is a special case in that it can recognise both. (A) MBD family. (B) 
Kaiso and related proteins. (C) SRA-domain proteins. (D) MLL and CGBP. Black lines above 
the proteins show the regions excluded in alternative transcripts. The domains, organised 
according whether they are shared or not by more that one categories of the proteins shown 
here, are shown at the bottom. 
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are paralogues that all have a conserved MBD domain and share a maximum 63.8-94 
% similarity (Roloff et al. 2003). The MBD domains of these proteins, except 
MBD3, bind specifically methyl-CpGs. NMR analyses of the MBD domain of 
MeCP2 have shown that it forms a wedge-like structure of four antiparallel β-sheets 
which fits into the major groove of the DNA with a positively charged surface 
andbinds the protruding methyl-group (Wakefield et al. 1999; Ohki et al. 1999). 
  In general, MBDs are transcriptional repressors with little or no overlap of 
their target genes (Klose et al. 2005). As it will be discussed in more detail later, they 
are known to associate with various histone modification enzymes and chromatin 
remodelling complexes. This shows the close link between transcriptional status, 
DNA methylation and chromatin. The causal relationships however remain to be 
shown. 
 The only MBD protein that is not a transcriptional repressor is MBD4, which 
is a mismatch repair enzyme. MBD4 is a DNA glycosylase that preferentially binds 
to methylCpG:TpG mismatches produced by spontaneous methylcytosine 
deamination (Hendrich et al. 1999; Wu et al. 2003; Millar et al. 2002; Petronzelli et 
al. 2000). A recent report has shown that MBD4 has HDAC- and DNA methylation-
dependent repressor activity (Kondo et al. 2005). Because of the limited evidence for 
a methylation dependent role of MBD4 however, it will not be considered here. 
MeCP2 
 MeCP2 is an X-linked gene that has two isoforms, MeCP2α and MeCP2β 
that are the products of alternative splicing of exon 2 (Kriaucionis and Bird 2004). Of 
the two isoforms, the shorter MeCP2α is more abundant in tissues and is translated 
more efficiently. MeCP2 null mice have neurological defects and limited viability 
(Guy et al. 2001) as well as mitochondrial abnormalities (Kriaucionis et al. 2006). In 
humans, mutations in MeCP2 cause the autism spectrum disorder disorder Rett 
syndrome (Van den Veyver and Zoghbi 2001). The aminoterminal region of MeCP2, 
which also contains the MBD domain, co-immunoprecipitates with an H3K9 
methyltransferase activity (Fuks et al. 2003b). Other reported interactions of MeCP2 
include, but are not confined to, DNMT1 (Kimura and Shiota 2003) and HDACs 
(Nan et al. 1998). The latter seem to be in the context of the Sin3a chromatin 
remodelling complex. Nevertheless, detailed analysis has shown that MeCP2 is 
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usually found as a monomer in the cell and probably the above interactions are only 
transient (Klose and Bird 2004).The observation that MeCP2 localises to 
heterochromatic foci (Brero et al. 2005),  indicates a general role in 
heterochromatinisation. Nevertheless, specific targets of MeCP2 include H19 (Fuks 
et al. 2003b), xHairy2a (Stancheva et al. 2003), Bdnf (Martinowich et al. 2003) and 
Dlx5/6 (Horike et al. 2005; Klose et al. 2005). 
 MeCP2 in vitro and in vivo binds to a single methyl-CpG with an AT-run in 
close proximity through its MBD domain (Klose et al. 2005). The transcription 
repression domain (TRD) which is necessary for transcription repression is also 
responsible for some of the protein-protein interactions described above. MeCP2-
induced transcription repression is sensitive to TSA and it is probably caused through 
histone deacetylation (Nan et al. 1998; Jones et al. 1998).  
MBD1 
 Absence of MBD1 in mice causes neuronal defects (Zhao et al. 2003). MBD1 
is unique among the other MBDs in that it contains CxxC domains. CxxC domains 
are zinc-finger DNA binding domains present in a variety of DNA-binding proteins. 
There are four MBD1 (a to d) isoforms, all products of alternative splicing (Fujita et 
al. 1999). MBD1b and MBD1d are missing the third CxxC domain. This, but not the 
other two CxxC domains, has been shown to target MBD1 to non-methylated DNA 
both in vivo and in vitro independently of the methyl-binding specificity of the MBD 
domain (Jørgensen et al. 2004). The dual specificity of MBD1 is intriguing. A recent 
study has shown that in transient transfection assays MBD1 associates with the 
PLM-RARα transcription factor, which is an oncoprotein, and is recruited to the 
promoter of the target RARβ2 gene (Villa et al. 2006). This is independent of 
methylation and is followed by HDAC recruitment to the promoter and establishment 
of DNA methylation. At the end of this process MBD1 occupancy seems to have 
spread over the gene. One can imagine that in this example the CxxC domain 
facilitates the initial binding to the unmethylated promoter and the MBD domain 
takes over after methylation has been established. This is nevertheless only a 
hypothesis and more experimental evidence is required to establish the roles of the 
CxxC and MBD domains of MBD1.  
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 MBD1 is reported to interact with the H3K9 methyltransferase SUV39H1, 
HP1, as well as with HDAC3 (Fujita et al. 2003; Villa et al. 2006) . MBD1 
associates also with another H3K9 methyltransferase, SETDB1 (Sarraf and 
Stancheva 2004). SETDB1 association is important for the MBD1 repressor activity 
and is interrupted by sumoylation of MBD1 (Lyst et al. 2006).  Finally, 
MBD1:SETDB1 forms a complex with CAF-1 during replication, probably 
contributing to the heritable maintenance of the chromatin’s epigenetic information 
after DNA replication (Sarraf and Stancheva 2004). 
MBD2 and MBD3 
 MBD2 and MBD3 are very closely related proteins (Roloff et al. 2003) that 
have divided from their common phylogenetic ancestor recently, probably after the 
separation of invertebrates and chordates. Indeed, the invertebrates C. intestinalis and 
D. melanogaster seem to have one MBD2/3 protein. It is assumed that MBD2/3 in D. 
melanogaster binds specifically to methylCp(T/A) (Marhold et al. 2004). MBD2 is 
characterised by an arginine-glycine (RG) rich domain that, as it will be explained 
later, is important for the regulation of the protein. An alternative splicing isoform of 
MBD2, MBD2b, does not contain this region (Hendrich and Bird 1998).  
 Despite their close phylogenetic relationship, MBD2 and MBD3 in mammals 
are very different proteins. Although they both have a conserved MBD domain, 
MBD3 binding to DNA is independent of methylation, whereas MBD2 binds 
specifically to methylcytosines  (Hendrich and Bird 1998). Moreover, MBD3 -/- 
mice die during early development, while MBD2 -/- mice are viable and healthy and 
show only small behavioural abnormalites (Hendrich et al. 2001). Closer study of 
MBD2 -/- mice has revealed that they exhibit abnormal expression of pancreatic 
enzymes in the colon (Berger et al. 2007) and also have a phenotype of increased 
tumour resistance in the Apc
Min/+ 
 background (Sansom et al. 2003).  
 Regarding their interaction with other proteins, both MBD2 and MBD3 have 
been shown to associate with HDAC1 and 2 (Saito and Ishikawa 2002; Le 
Guezennec et al. 2006). Importantly both methylcytosine binding and HDAC 
association of MBD2 is impaired when the RG-rich aminoterminal region is 
methylated by PRMT5 (Tan and Nakielny 2006). This seems to be a regulatory 
mechanism for MBD2 action. In an analogous manner, the protein MBD3L (which is 
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not part of the MBD family) is speculated to have a role on the regulation of MBD3 
(Jin et al. 2005). Both MBD2 and MBD3 are core components of the Mi-2/NuRD 
complex (Ng et al. 1999; Zhang et al. 1999; Wade et al. 1999; Feng and Zhang 
2001). Nevertheless, a recent study has demonstrated that MBD2 and 3 do not 
coexist in the Mi-2/NuRD complex and the presence of one in the complex excludes 
the other (Le Guezennec et al. 2006).  
1.4.2. Kaiso 
 Kaiso binds to sequences with multiple methyl-CpGs and this binding 
depends on its zinc-finger domain (Prokhortchouk et al. 2001). Similar to MBD2 -/- 
mice, Kaiso -/- mice are viable and fertile and have a phenotype of resistance to 
intestinal cancer in the Apc
Min/+
 background (Prokhortchouk et al. 2006). 
Surprisingly, in Xenopus laevis, Kaiso depletion caused severe developmental 
abnormalities and apoptosis (Ruzov et al. 2004). There is no adequate explanation 
for this difference between organisms. Kaiso is particularly interesting because it is 
the only methylation-dependent repressor that is known to be part of signalling 
cascades; it associates with p120 catenin (Daniel and Reynolds 1999) and seems to 
be important for Wnt signalling (Kim et al. 2004; Park et al. 2005). It is also part of 
the N-CoR (Yoon et al. 2003) chromatin remodelling complex. Further study of 
Kaiso-mediated repression could provide the first clues about how environmental 
signals and epigenetic phenomena cooperate to regulate gene transcription. 
 Two more proteins have been discovered recently in humans that share 
significant similarities with Kaiso (Filion et al. 2006). They are the ZBTB4 and 
ZBTB38 proteins which contain both a POZ domain and Kaiso-like conserved zinc-
fingers. They are expressed in adult tissues but not embryos. They bind to methylated 
DNA both in vivo and in vitro and reporter assays have shown that they are 
methylation-dependent transcription repressors. 
1.4.3. SET- and RING-associated (SRA) domain-
containing proteins 
 KRYPTONITE (KYP) is a protein of A. thaliana known for its H3K9 
methyltransferase activity. It was recently shown that it can also specifically bind to 
methylcytosines in every dinucleotide context (Johnson et al. 2007). In vivo, it 
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associates with the methylated AtSN1 and AtCOPIA retrotrasposons. The same study 
showed that the SRA domain of the protein was mainly responsible for its methyl-
binding activity.  
 Investigation demonstrated that another plant histone methyltransferase, 
SUV6, and two previously uncharacterised proteins, ORTH1 and 2, that also contain 
SRA domains could specifically bind methylcytosines in vitro too (Johnson et al. 
2007). Of these, SUV6 did not show any binding specificity towards the sequence 
context of the methylcytosine, while ORTH1 and 2 seemed to prefer CpGs. There is 
no evidence yet for in vivo methylcytosine-specific binding of these proteins.  
 Another SRA domain protein in A. thaliana recently identified by its methyl-
binding activity is VARIANT IN METHYLATION 1 (VIM1) (Woo et al. 2007). 
This protein binds specifically to methylcytosines in a CpG or CpNpG context in 
vitro and is associated with centromeric repeats, as well as the tandemly repeated 5S
 
rRNA genes, the repetitive Athila retrotransposable elements
 
and a Cinful-like 
retrotransposon in vivo.  
 The only mammalian protein that shows some similarity to the SRA-domain 
proteins of A. thaliana and is reported to have methylcytosine specificity is the 
human ICBP90. Another protein in mouse, Np95, also has a SRA domain and has a 
role in centromere heterochromatinisation (Papait et al. 2007), but has never been 
shown to bind methylated DNA. ICBP90 was first identified as a CCAAT binding 
protein contributing to the regulation of topoisomerase IIα and showed distinct 
expression patterns in different tissues (Hopfner et al. 2000).  Further investigation, 
however,  has shown some affinity of  ICBP90 for methylated CpGs and that it could 
have a role in methylation-dependent transcription regulation of certain tumor 
suppressor genes (Unoki and Nakamura 2003; Unoki et al. 2003).  Nonetheless, its 
exact role as a methylation-dependent transcriptional factor still remains to be 
shown.  
 In summary, the SRA domain proteins are a new class of methylcytosine-
binding proteins. In plants, they contain a SET domain and previous studies had 
shown a role for the heterochromatinisation of DNA by catalysing histone 
modifications, but it is only now that their DNA-binding ability has been shown. 
Additionally, they are the only methylcytosine-binding proteins that seem to have a 
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specific role on methylated repetitive elements found at centromeres. These 
observations dictate that they could be mediating the effect of DNA methylation on 
chromosome structure. Nevertheless, more experiments are needed to establish this 
function. 
1.4.4. A link between DNA methylation and histone 
modifications 
 Heterochromatin is typically defined as chromatin rich in DNA methylation, 
deacetylated histones and repressive histone marks such as H3K9 methylation. As 
described previously (section 1.3.2), DNMTs associate with the enzymes that are 
responsible for the histone modifications that are present in heterochromatin 
providing a spatial link between DNA methylation and histone modifications. 
Additionally, the evidence outlined above show that the enzymes that are responsible 
for repression of the methylated promoters are also associating with histone 
modifying enzymes. In the case of MBDs and Kaiso this happens through their 
interaction with HDACs and H3K9 methyltransferases. The SRA domain-containing 
proteins on the other hand contain themselves a SET or SET and RING associated 
motif. The SET motif is typical of histone methyltransferases and indeed, at least in 
the case of KYP, it has been shown to be able to catalyse H3K9 methylation. It 
seems that methyl-binding is functionally connected with H3K9 methylation and in 
the case of SRA proteins evolution has merged the two functions into one enzyme.  
 I would here like to mention an experiment that emphasises the link between 
H3K9 methylation and DNA methylation. Lyko et al. (1999) showed that expression 
of mouse DNMT enzymes in Drosophila forced establishment of DNA methylation 
and had dramatic effects on its phenotype. This happened despite the fact that this 
organism, naturally lacking DNA methylation, does not have the machinery that can 
read the methylation signal in order to suppress a gene or alter the histone 
modifications. They later showed that togther with DNA methylation, overexpression 
of DNMTs caused increase in the global levels of H3K9 methylation. 
 As described already and will be discussed more extensively later, DNA 
methylation has a role in transcription repression. A simple model would suggest that 
DNA methylation attracts the methylcytosine binding transcription repressors. 
Nevertheless, repression by these proteins is dependent on the histone modification 
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machinery that is recruited by both the DNA methyltransferases and the repressors 
themselves. All these interactions (Figure 1-5) form a feed-forward loop of DNA 
methylation and histone modifications. The causal relationships of these interactions 
as well as their relative importance is the subject of intense research. The fact that 
organisms such as D. melanogaster, C. elegans and S. serevisae, which do not have 
DNA methylation machinery, have nevertheless a complete set of histone modifying 
enzymes, suggests that histone modifications likely higher in the hierarchy of 






















Figure 1-5. Schematic diagram of the known interactions of methylcytosine binding 
proteins. The diagram focuses on the interactions with the histone modification machinery. 
Interactions are shown with a line. The methylcytosine binding proteins have a repressive 
effect on methylated DNA. DNMTs are methylating DNA. The proteins that have the same 
effect on DNA are grouped together.  
 
1.4.5. Proteins that bind unmethylated CpGs 
 The methylation pattern in the genome is made up of both methylated and 
unmethylated DNA. The previous sections focused on the proteins that can read 
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methylation. This section describes the two known proteins in mammals that 
specifically bind non-methylated CpGs.  
CpG-binding protein (CGBP)  
 CGBP (also known as CXXC finger protein 1 (CFP1)) is a transcriptional 
activator (Shin Voo et al. 2000) that specifically binds unmethylated CpGs through a 
CxxC domain that recognises a single CpG in a (A/T)pCpGp(A/T) context (Lee et al. 
2001). CGBP -/- mice die around implantation indicating an important role of the 
protein for development (Carlone and Skalnik 2001). Interestingly, CGBP -/- ES 
cells show reduced methylation levels in both repetitive elements and gene-
associated sequences, which is considered to be a secondary effect of the observed 
DNMT1 downregulation (Carlone et al. 2005). Recent experiments have shown that 
CGBP is also involved in the methylation of histone H3 at lysine4 (K4) (Lee and 
Skalnik 2005). 
Mixed lineage leukaemia (MLL) 
 Another protein that is specific for unmethylated CpGs is MLL. The region 
that is responsible for this specificity appears to be a CxxC-like domain (Birke et al. 
2002). Site selection experiments have shown that this protein prefers CpG-rich 
stretches of DNA rather than single CpGs (Birke et al. 2002), making it a good 
candidate for a CpG island-specific transcription factor. Indeed, all of the genes that 
MLL has been shown to associate with, have CpG islands (Milne et al. 2005). An 
interesting class of genes that depends specifically on MLL for their expression is the 
Hox family (Terranova et al. 2006) and the misregulation of these genes explains 
satisfactorily the homeotic phenotype of the MLL mutant mice. Finally, MLL is also 
an H3K4 methylatransferase and the SET domain at its carboxyterminal end is 
responsible for this activity (Milne et al. 2005; Nakamura et al. 2002). 
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1.5. Roles of DNA methylat ion 
1.5.1. Role in transcription 
 As discussed extensively above (section 1.4), DNA methylation at the 
promoter has a negative effect on transcription because of the repressive action of 
methylcytosine binding proteins, such as the MBDs and Kaiso. The situation is 
nevertheless not so straightforward, as experiments suggest that, at least in the cases 
studied, DNA methylation may be the result rather than the cause of transcriptional 
repression. Early studies on the time course of transcriptional repression of an in 
vitro methylated gene injected into X. laevis oocytes (Kass et al. 1997), have shown 
that transcription is not affected by the presence of methylation in the promoter but 
by the assembly of repressive nucleoprotein complexes. More recently, Mutskov and 
Felsenfeld  (2004) have shown that a transgene’s expression levels were closely 
mirrored by a reduction in histone acetylation and H3K4 methylation but DNA 
methylation at the promoter was established more gradually as repression proceeded. 
A similar situation has been observed in the endogenous Oct4 gene in early 
development (Feldman et al. 2006; Gu et al. 2006) and will be discussed in more 
detail in the third chapter.   
 Another mechanism by which promoter methylation affects transcription is 
by forbidding the binding of transcription factors that are necessary for the activation 
of the gene. Examples of such a mechanism include Sp1 binding at the Abcc6 
promoter (Douet et al. 2007) and E2F binding at the promoters of dihydrofolate
 
reductase, E2F1, cdc2, c-myc and c-myb (Campanero et al. 2000). An observation 
that could be related to methylation-sensitive transcription factor binding is that the 
presence of methylcytosines might cause conformational changes on the DNA, 
potentially preventing binding (Muiznieks and Doerfler 1994).  
 Additionally, it seems that DNA methylation might have an effect on RNA 
polymerase II itself. Lorincz et al. (2004) have demonstrated that methylation of a 
transgene resulted in a specific decrease of the elongating form of RNA polymerase 
II occupancy in the methylated region. The authors argue that this might be an 
indirect effect of the accompanying repressive histone modifications. Finally, 
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misregulation of transcription due to abnormal methylation patterns is known to 
happen in cancers, in which, part of the aberrant transcription phenotype can be 
attributed to methylation. 
1.5.2.  Role in imprinting 
 A specialised role of DNA methylation in transcriptional repression is the 
case of imprinted genes. Imprinting is the phenomenon in which a gene is 
monoallelically expressed depending on whether it is of maternal or paternal origin. 
In a simplified model, parent-specific methylation of the imprinted gene is 
determining its transcription status. Although the purpose of such a mechanism in 
higher organisms is not known, the most popular current theory proposes that it is the 
product of competition for resources during embryogenesis. In more detail, this 
“conflict hypothesis” (Moore and Haig 1991) speculates that imprinting is the 
product of evolution forces acting on genes that affect embryonic development. In 
more detail, in organisms that rely on maternal resources during their embryonic 
development, maternal imprinting acts against the physical growth of the embryo 
that draws from the host’s resources. On the other hand, paternal imprinting tries to 
promote growth ensuring strong progeny.  The situation becomes more complicated 
by the discovery that certain genes are imprinted in some tissues and not others. 
 Imprinted genes are often found in clusters in which a common regulatory 
mechanism is responsible for the expression and repression of the appropriate set of 
genes in the cluster. A well studied case is that of the Igf2/H19 locus (Thorvaldsen et 
al. 1998a; Thorvaldsen et al. 1998b; Bell and Felsenfeld 2000; Hark et al. 2000; 
Murrell et al. 2004; Ling 2006; Engel et al. 2006). In this case an enhancer element 
is located far downstream of the two genes. In the paternally derived chromosome, 
the differentially methylated region (DMR) that is located between the two genes is 
methylated, and the enhancer acts on the distal Igf2 gene inducing its expression. On 
the maternal chromosome, the DMR is free of methylation and bound by CTCF, 
which acts as an insulator that cuts off communication of the enhancer with the Igf2 
gene and causes it repression. This in turn allows the more proximal H19 gene to be 
expressed. CTCF binding has been reported for the imprinted Rasgrf1 locus (Yoon et 
al. 2005) and also seems to have a general role on insulator activity (Bell et al. 1999; 
Ohlsson et al. 2001).  
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 Another mechanism for the regulation of expression in imprinted clusters is 
the one found at the Igf2r/Air system (Wutz et al. 1997; Zwart et al. 2001; Sleutels et 
al. 2002; Sleutels et al. 2003). In this case methylation of the Igf2r promoter and 
transcription initiation from within the Igf2r gene causes expression of the antisense 
non-coding transcript Air. When Air is expressed, the other imprinted genes of the 
locus are repressed. Methylation of the Air promoter on the other hand, suppresses its 
transcription allowing uniparental expression of the imprinted genes. A mechanism 
that involves a non-coding antisense transcript is present in several known imprinted 
loci (for an overview see O'Neill 2005) and bears significant similarities with the 
Xist/Tsix system of X chromosome inactivation that will be discussed in more detail 
in the next section. 
1.5.3. Role in X inactivation 
 Sexual reproduction has an unexpected consequence, the different karyotype 
between males and females. This means that depending on its gender, an organism 
will be diploid or aneuploid for one of the sex chromosomes, which could lead to 
different expression levels of the associated genes with unpredicted effects on the 
phenotype. Different organisms seem to deal differently with the problem of dosage 
compensation; in D. melanogaster  the unique X chromosome in males is doubling 
its transcription rate, in C. elegans both the X chromosomes of hermaphrodites are 
halving their transcription, while one of the two X chromosomes of female mammals 
undergo inactivation. The latter mechanism of inactivation is best studied in 
mammals and is directly associated with chromosome-wide epigenetic modifications 
(Riggs and Pfeifer 1992).  
 There are two important decisions to be made during X chromosome 
inactivation is mammals, if inactivation is needed (i.e. counting) and which X 
chromosome to inactivate (i.e. choice). In mouse extraembryonic tissues, it is always 
the paternal X chromosome that is inactivated, in the embryo proper though the 
choice seems to be random. Recent research has shown that counting occurs 
probably through the transient pairing of the two X chromosomes at the Xite locus of 
the X-inactivation centre (Xic) (Xu et al. 2006; Bacher et al. 2006). Xic contains 
three elements, Xist, Tsix and Xite that are all transcriptional units of non-coding 
RNAs, of which Xist and Tsix are in opposite orientation, partially overlapping. Xite 
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is responsible for Tsix expression in cis (Ogawa and Lee 2003). In the chromosome 
where Tsix is expressed, the corresponding Xist is suppressed, and the chromosome 
remains active (Xa) (Stavropoulos et al. 2001). The opposite is true for the inactive X 
(Xi). In all cases, repression of Xist or Tsix is associated with DNA methylation at the 
corresponding promoters. 
 The Xist non-coding RNA is believed to initiate inactivation of the 
chromosome by coating it (Penny et al. 1996; Marahrens et al. 1998; Wutz and 
Jaenisch 2000) but the exact mechanism is not yet fully understood. 
Heterochromatinisation is then thought to spread across the Xi causing chromosome-
wide silencing. Importantly, it has long been known that DNA methylation in the Xi 
takes place after the inactivation (Lock et al. 1987). There is evidence that 
complicate the picture as they show that, on average, Xi methylation levels are not 
uniformly higher than in the Xa (Viegas-Pequignot et al. 1988; Weber et al. 2005; 
Hellman and Chess 2007). It seems that the distribution of DNA methylation differs 
between the two X chromosomes; Xa has high intragenic DNA methylation while Xi 
has high proportion of CpG island and promoter methylation. Further experimental 
evidence is required to elucidate the X inactivation process. 
  
1.5.4. Role in development 
 Establishment and maintenance of the DNA methylation patterns are of 
utmost importance for the correct developmental program of mammals. This is 
exemplified by the effect that DNA methylation depletion has on mice; deletion of 
the catalytic domains of DNMT1 (Li et al. 1992) or DNMT3a and b (Okano et al. 
1999)  resulted in a dramatic reduction in the genomic methylation levels and 
embryonic lethality. The same gene deletions however did not seem to affect the 
growth of embryonic stem cells in culture (Tsumura et al. 2006). This establishment 
of the genome-wide DNA methylation patterns in mice occurs mainly during the two 
massive waves of epigenetic reprogramming, one in germ cells and one in the early 
embryo (Figure 1-6). Although this epigenetic reprogramming also involves big 
changes in the pattern of  H3K27 methylation by the polycomb group proteins and 
fluctuations in the levels of H3K9 and H3K4 methylation (Seki et al. 2005), the 
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DNA methylation changes that are associated with this event are the focus of this 
section. 
Reprogramming of DNA methylation during germ cell differentiation 
 Epigenetic reprogramming of the germ cells serves mainly to establish all the 
gender-specific methylation marks independently of the marks in the soma and  
 
Figure 1-6. Simplified diagram of DNA methylation waves during mouse development. 
The black line represents imprinted genes, the red line the maternal genome and the blue 
line the paternal genome. The methylation levels at the y-axis are not to scale. (Taken from 
Reik and Walter 2001). 
 
happens during maturation of the primordial germ cells (PGC). The PGC are of 
mesodermal origin and appear as a small population of alkaline phosphatase-positive 
cells at Embryonic Day (E) 7.0 in mouse soon after the formation of the primitive 
streak (Ginsburg et al. 1990). Subsequently, during gastrulation, this initial 
population of cells migrates towards the hindgut at the genital ridges and proliferates, 
processes that last until E11.5 and E13.5 respectively (Hogan et al. 1994). The PGC 
then enter the phase of sex-specific maturation to germ cells, which in males is 
completed before birth with mitotic arrest and with mitotic arrest at the diplotene 
stage of meiosis in females. After birth, the events that cause reproductive maturation 
of the organism trigger the final stage of germ cell maturation into sperm and 
oocytes.   
 During the embryonic stage of differentiation (or de-differentiation from 
another point of view) and  despite the presence of DNMT1 in their nucleus (La Salle 
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et al. 2004), the PGC undergo genome-wide demethylation of DNA. This 
demethylation involves erasure of imprints, removal of methylation from single-copy 
genes and repetitive elements and the reactivation of the Xi  chromosome in females. 
In more detail,  Hajkova et al. (2002) have shown a dramatic loss of methylation in 
imprinted and non-imprinted loci within one day of the end of migration of the 
PGCsto the genital ridges (E12.5). The authors further speculate on an active 
mechanism for demethylation, as the extent of methylation loss in the given time 
frame could not be explained by a replication-dependent passive loss of methylation. 
Further analysis of different imprinted regions has shown that the exact timing of this 
reprogramming is individually controlled on each imprinted gene (Lee et al. 2002). 
Contrary to the erasure of imprints, reactivation of the Xi appears to be a slow 
process. It starts as soon as the PGC appear at the primitive streak, continues after the 
initiation of meiosis and is completed at the mature oocyte (Sugimoto and Abe 
2007). The evidence however of how this reactivation is temporally associated with 
DNA demethylation is scarce.  Finally, loss of methylation after E11.5 has also been 
observed in repetitive elements. The rate of demethylation for these elements is  
however slow, varies according to the sex of the organism and is not complete (Lees-
Murdock et al. 2003; Lane et al. 2003). 
 After demethylation, a wave of de novo methylation restores methylation on 
the genome of the mature gametes in a sex-specific manner. In other words the 
correct imprints are being re-established according to the gender of the organism and 
the extent of remethylation of the repetitive elements is regulated according to the 
gamete type too. In more detail, remethylation of repetitive elements such as IAP, L1 
and minor satellites in male germ cells is completed by E17.5 (Lees-Murdock et al. 
2003; Lane et al. 2003), while in female germ cells the process begins after birth and 
is less efficient, resulting in lower overall methylation levels in the oocytes (Walsh et 
al. 1998). Establishment of the imprints also happens asynchronously in the two 
types of germ cells; in male germ cells methylation starts at around E15.5 and is a 
slow process that continues after birth (Davis et al. 2000; Li et al. 2004), while in the 
female germ cells methylation of the imprinted genes begins post-natally, in the 
growing oocyte (Lucifero et al. 2002; Obata and Kono 2002). Deletion analyses 
(Bourc his et al. 2001; Kaneda et al. 2004; Arnaud et al. 2006) have shown that 
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DNMT3a and DNMT3L, both acting together and on their own, are the main 
methyltransferases responsible for the establishment of the correct imprints and that 
they are enough for the correct targeting of methylation at this stage. Aditionally, the 
unique expression of the DNMT3a-β isoform in testes (Weisenberger et al. 2002) 
and the testes- and ovary-specific isoforms of DNMT3L in the corresponding tissues 
(Shovlin et al. 2007) might provide the cell-type specificity needed for correct 
imprint establishment. 
 Finally, in contrast to the orderly model of epigenetic reprogramming in the 
gametes described above, recent evidence has come to light that somehow 
complicates the phenomenon. Oakes et al.  (2007) have examined the methylation 
status of hundreds of genomic loci during distinct stages of post-natal male germ cell 
maturation. In this study, except from the loci that gained methylation, as expected, 
several loci seemed to be going against the massive global methylation wave and 
become demethylated instead. Better appreciation of the mechanisms that underlie 
the correct methylation and demethylation of specific loci is probably required for 
the understanding of this biological process. 
Post-fertilisation reprogramming of DNA methylation  
 Soon after fertilisation, the sperm pronucleus decondenses and the DNA 
becomes demethylated (Mayer et al. 2000; Oswald et al. 2000). This process is 
completed before the first division of the zygote, which excludes the possibility of a 
passive demethylation mechanism and has caused speculations about an active DNA 
demethylase enzyme. Despite intensive research however the speculative DNA 
demethylase remains uncharacterised and there is some discussion that this role 
might be taken temporarily by a DNA repair enzyme (Morgan et al. 2004; Gehring et 
al. 2006; Barreto et al. 2007). The only elements in the paternal genome that seem to 
escape active demethylation are the imprinted genes and IAP elements. (Nakamura et 
al. 2007). 
 The maternal genome also undergoes global demethylation with the 
exception of the imprinted genes but this process lasts much longer, until the 
blastocyst stage, and is probably a passive mechanism. The passive demethylation of 
the maternal genome can be explained by the active exclusion of the oocyte-specific 
DNMT1 isoform (DNMT1o) from the nucleus during this period (Mertineit et al. 
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1998; Howell et al. 2001). There is no explanation as to why there is a need for two 
separate mechanisms for the demethylation of the paternal and maternal genomes or 
indeed what purpose does this wave of demethylation serve. The somatic 
methylation pattern is nevertheless reastablished around implantation. This is also the 
time of the onset of X inactivation in the embryo proper. 
Epigenetic reprogramming in development across organisms 
 The evidence outlined above comes mainly from experiments in mice. For 
ethical reasons human embryonic development is not as well studied, but the limited 
experimental evidence that is available support the existence of similar 
reprogramming waves during human development as in mouse. Comparative studies 
of the post-fertilisation reprogramming waves have shown that the mechanism is not 
conserved in all mammals (Dean et al. 2001; Beaujean et al. 2004). In these studies, 
immunostaining of methylcytosine in the male and female pronuclei of the zygote 
has demonstrated that the male pronucleus of rat and pig, but not that of sheep and 
rabbit, undergoes active demethylation. The male bovine pronucleus is only partially 
demethylated before the first zygotic division but does undergo remethylation before 
implantation. 
 In the non-mammalian species studied, reprogramming waves seem to be 
missing. In more detail, studies of the methylation in single-copy genes and 
repetitive elements in zebrafish at various developmental stages revealed no loss of 
methylation in the oocytes, sperm or the early embryo (Macleod et al. 1999). 
Similarly, the Xenopus zygote does not seem to undergo demethylation and on the 
contrary appears to depend on DNA methylation for its correct development 
(Stancheva and Meehan 2000). It looks like the significance of the DNA methylation 
patterns in fate determination and developmental competence varies among 
organisms. This situation is reminiscent of the fact that DNA methylation is absent 
from many invertebrates and begs for an answer to the question of what is the 
particular contribution of DNA methylation that benefits the organisms that have it. 
DNA methylation in ES cells 
 Embryonic stem (ES) cells are derived from the inner cell mass of the 
preimplantation blastocyst. As discussed previously, the time of implantation is also 
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the time when the second de novo methylation wave occurs. As a consecuence of 
that, a mixture of DNA methylation marks, characteristic of both the pre- and post-
implantation stages, are present in ES cells. On one hand, the global DNA 
methylation levels, as well as the methylation levels of repetitive elements, are high 
in ES cells, like in the epiblast (Jackson et al. 2004; Yeo et al. 2007). On the other 
hand, in female ES cells, X inactivation has not yet occured. Additionally, ES cells 
also exhibit DNA methylation characteristics that are not reflecting the in vivo 
situation; analysis of the methylation status of certain imprinted genes in mouse ES 
cells showed variation in their methylation levels among different ES subclones 
(Humpherys et al. 2001). It is also important to note that cell lines have been known 
to accumulate aberrant methylation in tissue culture (Antequera et al. 1990) and the 
possibility that this also happens in ES cells cannot be excluded. The empirical 
observation that early passage ES cells are more competent for the formation of 
embryos could be linked to this. Finally, upon induction of ES cell differentiation in 
vitro, there is a reproducible change of the DNA methylation levels in specific loci 
(Shiota et al. 2002; Kremenskoy et al. 2003). This is presumed to be linked to the 
transcriptional regulation of specific genes that are expressed in different cell 
lineages and is believed to reflect similar changes that happen during development. 
1.5.5. Defence against parasitic sequences 
 The idea that methylation is a defence mechanism against parasitic sequences 
comes from bacteria where DNA methylation was first detected as a specific 
mechanism for the protection against invading DNA. In mammals, this view is 
supported by the observation that in transgenesis experiments, the foreign DNA very 
often becomes heavily methylated in the host cell. Concrete evidence however for a 
role of DNA methylation in mammals as a defence mechanism comes from 
observations on transposons. 
  Repetitive sequences comprise 40-50 % of the mouse and human genomes 
respectively (Mouse Genome Sequencing Consortium 2002; Human Genome 
Sequencing International Consortium 2004), the large majority of which is repetitive 
elements. Although there is arguably a function for the presence of repetitive 
sequences in the genome (Shapiro and Von Sternberg 2005) random 
retrotransposition can have deleterious effects for the organism (Gilbert et al. 2002; 
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Symer et al. 2002).  It is believed that the high levels of methylation that are found at 
retrotransposons (Yoder et al. 1997)  help relieve the load of mutagenesis through 
transposition in many organisms. Indeed, mice with reduced global methylation 
levels have been shown to have increased activation of IAP elements (Walsh et al. 
1998) and methylation seems to inactivate human endogenous retroviral sequences 
(Lavie et al. 2005). Similar studies in A. thaliana have confirmed a similar 
mechanism (Kato et al. 2003).  
 A specialised case of DNA methylation happens is Neurospora crassa. This 
organism has very low levels of DNA methylation that seem to be acting uniquely 
through the mechanism of Repeat Induced Point Mutation (RIP). In more detail, N. 
crassa seems to inactivate repetitive elements by inducing C to T transitions in their 
sequence rendering them inactive. The relics of repetitive elements found in this 
organism’s genome are also the only sites where methylation can be found (Selker et 
al. 2003; Freitag et al. 2002). Although the exact mechanism of RIP is not yet fully 
understood, it should be noted that the presence of methylcytosines coincides with 
regions of C to T transitions. It is possible that in this case N. crassa might have 
taken advantage of methylcytosine deamination for its benefit (Selker 1990). This is 
also supported by the observation that the rid-1 (RIP- defective) gene, which is 
required for RIP, encodes a putative DNA methyltransferase protein (Freitag et al. 
2002). 
1.5.6. Role in chromatin structure and integrity 
 Nucleosomes comprise the most elementary level of DNA compaction, in 
which the DNA is wrapped around the core histone octamer. It has been known for a 
long time that certain DNA sequences make better nucleosome positioning signals 
than others. In vitro experiments on the strong nucleosome positioning sequence of 
the chicken β-globin promoter have shown that the presence of certain central CpGs 
is essential for nucleosome positioning (Davey et al. 2004) and that their methylation 
could displace the in vitro reconstituted nucleosome (Davey et al. 1997). A similar 
effect of DNA methylation on some, but not all, nucleosome positions was detected 
in the human H19 imprinting control region (Davey et al. 2003). However, all these 
experiments are on reconstituted chromatin, it remains to be shown whether the 
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effect that DNA methylation has in nucleosome assembly and positioning has a 
biological meaning. 
  The next level of chromatin compaction is the 30 nm fibre that 
spontaneously forms in vitro by the addition of histone H1. The experimental 
evidence for a causative role of methylcytosines in H1 recruitment is inconclusive. 
Different reconstitution and electrophoretic mobility experiments of methylated and 
unmethylated DNA sequences have produced conflicting results that show both a 
preference and indifference of H1 for methylated DNA (Nightingale and Wolffe 
1995; Campoy et al. 1995; McArthur and Thomas 1996). An older in vivo study 
however that employed differential sedimentation of mono- and oligo-nucleosomes 
and immunodetection of methylcytosines in the purified fractions had shown a clear 
preference of H1-containing dinucleosomes for methylated DNA (Ball et al. 1983). 
This experiment however does not exclude the possibility that there is a third factor 
who brings the two together and not DNA methylation per se. Moreover, 
fluorescence recovery after photobleaching  (FRAP) experiments on DNMT3a/b-
depleted and wild-type ES cells revealed reduced motility of H1 in the former 
(Gilbert et al. 2007). The same authors however showed that the absence of DNA 
methylation from the genome of the mutant cells did not affect general chromatin 
compaction. On the other hand, immunoprecipitation experiments showed no 
preference of H1 for a methylated or an unmethylated version of a transgene 
(Hashimshony et al. 2003). It looks like more experiments are needed to show 
whether DNA methylation recruits H1 and what its role on heterochromatin 
formation is. 
 A well studied function of DNA methylation on chromatin structure is that at 
nucleolus organising regions (NORs). NORs contain the portion of the genome that 
encodes for the 18S, 5.8S and 25S ribosomal RNAs (rRNA). These genes are found 
in tandem repeats that are separated by a spacer and can span a region of several 
megabases. Active NORs form secondary constrictions in metaphase chromosomes 
and make up the structures that are recognised as nucleoli during interphase. A NOR 
is active when transcribed by RNA polymerase I and inactive when transcription is 
inhibited by methylation at the spacer region (Bird et al. 1981; Labhart 1994). In this 
way, DNA methylation ‒or better the absence of it‒ plays a role on nucleoli and 
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secondary constriction formation. Recent research  has shed light on the mechanism 
of NOR activation which appears to be regulated by specific transcription factor 
binding and heterochromatinisation, similarly to the activation of polymerase II 
transcribed genes (Laengst et al. 1998; Zhou et al. 2002; Santoro et al. 2002). 
Further detailed analysis of this mechanism however, is beyond the scope of this 
introduction. 
 Perhaps the best evidence that DNA methylation has an active role on 
chromatin structure and integrity comes from the fact the immunodeficiency, 
centromeric instability and facial anomalies (ICF) syndrome in humans is caused by 
mutations in DNMT3b (Hansen et al. 1999). As its name implies, some of the 
phenotypes of this syndrome are decondensation of the centromeres of chromosomes 
1, 9 and 16, chromosomal rearrangements, and reduced methylation of satellite DNA 
repeats. Importantly, most of the known DNMT3b mutations in patients with ICF 
affect the catalytic function of the protein and not protein-protein interactions 
(Lappalainen and Vihinen 2002). Further evidence for a structural role of DNA 
methylation at the centromeres comes from the observation that all three DNMT1, 
DNMT3a and DNMT3b seem to be preferentially localised at the centromeres of 
both human and mouse chromosomes during metaphase (Craig et al. 2003). The role 
of DNA methylation on centromere formation was shown more directly in 
experiments where demethylation by 5-azacytidine caused redistribution of the 
central centromeric scaffold protein CENP-B (Mitchell et al. 1996). All of this 
evidence supports the idea that DNA methylation at centromeres is not merely a 
consequence of their heterochromatinisation, but plays an active role in their 
formation. 
1.6. Perspective 
 As shown in the previous pages, there is a wealth of information about the 
molecular machinery that is associated with the DNA methylation patterns. 
Moreover, we have a relatively good account of when and where DNA methylation 
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occurs, although there is definitely room for more descriptive studies of this type. 
Our understanding of the DNA methylation phenomenon however does not seem to 
have leaped accordingly. On the contrary, it seems like the more information comes 
to light about all the phenomena that surround DNA methylation, the less we 
understand it. It is for example now known that DNA methylation is not universal 
among eukaryotes and that different organisms have different patterns and levels of 
methylcytosine in their genomes. There are many theories which try to explain these 
patterns, but with the exception of a few cases, a definitive answer to why and how 
they exist is still beyond our grasp. Moreover, a link between DNA methylation and 
transcriptional repression has been known for a long time and it seems that many of 
the roles of methylation are based on this link. Recent evidence however indicates 
that DNA methylation might actually follow transcription repression and that the 
universally conserved histone modifications are temporally more closely related to 
transcription. If this is the case, why should methylation be established at already 
inert promoters?  The question becomes more urgent by the realisation that 
methylation establishment only happens in a subgroup of organisms. Which 
evolutionary process and biological function would necessitate this DNA 
modification in some organisms and not others? 
 These questions have been the motivation behind the research work presented 
here. In the following chapters, the significance of DNA methylation for 
transcriptional repression and correct embryonic development as well as the 
formation of the methylation patterns in the mammalian genome are explored. In 
more detail, in the third chapter the process of silencing of the Oct4 gene during 
development is used as a model for the investigation of how methylation is 
established and what it contributes to the silencing process. A genome-wide analysis 
of the distribution and the methylation status of CpG islands in mouse and the 
possible existence for a developmental program for the establishment of the CpG 
island methylation is presented in the fourth chapter. An overview of the results with 
regard to the questions posed here is presented at the end. 
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2. Materials and methods 
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2.1. Murine embryonic stem cell  cul ture and 
dif ferentiation 
2.1.1. Cell l ines 
 The mouse embryonic stem  (ES) cell lines used in this study were the wt E14 
(129/Ola background) (Handyside et al. 1989) , DNMT1 KO (129/Ola background) 
(Li et al. 1992), DNTM3a/b KO 7aabb (129/Ola background) (Okano et al. 1999 and 
wt and G9a-/-  derivatives of the TT2 ES cell line (C57BL/6 background) (Yagi et al. 
1993), COL4 and 2-3 (Tachibana et al. 2002) respectively. The DNMT1 KO and 
7aabb cell lines were a gift from the lab of Dr Bernard Ramsahoye. The COL4 and 2-
3 cell lines were a gift from the lab of Dr Amanda Fisher. 
2.1.2. Mouse embryonic stem (ES) cell  tissue culture 
 The stem cells were grown on precoated gelatinized flasks at 37
o
C in the 
presence of 5% CO. The full medium was 1x Glasgow modified Eagle’s Medium 
(GMEM) (Invitrogen) supplemented with 1 mM sodium pyruvate (Invitrogen), 1x 
non-essential amino acids (Invitrogen), 10% foetal bovine serum (HyClone) 
previously tested for stem cell culture suitability, human recombinant leukaemia 
inhibitory factor (LIF) and 1:1000 β-mercaptoethanol (Invitrogen). The cells were 
dissociated by incubating briefly with 0.05% v/v trypsin (Cambrex) in PBS, 
prewarmed at 37
o
C The trypsin was inactivated with an equal volume of full medium 
and the cells were pelleted by spinning at 1300 rpm for 3 min. The cells were split 
approximately every two days to a confluency of 30%.  
2.1.3. In vitro differentiation of mouse ES cells to 
embryoid bodies 
 The embryonic stem cells were trypsinized and pelleted and then washed with 
full medium without LIF. One T75 flask of confluent cells was transferred to a 100 
mm
2
 bacteriological Petri dish with 15 ml full medium without LIF and incubated at 
37
o
C in of 5% CO. From this point on, all handling of the cells differentiating in 
suspension was done with a 25 ml pipette with wide orifice to avoid disaggregation 
of the cells. The medium was changed the next day and then every two days for the 
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desired differentiation period. The embryoid bodies were harvested after 3, 7, 14 and 
21 days in culture without LIF (EB3, EB7, EB14 and EB21 respectively). 
Alternatively, 1:10,000 of RA stock solution was added to the full medium without 
LIF after the EB3 stage and the cells were harvested after 2, 4, 6 or 10 days (RA2, 
RA4, RA6, and RA10 respectively). For harvesting, the embryoid bodies were 
transferred to a 30 ml centrifuge tube and allowed to settle at the bottom of the tube, 
the medium was aspirated and the cells washed with PBS twice.   
2.2. Isolation of high molecular weight genomic 
DNA  
 Two separate protocols were used for genomic DNA extraction, one for cells 
grown in culture (ES cells and embryoid bodies) and one for the extraction of DNA 
from mouse brains. The protocol used for DNA extraction from cells grown in 
culture relies on the denaturation of most proteins under very high salt conditions. A 
phenol/chlorophorm step was nevertheless added at the end, to ensure the absence of 
nucleases from the sample for long-term storage. For the extraction of DNA from 
brain, the emphasis lies on efficiently lysing the tissue sample and has a very 
thorough phenol/chlorophorm extraction step at the end to remove all proteins. In 
either protocol the concentration of the isolated DNA was determined with a 
NanoDrop ND-1000 spectrophotometre. The presence of contaminant proteins was 
assessed by the A260/A280 ratio which needed to be close to 2 and above 1.8. The 
DNA quality was confirmed with 0.8% agarose gel electrophoresis in 1x TAE buffer 
with 0.5 µg/ml ethidium bromide. 
2.2.1. DNA extraction from cells grown in tissue culture 
  2 ml of Lysis buffer I was used for approximately 5x10
6
 cells, precipitated 
and washed in PBS as described before. The cells were allowed to lyse overnight at 
37
o
 C with mild agitation. The next day, 1/3 volume of saturated NaCl was added to 
the lysate and the mix was shaken vigorously for 30 sec. At this stage a lot of protein 
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foam should appear. Next, the sample was centrifuged at room temperature at 900g 
for 30 min. The supernatant was transferred to a new tube and precipitated with two 
volumes of ice-cold absolute ethanol. The DNA was recovered with a Pasteur pipette 
hook, washed with 70% ethanol and resuspended in 1-2 ml TE buffer. A final 
concentration of 0.1 mg/ml RNase A was added and the sample was left at 37
o
 C for 
two hours with mild agitation. The DNA was extracted once with an equal volume of 
SAGE solution, precipitated and resuspended in TE buffer.  
2.2.2. DNA extraction from mouse brain 
 The mice that were sacrificed were all wild type, between four and six 
months old from a C57BL/6 and 129/Ola mixed background. The brains were 
dissected from the skull, sectioned free of the spinal cord and optical nerve and 
washed in PBS. Brains of three animals of the same sex were pooled before DNA 
extraction. The pooled brains were transferred into approximately five volumes of 
Lysis buffer II and the tissue was homogenised with a Dounce homogeniser. A final 
concentration of 1% w/v SDS and 0.4 mg/ml Proteinase K was added and the brains 
were lysed over night at 55
o
 C. Next day, RNase A was added to a final 
concentration of 0.1 mg/ml and the RNA was digested at 37
o
 C for 2 hours. The 
DNA was extracted with SAGE solution for 2-4 times and the DNA precipitated with 
two volumes ice-cold ethanol, recovered with a Pasteur pipette hook and 
resuspended in TE buffer. 
2.3. Bisulf i te genomic sequencing 
 Sodium bisulfite causes the specific deamination of cytosine through a 
sulfonated intermediate, and its conversion to uracil. The bisulfite genomic 
sequencing principle relies on the fact that the reaction rate for 5’ methylcytocine is 
much slower than that of cytocine Wang et al. 1980 making it virtually impossible to 
convert methylated cytocines  to uracils by sodium bisulfite. The treated DNA is then 
PCR amplified and sequenced. Comparison of the sequenced DNA with the original 
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genomic sequence reveals which cytosines were resistant to the treatment and 
therefore methylated. 
2.3.1. Bisulfite treatment.  
 The protocol used for the bisulfite treatment is modified from Frommer et al. 
1992. In more detail, 2µg of genomic DNA were digested at 37
o
 C for 8 hours with 
10U of the restriction endonuclease Kpn I (New England Biolabs) in a 50 µl reaction 
according to the manufacturer’s instructions. The digestion facilitates the complete 
denaturation of DNA at the next stage. The digested DNA was extracted with SAGE 
solution, precipitated with absolute ethanol and resuspended in 25 µl TE buffer.  The 
DNA was then boiled for 5 min and further denatured for 20 min in 42
o
 C in the 
presence of 0.3 M NaOH. This stage is very important as non-denatured, double 
stranded DNA can not be converted by sodium bisulfite. In the next step, the 
denatured DNA was incubated in a total volume of 300 µl with freshly prepared 
sodium bisulfite solution. The reaction proceeded under mineral oil at 55
o
 C in the 
dark. After exactly 5 hours, the DNA was precipitated and resuspended in 25 µl TE 
buffer. Next, the treated DNA was desulfonated by addition of 2.5 µl 3M NaOH and 
incubation at 37
o
 C for 15 min. Finally, the DNA was once more precipitated by 
adding 32.5 µl 5 M ammonium acetate (pH 7.0) and 180 µl absolute ethanol and then 
washed with 300 µl 70% ethanol and resuspended in 25 µl TE buffer. 
2.3.2. PCR amplification and sequencing 
 The bisulfite-treated DNA was PCR amplified with primers specific for the 
genomic region of interest. The primers were designed so that they were not 
interrupted by a Kpn I restriction site and in some cases nested PCR was performed 
in order to acquire a specific product. A list of the primers used for bisulfite 
sequencing in this study, their annealing temperatures and product size is given in 
Table 2-1. The PCR program was: 92
o
 C 1min, 35x(92
o
 C 30 sec, Tan 30 sec,72
o
 C 30 
sec), 72
o
 C 5 min, on 2 µl of the treated template.  The PCR reactions were 
performed in 30 µl with 0.5 U Fast Start Taq DNA polymerase (Roche), 0.2 mM 
dNTPs (ABgene) 0.6 µM of each primer in the reaction buffer provided by the 
manufacturer (contains 2 mM MgCl2). The amplified product was resolved in a 2% 




Table 2-1. Primers used in bisulfite PCR. 
 
Primer Sequence Primer Sequence bp Tan 
oct4 fw    
(-208) 
TTTGAAGGTTGAAAATGAAGTTTT 













oct fw      
(-485) 
GTTGTTTTGTTTTGGTTTTGGATAT 





oct fw      
(-848) 
AGGTTTTTTTG ATTTGAAGTAGA 





oct fw      
(-1199) 
AGGGTAGGTTT TTGTATTTTTTTT 








oct rev   
(-1027) 
5'-CAATCCCCTCA CACAAAAC-3' 172 59
o
 C 
oct fw      
(-1670) 
GTGTTATGTGTAGTTGTGTGTAGGT 





oct fw      
(-2088) 
GGTTTTAGAGGTTGGTTTTGGG 















AGTTTTTTAGAGATTTTTATTAGGGT celsr2 bis 
ex1 rev 
AACTAATAACATACCCTTATCCACC 263 56o C 
celsr2 bis 
ex2  fw 
TTTGTTTTTAGGGATTTTTAGGAG' celsr2 bis 
ex2 rev 











AACTTTCCATAATTCCCTATCCAC 187 56o C 
celsr1   
(3-1) fw 
GTGTTAGTGTTTGAGAATGAGTTTG celsr1   
(3-1) rev 
AATACATAAATATCCTTAATCTCCC 209 54o C 
celsr1   
(3-2) fw 
GGTGGGTTATGAGGTTTTGATTAT celsr1   
(3-2) rev 
TCATTAACCTCACCAACAACTAA 192 60o C 
celsr1   
(4-2) fw 
GTTTGAGGTTA TTATTAATTTTTT celsr1  
(4-2) rev 
CAACTCAACTAAACCTCCTAACC 106 50o C 





correct size was excised from the gel and the DNA was extracted using the QIAquick 
Gel Extraction kit (Qiagen). 
 The amplified DNA was cloned into the TOPO-TA vector (Invitrogen) 
according to the manufacturer’s instructions. Sufficient number of white colonies 
was picked with a sterile pipette tip the next day and the insert was amplified directly 
from the colonies using the T7 forward and M13 reverse primers (Table 2-1). These 
primers are complementary to the vector sequence and flank the insertion site adding 
180 bp to the amplification product. The colony-PCRs were performed in 20 µl with 
0.5 U Red Hot DNA Polymerase (ABgene), 1.5 mM MgCl2, 0.25 mM dNTPs 
(ABgene)  and 0.2 µM of each primer, in the reaction buffer of the manufacturer. 
The PCR program was: 95
o
 C 1min, 30x(95
o
 C 1 min, 54
o
 C 1 min,72
o
 C 1 min), 72
o
 
C 7 min. The correct size of the PCR product was confirmed with agarose gel 
electrophoresis and 15 µl of each PCR reaction were treated at 37
o
 C for 30 min with 
5 U Exonuclease I (New England Biolabs) and 0.25 U Shrimp Alkaline Phosphatase 
(Roche), followed by inactivation of the enzymes at 80
o
 C for 15 min. This reaction 
is important for removing any unused primers and dephosphorylating unused dNTPs 
before the sequencing reaction.  
 The sequencing reaction was performed in 10 µl reactions on 3ul of the 
treated PCR product with 2 µl BigDye Terminator v3.1 (Applied Biosystems) 
reaction mix, 8 mM  Tris-HCl pH8, 0.25 mM MgCl2 and 0.16 µM of either the M13 
reverse or T7 forward primers. The sequencing was performed on an ABI 3730 
sequencer. 
2.3.3. Analysis of the sequencing data 
 Analysis of the sequenced results was performed with the aid of the software 
BiQ Analyser (http://biq-analyzer.bioinf.mpi-sb.mpg.de). In more detail, the original 
genomic sequence was aligned with the sequenced clones and the quality of the 
sequences was assessed. The efficiency of the bisulfite conversion was judged by the 
absence of non-converted cytosines in a non-CpG context in the sequencing result 
and clones with conversion rates below 90% were removed. Similarly, clones that 
shared homology with the genomic sequence below 80% or had clonal methylation 
patterns were all removed. The only exception was the specific case of 
homogeneously methylated or homogeneously unmethylated clones which were 
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included in the results. The methylation pattern of all the clones that had passed the 
quality control was then recorded and graphically represented. 
 The statistical analysis of the bisulfite data was performed as follows. For the 
comparison of the methylation patterns in the various 5’ upstream regions of the 
Oct4 gene the Kolmogorov-Smirnov and the Wilcoxon two sample rank tests were 
performed. Both tests are non-parametric and do not make a normal distribution 
assumption. The Kolmogorov-Smirnov test investigates against the null hypothesis 
that the data of the two samples come from the same distribution, while the 
Wilcoxon test has the null hypothesis that the medians of the two samples do not 
vary significantly. The null hypotheses were rejected if P≤ 0.05. The values that were 
used in the statistical analysis of each sample were the proportion of methylated 
versus total CpGs per clone sequenced for each region, thus the sample size was the 
number of clones sequenced in each case. 
2.4. Analysis of RNA 
 All the plasticware and all the solutions used in RNA analysis were treated 
with DEPC. 
2.4.1. RNA isolation 
 RNA was isolated with the TRI reagent (Sigma) according to the 
manufacturer’s instructions. 1 ml TRI reagent was used for every 10
7
 cells. Great 
care was taken to avoid contact with the DNA-containing interphase during the RNA 
extraction. The RNA was redissolved in RNase and Nuclease-free water (Ambion) 
containing 1:100 RNasin RNA inhibitor (Promega). The concentration of the RNA 
was determined with a NanoDrop ND-1000 spectrophotometre. The presence of 
contaminant proteins was assessed by the A260/A280 ratio which needed to be close to 
2 and above 1.8. 
The RNA quality and quantity was confirmed with denaturing gel 
electrophoresis. In detail, 1 µg RNA, as measured, was heated in 1x RNA loading 
buffer at 70
o
 C for 5 min and then transferred to ice. The RNA was resolved in a 
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1.2% agarose gel in 1x MOPS buffer with 0.24 M formaldehyde and 0.5 µg /ml 
ethidium bromide. 
2.4.2. Reverse transcription 
 2 µg RNA were reverse transcribed in a 20 µl reaction containing  1.5 mM 
dNTPs (ABgene), 1x hexanucleotide mix (Roche), 1 µl of RNasin ribonuclease 
inhibitor  (Promega), 1x first-strand buffer (Invitrogen), 10 mM DTT (Invitrogen) 
and 200 U M-MLV Reverse Transcriptase (Invitrogen). The RNA was first mixed 
with the random hexanucleotides and dNTPs, denatured at 70
o
 C for 10 min and then 
quickly cooled in ice. The reaction was incubated at 37o C for 1 h and the enzyme 
was inactivated at 70o C for 15 min. For each RNA sample, a mock reverse 
transcription reaction was performed that contained 1 µl of water instead of reverse 
transcriptase.  Typically, a 1:20 dilution of the reaction was used in PCR. 
2.4.3. RT-PCR 
 The primers used for RT-PCR, their sequences, annealing temperatures and 
product length are listed in Table 2-2. The reactions were carried out in 15 µl volume 
with 1.5 U Taq DNA polymerase (Roche), 0.25 mM dNTPs (ABgene), 0.2 µM of 
each primer, in the reaction buffer provided by the manufacturer (contains1.5 mM 
MgCl2). Gapdh was used as a loading control. The elongation times were 20 sec for 
the shorter products and 40 sec for the longer ones. The reactions were not allowed 
to proceed for more than 35 cycles with most reactions repeated for 30 cycles. 
2.4.4. Quantitative real-time RT-PCR (RT-qPCR) 
 The primers used for RT-qPCR are listed in Table 2-3. All the primers have 
efficiency between 80 and 120%. The efficiency of the primers was calculated on 10-
fold dilutions of cDNA using the iCycler software (BIO-RAD). All the primers were 
designed so that they produced a product 70-130 nt long, so that the PCR reactions 
could be performed with a simple two-step program:  95
o
 C 2 min, 40x(95
o
 C 30 sec, 
65
o
 C 45 sec). All the reactions were done in quadruplicates. The specific 
amplification of a single product was ensured by confirming that a single melting 
curve peak was produced after each reaction. Since the gapdh primers could also 
amplify genomic DNA, control reactions with mock-reverse transcribed RNA were  
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Table 2-2. Primers used in RT-PCR 
 
















TGCCAAGGTCAACGCCTTC 154 58o C 











TTR 1 AGTCCTGGATGCTGTCCGAG TTR 2 TTCCTGAGCTGCTAACACGG 440 58
o
 C 
TRA 1 TCCTGCTGATTCCGAATG TRA 2 TGGCACAGGAACACTTTG 178 58
o
 C 
Pax-6 1 AGACTTTAACCAAGGGCGGT Pax-6 2 TAGCCAGGTTGCGAAGAACT 561 64
o
 C 
Msx fw ACTCCCCTTCAGCGTCGAGTCTCTG Msx rev GCGTCCGTGGTTTGCGATTG 202 68
o
 C 
Sox1 fw TGCAGGAGGCACAGCTGGCCTAC Sox1 rev TGCCGCCACCGCCGAGTTCTGG 171 57
o
 C 
Fgf5 fw GCGACGTTTTCTTCGTCTTC Fgf5 rev ACAATCCCCTGAGACACAGC 239 64o C 
Flk-1 1 CCTGGTCAAACAGCTCATCA Flk-1 2 AAGCGTCTGCCTCAATCACT 599 60
o
 C 
Nkx 1 ACATTTTACCCGGGAGCCTACGGTG Nkx 2 CTTTCCGTCGCCGCCGTGCGCGTG 152 60
o
 C 







CCTGCTTTTTGGTCAGTGGT 161 61o C 
 
performed for them to ensure that this was not the case. All the other primers were 
either interrupted by introns or spanned very large introns. Finally, all the reactions 
had no-template controls to ensure there was no cross-contamination between wells. 
The PCR reactions were performed in 25 µl, on 2.5 µl of the 1:20 diluted cDNA, 1x 
SYBRGreen master-mix (BIO-RAD) and 0.2 µM of each primer. The quantity of 










where ĊT(gene) is the mean threshold cycle of the particular gene under examination 
and ĊT(gapdh) the mean threshold cycle of gapdh. 
 
Table 2-3. Primers used in RT-qPCR 
 
Primer Sequence Primer Sequence 
Gapdh3 TACCCCCAATGTGTCCGTCG Gapdh4 CCTGCTTCAGCACCTTCTG 
Oct RT fw GAGGAGTCCCAGGACATGAAAGC Oct RT rev CCTTTCCAAAGAGAACGCCCAGG 
Nanog fw TGGGAACGCCTCATCAATGC Nanog rev AGGTCTTCAGAGGAAGGGCG 
D3a-RT-F-Ex6 GTGTCTTGGTGGATGACAGGC D3a-RT-R-Ex7 GCGGCATGAGCTTCTCCACAC 
D3b-RT-Ex7_F TGGTGTCCTGGAAAGCCACCT D3b-RT-Ex8-R AGCCACCAGTTTGTCAGCAGA 
 
2.4.5. Northern hybridization 
The radio-labelled probes used for the Northerns were prepared as follows; 
the region of interest was PCR-amplified from cDNA and the PCR product was gel-
extracted from a 0.8% agarose gel in 1x TAE using the QIAquick Gel Extraction kit 
(Qiagen). The Oct4-specific primer sequence was 5’-GTGGTTCGAGTATGGTTC-
3’ and 5’-AATGATGAGTGACAGACAGG-3’ and the amplified region was a 452 
bp-long fragment of the gene’s last exon. The probe used as a loading control was 
against the S26 RNA and was a kind gift of Dr J. Selfridge. 3 µl of the gel-extracted 
probe were then diluted with 6 µl water and heated at 100
o
 C for 10 min. The 
reaction mix was prepared with addition of 1x hexanucleotide mix (Roche), 0.5 mM 
of each dATP,dTTP and dGTP, 5 µl of newly ordered dCTP
32
  and 5 U Klenow 
DNA polymerase I (New England Biolabs) and incubated at 37
o
 C over night. Any 
unincorporated dCTP
32
 was removed with a Sephadex G-50 NICK Column 
(Amersham) according to the manufacturer’s instructions. 
 10 µg RNA were resolved in a 1.2 % denaturing agarose gel as described 
previously (2.4.1). The gel was washed with 10x SSC for 15 min and the RNA was 
transferred to a Hybond-N+ membrane over night with capillary blotting, using 10x 




). The membrane was then blocked for 30 min at 65
o
 C 
with prewarmed modified Church and Gilbert buffer. The buffer was then replaced 
by 0.2 ml/cm
2
 modified Church and Gilbert buffer containing the radiolabelled probe 
and the hybridization continued at 65
o
 C overnight.  
 The washes were performed in room temperature as follows: 2x low 
stringency wash (2xSSC, 0.1% w/v SDS) for 5 min, 2x medium stringency wash 
(1xSSC, 0.1% w/v SDS) for 10 min and 1x high stringency wash (0.1xSSC, 0.1% 
w/v SDS) for 5 min. The blot was exposed to a phosphor screen (Amersham) for 2 h 
and the signal was scanned with a STORM Phosphorimager (Amersham). The image 
analysis and signal quantification was performed with the Scion Image software. 
2.5. Chromatin immunoprecipitat ion (ChIP) 
2.5.1. Sample preparation 
 10
8
 cells (one T75 flask) were harvested and resuspended in 10 ml medium 
with 1% v/v formaldehyde and incubated in the rocking platform for 5 min. The 
crosslinking was quenched with addition of glycine to a final concentration of 125 
mM for 5 min. The cells were pelleted at 1.5 rpm and washed with 20 ml PBS 
containing protease inhibitor cocktail (Roche). The crosslinked cells were 
resuspended in 1 ml NE1 buffer and disrupted with 5-10 strokes in a Dounce 
homogeniser. The nuclei in the suspension were pelleted at 3000rpm for 5 min and 
resuspended 500 µl NE1 buffer. At this stage the cells were frozen at -80
o
 C if 
needed. 
 The prepared chromatin was mildly digested with 50 U micrococcal  nuclease 
(Fermentas) in ice for 2 h in the presence of 2 mM CaCl and the reaction was 
stopped with 100 mM EDTA. The samples were then sonicated with a digital  
Branson sonifier S-450D for 10 min (30 sec on/45 sec off) in an ethanol-ice bath to 
avoid sample overheating. The final average size of the DNA was 400 bp. 
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2.5.2. Immunoprecipitation 
 200 µl of sonicated chromatin were pre-cleared with 60 µl protein A beads 
(Amersham) at 4
o
 C for 1h. The beads had been previously blocked with 5 mg/ml 
tRNA and 0.1 mg/ml BSA for 2 h and equilibrated with NE1 buffer. The beads were 
removed with a brief spin and the chromatin was incubated with rotation with 10 µl 
antibody (or nothing for the no antibody control) over night at 4
o
 C. The antibodies 
used in this study are shown in Table 2-4. Next day 60 µl of protein A beads 
prepared as above were added and the incubation continued for 3.5 h.  
  
Table 2-4. Antibodies used in ChIP. 
 
Company Affinity Catalogue no 
Upstate acH4K(5,8,12,16) 06-598 
Upstate acH3K(9,14) 06-599 
Upstate 3meH3K4 07-473 
Upstate 2meH3K9 07-441 
Upstate 3meH3K9 07-442 
Upstate 3meH3K27 05-851 
Upstate 3meH4K20 07-463 
 
The beads were collected by spinning the sample briefly and washed with 1 ml of the 
following buffers for 10 min: once with TSE I, four times with TSE II, 
once with Buffer III and thee times with TE buffer.  The beads were resuspended in 
100 µl TE buffer containing 50 µg RNase A (Sigma) and the RNA was digested at 
37
o
 C for 30 min. Then the beads were washed once more with TE buffer and 
resuspended in 150 µl TE buffer containing 0.5% w/v SDS and 100 µg/ µl proteinase 
K and the crosslinking was reversed at 65
o
 C overnight. Next day the DNA was 
extracted once with an equal volume of SAGE solution, precipitated with 
isopropanol in the presence of 5 µg glycogen and resuspended in 50 µl water. 
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2.5.3. PCR amplification 
 The primers used for the amplification of the distal enhancer of Oct4  from 
the immunoprecipitated DNA were 5’-TGACAGAGTGGAGGAAACG-3’ and 5’-
ACACACAGCTACACATAGCA-3’. The reactions were carried out in 40 µl 
volume with 1 U Taq DNA polymerase (Roche), 0.25 mM dNTPs (ABgene), 0.2 µM 
of each primer, in the reaction buffer provided by the manufacturer (contains1.5 mM 
MgCl2) on 4 µl of immunoprecipitated sample. The PCR program was 92
o
 C 20 sec, 
62
o
 C 30 sec, 72
o
 C 20 sec. The reaction was paused after 30, 35 and 40 cycles and 
10 µl were removed from the reaction and resolved in 3% agarose gel in 1x TAE 
buffer, with 0.5 µg /ml ethidium bromide. The image analysis and signal 
quantification was performed with the Scion Image software. 
2.6. MBD aff inity puri f ication (MAP) 
 The MBD affinity purification is used for the enrichment of methylated CpG 
islands from genomic DNA and has been modified from Cross et al. (1994). 
2.6.1. MBD and CxxC recombinant proteins 
 The plasmids carrying the MBD and CxxC constructs were kind gifts from R. 
Illingworth and Dr H. Jorgensen. The MBD protein used for the selective targeting of 
methylated CpGs had been cloned into the pet30b plasmid between the Nde I and 
EcoR I restriction sites (pet30MBD76-167) downstream of a T7 promoter. The MBD 
protein was derived from the MBD domain of human MeCP2 and consisted of amino 
acids 76-167 of the full protein, tagged carboxy-terminally with six histidines. The 
Nde I restriction site (CATATG) served as the initiation codon. 
 The CxxC protein used as a control in the EMSA, contains the third CxxC 
domain of the mouse MBD1 with some flanking sequence (amino acids 352-448 of 
the full-length long form of MBD1) that has been shown to specificaly bind non-
methylated CpGs (Jørgensen et al. 2004). It is tagged with six histidines at the 
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amino-end and cloned into the pet30b plasmid between the Hind III and EcoR I sites, 
downstream of a T7 promoter (pet30bCxxC). 
2.6.2. Expression and purification of the MBD and CxxC 
recombinant proteins 
  BL21 DE3 pLysS chemically competent cells, prepared by K. Adie, were 
transformed with either the pet30MBD76-167 or pet30bCxxC vectors. This E. coli 
strain contains an inducible T7 RNA gene under the control of the lacUV5 promoter. 
Induction with IPTG allows production of T7 RNA polymerase which then directs 
the expression of the target gene located downstream of the T7 promoter in the 
expression vector. The BL21 DE3 pLysS also carries the plasmid pLysS that 
constitutively expresses T7 lysozyme. T7 lysozyme is a natural inhibitor or T7 RNA 
polymerase and serves to minimize the basal expression level of potentially toxic 
gene products before induction, allowing tight control of expression. 1:4 of the 
transformation reaction was plated on LB-agar containing 50 µg/ml kannamycin 
(pet30b selection) and 34 µg/ml chloraphenicol (BL21 DE3 pLysS selection). A 
single colony was picked and was expanded to a 200 ml liquid culture in LB with 
antibiotics at 37
o
 C over night with vigorous agitation. The overnight culture was 
diluted 1:50 in fresh LB broth (usually 6 lt) with antibiotics and was allowed to grow 
at 37
o
 C until it reached an OD600 0.45-0.5. At this OD600 the bacteria are in their 
exponential phase of growth, in their optimum for protein production. When the 
culture reached the desired OD600, IPTG was added to a final concentration of 1 mM 
and the cells were allowed to grow at 37
o
 C for another 2 hours. Previous 
optimization of the induction had shown that this period is optimal for good protein 
production. 
 The cells were spinned at 4200 rpm for 30 min at 4
o
 C and were subsequently 
washed twice with ice-cold PBS. Next, the cells were drained from excess buffer and 
frozen at -80
o
 C for 3 hours. The freeze-thawing is causing the fracture of the thick 
bacterial cell wall and aids lysis. The cells were thawed in ice and resuspended in 30 
ml of Bacterial Lysis buffer per initial 1 lt of culture. 30 mg of lysozyme were added 
in 30 ml of lysate and the lysis of the cells was allowed for 30 min on ice. The cells 
where further disrupted with sonication with a Branson Sonifier S-450A, for 5 min at 
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30% output on setting 4, on ice. The lysate was precipitated at 4
o
 C at 17,000g for 20 
min and the supernatant was transferred to new tubes. 
 The cell lysate was next mixed with 1ml Ni-NTA sepharose beads 
(Amersham) for every initial 1.5 lt of culture and left at 4
o
 C for 2 h with agitation. 
The Ni-NTA beads had been previously equilibrated in Bead Wash buffer. After this 
period the beads were sedimented at 4
o
 C and resuspended in 5 bead volumes of 
Bead Wash buffer. The beads were washed a further twice and the protein was eluted 
with one bead volume of Elution buffer for 5-7 times. The efficiency of the 
purification was assed with SDS-PAGE gel electrophoresis. The protein-containing 
fractions were pooled and dialysed twice in 2 lt of Dialysis buffer over night. The 
dialysed protein was centrifuged to remove any non-soluble material. The protein 
concentration was calculated from the A260 measurement with a NanoDrop ND-1000 
spectrophotometre and stored at 4
o
 C for up to one week. 
2.6.3. SDS-PAGE (polyacrylamide gel electrophoresis) 
 The 15% acrylamide gel contained 0.4 M Tris-HCl (pH8), 0.1% w/v SDS, 
0.1% w/v APS and 1 µl/ml TEMED, added in this order. The 5% stacking gel 
contained 0.125 M Tris-HCl (pH6.8), 0.1% w/v SDS, 0.1% w/v APS and 1 µl/ml 
TEMED. Samples from the induction and purification steps were heated in 1x 
Laemmli buffer at 100
o
 C for 10 min and then cooled in ice before loading them in 
the gel. The electrophoresis was performed in 1x Tris-Glycine at 200V until the 
bromophenol blue front reached the bottom of the gel. The resolved protein was 
visualised by immersing the gel for 30 min in Coomassie blue stain and destaining 
over night in Coomassie destaining solution. 
2.6.4. Electrophoretic mobility shift assay (EMSA) 
 The methyl-CpG binding activity of the purified recombinant proteins was 
assessed with EMSA. No protein, 25 ng, 50 ng, 100 ng and 200 ng of MBD protein 
or 750 ng of control CxxC protein were incubated in room temperature for 5 min in 
1x Binding buffer and 1 µg of the non-specific competitor dAdT (Amersham) at a 
final volume of 18 µl. After this short pre-incubation period, 2 µl of methylated or 
unmethylated radioactive CG11 probe were added to the mixture and the complexes 
were allowed to form for 25 min in room temperature. The CG11 probe (Meehan et 
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al. 1989)  is 135 bp long and contains 27 CpGs (20 Hha I and 7 Hpa II sites). It was a 




 The formed complexes were resolved with electrophoresis in 1.3% agarose in 
0.5x TBE at 120 V for 4.5 h in 4
o
 C. The gel was dried under vacuum at 80
o
 C, 
exposed to a phosphor screen (Amersham) for 2 h and the signal was scanned with a 
STORM Phosphorimager (Amersham). 
2.6.5. Packing of the column 
 40-60 mg of recombinant protein were bound to 1.2 ml of Ni-NTA sepharose 
beads (Amersham) for 2 h as described previously (section 2.6.2). The beads were 
then washed at 4
o
 C twice with two bead volumes of 1:9 Column buffer A:Column 
buffer B, twice with two bead volumes of 1:9 Column buffer A:Column buffer B as 
before but in the presence of 10 mM imidazole and again another twice with two 
bead volumes of 1:9 Column buffer A:Column buffer B. Finally the beads were 
resuspended in 10 bead volumes of 1:9 Column buffer A:Column buffer B and 
packed onto a 1 ml Tricorn 5/50 (GE Healthcare) FPLC column at a flow rate of 
1ml/min using a peristaltic plumb. Each column was stored at 4
o
 C and was used for 
approximately ten runs. 
2.6.6. Preparation of genomic DNA for MAP 
 The brain genomic DNA was extracted as described in section 2.2.2 and the 
ES (E14) and RA10 DNA was extracted as described in section 2.2.1. 100-130 µg of 
high molecular weight genomic DNA were digested with 250 U of Mse I (New 
England Biolabs) in a reaction volume of 200 µl at 37
o
 C for two hours in the buffer 
recommended by the manufacturer. To ensure complete digestion of the DNA, 
another 250 U of enzyme were added after two and four hours and the reaction was 
allowed to proceed over night. Mse I (TTAA) is a frequent cutter that preferentially 
recognizes sequences outside CpG islands. With this first step many AT-rich non-
CpG island-like sequences are destroyed and the genome is divided into predictable 
Mse I fragments. After the end of the reaction, a fraction of the digested DNA was 
resolved in 1% agarose gel in 1x TAE buffer, with 0.5 µg /ml ethidium bromide to 
ensure complete digestion. 
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 To prevent self-ligation later, the digested DNA was dephosphorylated with 
80 U Calf Intestinal Phosphatase (New England Biolabs) at 37
o
 C over night, 
according to the manufacturer’s instructions. To assess the efficiency of the 
phosphatase treatment, a small fraction of the dephosphorylated DNA was incubated 
with 1U T4 DNA ligase (New England Biolabs) for 1 hour and resolved in 1% 
agarose gel in 1x TAE buffer, with 0.5 µg /ml ethidium bromide. The protocol was 
continued only if there was no shift in the average fragment size in comparison to the 
non-ligated digested DNA.  
 Next, the DNA was ligated with the adaptors that would later be used for its 
amplification. The adaptors were ordered as complementary oligonucleotides: 5’-
GGTCCATCCAACCGATCT-3’ and 5’-Pi-TAAGATCGGTTGGATGGACC-3’. 
They were mixed in equimolar concentrations, boiled for 10 min and allowed to 
slowly cool down at room temperature. This enabled their annealing into the double-
stranded adaptor, phosphorylated at the 5’ of the “sticky” end: 
   5’-GGTCCATCCAACCGATCT-3’ 
   3’-CCAGGTAGGTTGGCTAGAAT-Pi-5’ 
For, the ligation, the digested and dephosphorylated genomic DNA was mixed with 
an excess (10 µmol) of the adaptor and 3,200 U of T4 DNA ligase (New England 
Biolabs), in the buffer supplied by the manufacturer. The reaction was carried out in 
a final volume of 500 µl, at 16
o
 C, overnight.  
 At the end of the ligation reaction the solution was expected to contain 
mainly, Mse I-digested genomic DNA ligated to an adaptor at each end, free adaptors 
and self-ligated adaptors. The free adaptors and self-ligated 38-mers were removed 
with the QIAquick PCR purification kit (Qiagen). Since there were a big excess of 
adaptors in the reaction, Mse I-digested genomic DNA ligated to an adaptor at only 
one end and non-ligated Mse I-digested genomic DNA were not expected in 
significant amounts unless the ligation had been unsuccessful. To check the ligation 
efficiency, 20, 50 and 100 ng of ligated DNA were amplified with 0.4 µM universal 
primer (5’-GGTCCATCCAACCGATCTTA-3’), 2.5 mM MgCl2, 0.4 mM dNTPs 
(ABgene) and 1.5 U Red Hot Taq polymerase (ABgene), in a final volume of 25 µl, 
in the buffer supplied by the manufacturer. The cycling program was: 95
o
 C 2min, 
30x(95
o
 C 50 sec, 58
o
 C 50 sec,72
o
 C 3 min), 72
o
 C 7 min. The reactions were 
resolved in 1% agarose gel in 1x TAE buffer, with 0.5 µg /ml ethidium bromide and 
 75 
were inspected for efficient and comparable amplification of all DNA dilutions. The 
successful ligation reactions were precipitated, a small fraction was kept as the input 
and the remaining was resuspended in 1:9 Column buffer A: Column buffer B before 
running it through the MBD column. 
2.6.7. MBD affinity chromatography 
 The methyl-CpG island purification was performed on an ACTA purifier (GE 
Healthcare). The DNA sample was injected in the column and the methyl-CpG 
islands were eluted with a linear NaCl gradient (0.1 to 1 M, mix of Column buffers A 
and B) in 3ml fractions. A graphical overview of the elution program is given in 
Figure 2-1. To evaluate the degree of separation and to identify the methyl-CpG 
island containing fractions, 300 µl of each fraction were precipitated and 















Figure 2-1. Column run profiles. Plots showing the salt gradients used for the first and 
second column runs. The first gradient was always the same while the second depended on 
the salt concentration that was required for the non-specific and specific elution of DNA. 
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amplified using the diagnostic primers listed in Table 2-5. All the primers were 
designed so that they are not interrupted by an Mse I recognition site and they were 
specific for differential methylated regions (DMRs) of known methylation status in 
males and females. 2 µl of each fraction were  amplified with 0.3 µM of each primer, 
2.5 mM MgCl2, 0.4 mM dNTPs (ABgene), 5% v/v DMSO and 1.5 U Red Hot Taq 
polymerase (ABgene), in a final volume of 30 µl, in the buffer supplied by the 
manufacturer. The cycling program was: 95
o
 C 3min, 30x(95
o
 C 30 sec, 58
o
 C 30 
sec,72
o
 C 30 sec), 72
o
 C 10 min. The reactions were resolved in 2% agarose gel in 1x 
TAE buffer, with 0.5 µg /ml ethidium bromide. 
 The fractions that where identified to contain the methylated CpG islands 
were pooled, diluted to 0.1 M NaCl with Column buffer A and were passed through 
the column for a second time. The precise salt gradient of this second run was 
determined by the salt concentrations that appeared to elute DNA non-specifically 
and specifically in the first run (Figure 2-1). In more detail, it consisted of a linear 
NaCl gradient between the lowest and highest non-specific elution concentrations, 
then a wash at the highest salt concentration that does not elute methylated CpG 
islands and then linear gradient of the higher NaCl concentrations for the specific 
elution. Finally, the column was washed from remaining DNA with a long wash at 1 
M NaCl and re-equilibrated at 0.1 M NaCl. As before, the fractions were tested by 
PCR with the same diagnostic primers to identify the ones that contain the specific 
eluate that were pooled, precipitated and resuspended in 300 µl TE buffer. 
2.6.8. Preparation of the affinity-purified methyl-CpG 
islands for array hybidization 
 The MAP-purified methyl-CpG islands were amplified with the Universal 
primer described previously (section 2.6.6). In more detail 2 µl of the MAP-purified 
sample and 2 µl of 1:100 dilution of the input (pg range) were PCR amplified with 
1.8 µM of the primer, 2.5 mM MgCl2, 1 mM dNTPs (ABgene), 5% v/v DMSO and 
1.5 U Red Hot Taq polymerase (ABgene), in a final volume of 50 µl, in the buffer 
supplied by the manufacturer. The annealing temperature in the cycling program was 
58
o
 C and the elongation time 4 min. The number of cycles was kept in the linear 
range of amplification. The amplified DNA was cleaned from non-incorporated 
nucleotides, primers, salt and protein with the QIAquick PCR purification kit 
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(Qiagen), adjusted to a concentration of 250-500 ng/µl and send to Nimblegen 
(NimbleGen Systems, Inc.).  
 
Table 2-5. Diagnostic primers used in MAP 
DMR-gene Forward primer Reverse primer 
Igf2r TATCGGCCCTCGTGTAGTTC GAGGATTCCACGCGTTAGAG 
HPRT TCAGGCCCACCTAGTCAGAT CGGAAAGCAGTGAGGTAAGC 
Xist AATTAGGACACCGAGGAGCA TACGAGCACTCCTTGGCTTT 
Ccne GCTGGTCCACAGGAGACCTA CACTGTCCCTCCTGACTCGT 
Ddx 4 CTGGAGCGGAGAGGTGAGT GCCTCAGGCCTTCACACC 
 
2.6.9. Preparation of the custom-made mouse CpG 
island oligonucleotide ti l ing array 
 The database mining for the selection of the mouse genomic regions to be 
included in the array was carried out by Dr Alastair Kerr. Briefly, the mouse genome 
(NCBI build 34) was in silico digested with Mse I and repeat masked. Then, all the 
Mse I fragments that contained less than 100 nt of informative sequence or more that 
one third of low complexity sequence were removed. Of the remaining 
approximately three million Mse I fragments, only the ones that fulfilled our CpG 
island criteria, i.e. observed versus expected CpG ratio (o/e) equal or greater than 0.6 
and GC content equal or greater than 50%, were kept.  The CpG island criteria were 
applied in a window of 500 nt with a 50 nt step. Taking into consideration that the 
DNA had been fragmented, neighbouring Mse I fragments that fulfilled the criteria 
only when taken together were also included. The selected TTAA-flanked CpG 
island sequences were sent to the Nimblegen design team were they were scanned 
once more for regions of low complexity. The probes for each Mse I fragment were 
designed to be isothermic, tiled at 48 bp. At the end of this process the mouse CpG 
island array contained 26,687 TTAA-flanked sequences, represented by 385,215 
probes. 
2.6.10. Identification of the CpG islands 
 The CpG islands were assempled from the Mse I fragments by grouping 
together those fragments that were separated by less than or equal to 200 nucleotides 
 78 
of genomic sequence. The Mse I fragments that were grouped in this way were 
further screened according to their length and if two or more of them were covering a 
sequence less than 2500 nucleotides long then they were all grouped together as one 
CpG island. After this process, the 26,687 Mse I fragments were assembled into 
20,755 CpG islands. For the calculation of the position of a CpG island relative to a 
gene, those that were on the 5’ untranslated region, the first inton or the first exon 
were termed 5’-associated. Those that were on the 3’ untranslated region consisted 
the 3’-associated CpG islands and those that were not in the vicinity of any gene 
were intergenic. The remaining CpG islands that did not classify in any of the 
categories defined above, were characterised as intragenic.  
2.6.11. Normalisation and pre-processing of the array 
data 
 The returned array data were analyzed using the package Limma (Linear 
models for microarray data) (Smyth 2004) of R in Bioconductor 
(http://www.bioconductor.org).  
 The arrays were normalised using a variation of the composite Loess 
normalisation method based on observed data as suggested in Wang et al. (2002). 
The invariant probes used for the calculation of the Loess regression line were 
identified by having an M value (log2 of the two channel ratio) between -0.5 and 0.5, 
ie. very close to zero, after global Loess normalisation and it was ensured that the 
selected probes spanned the entire intensity range. After determination of the 
invariant probes, the raw hybridisation data were normalised by fitting them to the 
Loess regression determined by the invariant spots. Then statistical analysis of the 
microarray data was performed with an empirical Bayes model. A moderated t-
statistic test for differential enrichment was computed for each contrast for each 
gene. The confidence values produced by the t-statistic were expressed as q values 
for false discovery rate (Storey and Tibshirani 2003).  
2.6.12. Real-time qPCR verification of the MAP results 
 All the primers used for the real-time quantitative PCR (qPCR) on genomic 
DNA that was purified with the MAP method are shown in Table 2-6.  
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Table 2-6. Primers used in qPCR for the verification of microarray data. 
Region Mse I fragment Forward primer Reverse primer 
Br1-1 CHR1:6923991-6924628 GGCAGTGCATAGTGGGACT ACCCTGGTGAAGAACTGCATTG 
Br1-2 CHR1:186740536-186741471 GTCAGGGTAGGCTAAGGTGAG TTCCACACAGGACTTCAGCATTT 
Br2-1 CHR2:32266324-32267646 CTGTGGGTGACAGGATCT CGACGAGACGCACACTCAAG 
Br2-2 CHR2:74593463-74594377 CTGCTATTGTGACCTTCC TCGAGGCTTGCACACAGTCA 
Br2-3 CHR2:166928637-166929536 GAGAAGCCCAACTCATCGG ACTCATCGTGAGGAGCCAGGAG 
Br4-2 CHR4:88192272-88195185 GCCGTTCTCTCTCCTGTCA TCCCTTCCTAAGGCCCTCTCTA 
Br4-3 CHR4:134596644-134597844 GACTCTGGCTGGGGTAGAGAA GCCCAAGCTCCACATTGTCA 
Br5-1 CHR5:113129180-113130846 GAAATGTGTAGAGCAAGC AGGCTTTCTCTCCGTCGTGGT 
Br7-1 CHR7:4601268-4609003 CTTCACTTAGCACCATTGC TATTGTATGTTTGTGCGCCAGTG 
Br7-3 CHR7:21794900-21796927 GGACGACAAGGGCTATTTC GCTGGACCAGATGTGAGGACTG 
Br9-1 CHR9:121196775-121197768 GTTCAGAAAAGGGTCTGTTAGC CTGAGCAGTAGACAGGCGGTGT 
Br9-3 CHR9:121487252-121490211 CTCTCCCCACAGGCACTT GCAGGAAGGCTGGTATCGTTC 
Br10-1 CHR10:30622534-30623567 GGGAAGCGGGTGCTAGAG AGTCCAGCTCCCTTCCAGTCG 
Br11-1 CHR11:100683807-100684882 AAGATCATCCCTGGCTCT AAGCACAAGAACCCTGATGTCC 
Br15-1 CHR15:76258629-76266599 CAGCCAAAGTAGGAACAGC CTCCCTCCTCTTTGCACCTGTC 
Br15-2 CHR15:80455703-80457753 CTGGGTCTTGGTGCTAGATTAT GGAGCTGGACTGCGGAAAGAC 
Br16-1 CHR16:22107956-22108336 GGAAGCCGGACTTGATTT ACGTGCCACAGTCGATAAGCAT 
Br16-2 CHR16:93750542-93751116 TCCGATGTGACACACTTAC CAACCTTCCCTCTCATGGACTTC 
Br17-1 CHR17:33949358-33951691 GACCTCTAATCATTCGCTTTA CTGGTTCCCTCCGAAGTTTCC 
Br17-2 CHR17:5286533-5288507 TACCCGTGGAGCTTAGAGG CGACACTACCGAGCACATCCAG 
Br18-2 CHR18:37351238-37352485 AAGGGACTACGAACTCCACC GGGCCGTAGATGAGGACTCTG 
BrX1 CHRX:68614710-68616575 TAGTCAGGTGTGAGGTGTC AAGCTGGCCGCTGGTATCCT 
BrX2 CHRX:69632339-69632911 AGCCAGAAGAAAATGCAC ATGCTCTCACGGTCCAGGAAT 
BrX3 CHRX:12278734-12280449 GAGCACGCCGTCTAAGAA GTCGCCTCTACTCCCAAGCTG 
Dev1-2 CHR1:6383009-6385694 TCTGGCAGCTCTTGAAGA GGACTCCATGTCAGTCTCAACTCC 
Dev6-1 CHR6:17780608-17781540 TGGCTCCGTAAGTCGTCT CCTCCGCTGAGATACTGACATCC 
Dev7-2 CHR7:13920979-13921968 CATCCTTTGTGAGGTAAACC GGGAGGGACACGAGAAGACAGA 
Dev8-1 CHR8:118186994-118187994 GGAGGAGTTAGCGAGCCA TAGGTGTCGGCTATGTGCTTGG 
Dev10-1 CHR10:120756802-120757699 ACAAAAGAAACAGGAAGGG ACAAGTCCGGCATTGGGAAC 
Dev10-2 CHR10:14224996-14225901 TCAGCAGGTGCCCAGTC TTGCTCAACAAATATAAGGCATGA 
Dev10-5 CHR10:59389229-59390186 CCCAATCTTGTTGGCAACGTC AGTCAATACCCTGATAAGGCC 
Dev11-2 CHR11:106127743-106128527 CACAGCCAATGAGCATGA CTTCACCTTCAGCAGCCTCACT 
Dev12-1 CHR12:52087446-52087926 CTTGCGCTCCAGAGTCTG ACCACAGCCGAGGGACTCTT 
Dev14-2 CHR14:40176456-40177819 CTCTATGACATGCACAGG AGGGACCCGTGCCTGTAGTCT 
Dev17-1 CHR17:85056684-85057302 TTGAACAAACTTGGGTGC AGAGGGCAAAGCGCAACTCT 
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24 Mse I fragments that showed various distributions of their M values in the brain 
microarray experiment were selected and qPCR primers were designed for them. 
qPCR was performed on 10 ng of the MAP-enriched and input PCR-amplified DNA 
from two female and one male samples (six female and three male individuals). The 
PCR reactions were performed in triplicates under similar conditions as described in 





where ĊT(MBD) is the mean threshold cycle of the MAP-enriched samples and ĊT(MBD) 
is the mean threshold cycle of the input samples. 
 The Mse I fragments that were consistently enriched in the RA10 samples but 
not in the samples from ES cells were identified according to the following criteria: 
M value equal to or less than 0 in the ES microarrays and equal to or less than 2 in 
the RA10 microarrays for more than 90% of the probes of each Mse I fragment. This 
process identified 24 potentially enriched Mse I fragments. For the verification of the 
enrichment, 12 fragments were randomly selected from the 24 identified by the 
microarray experiment and qPCR primers were designed for them. qPCR was 
performed on equal volumes of the ES and RA10 DNA. Equal quantities of input 
DNA from these two sources had been used for MAP purification, so PCR on equal 
volumes of the MAP-purified DNA could determine whether a fragment was 
enriched in one sample relative to the other. The PCR reactions were performed in 
triplicates under similar conditions as described in section 2.4.4. The formula used 




where ĊT(RA10) is the mean threshold cycle of the RA10 samples and ĊT(ES) is the 
mean threshold cycle of the ES cell samples. 
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2.7. Solut ions 
 The solutions used in all the protocols described are listed here in 
alphabetical order. 
 Bacterial Lysis buffer: 50 mM sodium phosphate buffer (pH 8), 300 mM 
NaCl, 10% v/v glycerol, 10 mM Imidazole, 15 mM β-mercaptoethanol, 0.5 mM 
PMFS  
 Bead Wash buffer: 50 mM sodium phosphate buffer (ph 8), 300 mM NaCl, 
10% v/v glycerol, 20 mM Imidazole, 15 mM β-mercaptoethanol, 0.5 mM PMFS 
 1x Binding buffer: 6 mM Tris-HCl (pH 8), 6 mM MgCl2, 150 mM NaCl, 3% 
glycerol, 1 mM DTT, 10 ng/µl BSA 
 Bisulfite solution: 3.1 M sodium bisulfite dissolved in the presence of 0.6 M 
NaOH, 0.5 mM hydroquinone previously dissolved in water at 55
o
 C, pH 5 
 Buffer III: 0.25 M LiCl, 1% v/v NP-40, 1% w/v deoxycholate, 1 mM EDTA, 
10 mM Tris-Hcl (pH 8.1) 
 Church and Gilbert buffer (modified): 0.5 phosphate buffer (pH 7.2), 10 mM 
EDTA, 7% w/v SDS  
 Column buffer A: 20 mM Hepes (pH 7.9), 0.1 % v/v Triton X-100, 10% 
glycerol, 0.5 mM PMSF, 10 mM β-mercaptoethanol 
 Column buffer B: 1M NaCl, 20 mM Hepes (pH 7.9), 0.1 % v/v Triton X-100, 
10% glycerol, 0.5 mM PMSF, 10 mM β-mercaptoethanol 
 Coomassie blue stain: 45% v/v methanol, 10% v/v acetic acid, 1g/lt 
coomassie blue 
 Coomassie destaining solution: 5% v/v methanol, 7.5% v/v acetic acid 
 Dialysis buffer: 50 mM sodium phosphate buffer (pH 8), 300 mM NaCl, 10% 
v/v glycerol, 15 mM β-mercaptoethanol, 0.5 mM PMFS  
 Elution buffer: 50 mM sodium phosphate buffer (pH 8), 300 mM NaCl, 10% 
v/v glycerol, 250 mM Imidazole, 15 mM β-mercaptoethanol, 0.5 mM PMFS  
 1x Laemmli buffer: 62.5 mM Tris-HCl (pH 6.8), 10% v/v glycerol, 1.25% 
w/v SDS, 2.5 % v/v β-mercaptoethanol, bromophenol blue 
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 Luria-Bertani (LB) broth: 10 g/lt bacto-tryptone, 5g/lt bacto-yeast extract, 
10g/lt NaCl 
 LB-agar: LB broth with 1.5% agar-agar 
 Lysis buffer I: 0.5 M Tris-HCl (pH8), 20 mM EDTA, 10 mM NaCl, 1% w/v 
SDS, 0.5 mg/ml proteinase K 
 Lysis buffer II: 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 100 mM NaCl 
 1x MOPS buffer: 20 mM 3-[N-morpholino]propanesulfonic acid, 5 mM 
sodium acetate, 1 mM EDTA, pH 7 
 NE1 buffer: 20 mM HEPES (pH 7), 10 mM KCl, 1 mM MgCl2, 0.5 mM 
DTT, 0.1% v/v Triton X-100, 20% v/v glycerol, 200 mM NaCl, protease inhibitor 
cocktail (Roche) 
 PBS: 137 mM NaCl, 10 mM Phosphate (pH 7.4), 2.7 mM KCl 
 RA stock solution: 100 mM all-trans retinoic acid in DMSO 
 1x RNA loading buffer: bromophenol blue, 30% v/v formamide, 20% v/v 
glycerol, 4 mM EDTA, 0.88 M formaldehyde, 0.4x MOPS buffer 
 SAGE solution: 25:24:1 v/v/v phenol:chlorophorm:isoamyl alcohol (pH 8) 
 10x SSC buffer: 0.15 M trisodium citrate (pH 7), 1.5 M NaCl 
 1x TAE buffer: 0.04M Tris-acetate (pH 8.3), 2mM Na2EDTA  
 0.5 TBE buffer: 445 mM Tris-HCl, 1 mM Na4EDTA, 445 mM boric acid 
 TE buffer: 10mM tris (pH 7.5), 1mM EDTA 
 1x Tris-Glycine buffer, 3g/lt Tris-HCl, 14.4g/lt glycine, pH 6 
 TSE I: 0.1% w/v SDS, 1% v/v Triton X-100, 2 mM EDTA, 20 mM Tris-HCl 
(pH 8.1), 150 mM NaCl 
 TSE II: 0.1% w/v SDS, 1% v/v Triton X-100, 2 mM EDTA, 20 mM Tris-HCl 
(pH 8.1), 500 mM NaCl 
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3. The role of DNA methylation in early 
development through regulation of 
the pluripotency transcription factor 
OCT4 
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3.1. Pluripotency transcript ion factors 
 Transcription factors that are necessary for the maintenance of pluripotency 
are termed pluripotency transcription factors. These factors are downregulated as the 
cells differentiate and thus are not the general transcription factors or co-factors that 
are expressed in many cell types. They are experimentally identified as the products 
of genes that, when knocked down, prevent maintenance of the stem cell character of 
the cells in culture. In their absence, expression of stem cell markers such as alkaline 
phosphatase is lost, differentiation markers are induced and/or the typical embryonic 
stem (ES) cell morphology changes to more flattened, larger cells that grow as a 
monolayer.  
 The first pluripotency factor identified was OCT4 (Niwa et al. 2000; Nichols 
et al. 1998), the product of the Pou5f1 gene, while now NANOG (Chambers et al. 
2003) and SOX2 are also widely accepted as important pluripotency factors. The list 
is slowly growing with ESRRB, RIF1, FOXD3 and TBX3 (Ivanova et al. 2006; Loh 
et al. 2006; Hanna et al. 2002) but more studies are required to establish the role of 
these factors in self-renewal and pluripotency. Pluripotency transcription factors are 
very interesting as they suggest the possibility of a rather simple way to de-
differentiate somatic cells just by forcing their re-expression (Okita et al. 2007; 
Takahashi and Yamanaka 2006; Wernig et al. 2007). These reverted pluripotent cells 
could then be moulded into any cell type needed in research and medicine. 
Identification of the targets of these factors provides further understanding of how 
pluripotency and differentiation is brought about, while elucidation of how these 
transcription factors are themselves regulated can answer fundamental questions 
about the timing and specificity of gene transcription.  
3.1.1. Targets of pluripotency transcription factors 
 Chromatin immunoprecipitation of OCT4, NANOG and SOX2 coupled with 
microarray hybridisation (Boyer et al. 2005) or DNA-tag sequencing strategies (Loh 
et al. 2006) has shown that they share a large proportion of their target genes.  These 
target genes in mouse can be classified as genes involved in transcription, 
morphogenesis, organogenesis, development, and metabolism. In human, a 
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prominent class of genes regulated by these transcription factors is the homeodomain 
gene family (Boyer et al. 2005). Only 9.1% of OCT4-bound genes and 13% of 
NANOG-bound genes are common to both human and mouse. This could be 
attributed merely to the different experimental approaches, or could imply that there 
are different mechanisms for conferring pluripotency in mouse and human. An 
interesting outcome of the analyses presented here is that pluripotency transcription 
factors seem to invariably regulate both themselves and each other, forming a 
complex regulatory network of feedback and autoregulatory loops.  
 OCT4 and NANOG appear to bind discrete regions in the shared promoters 
(Loh et al. 2006), while OCT4 and SOX2  form a heterodimer and synergistically 
bind to their targets (Nishimoto et al. 1999; Yuan et al. 1995).  Correspondingly, 
NANOG appears to be able to form a heterodimer with another protein, SALL4, and 
co-occupy at least some of the NANOG target genes (Wu et al. 2006).   
3.1.2. Regulatory interactions of pluripotency 
transcription factors 
 As mentioned in section 3.1.1, a characteristic of the pluripotency 
transcription factors is that they regulate the transcription of themselves and each 
other. Chromatin immunoprecipitation with OCT4, NANOG and SOX2 antibodies 
revealed they interact with their own regulatory regions as well as each others’ 
(Boyer et al. 2005). Depletion of Oct4 with RNAi resulted in the downregulation of 
Nanog and similar depletion of Nanog resulted in the downregulation of Oct4 (Loh et 
al. 2006).  Sox2, Esrrb and Rif1 were also downregulated in both cases. Moreover, 
there is clear evidence that the OCT4-SOX2 heterodimer is responsible for the 
activation of Oct4 and Nanog ( Okumura-Nakanishi et al. 2005; Rodda et al. 2005), 
and that OCT4 binding in the Sox2 enhancer regulates its activity (Catena et al. 
2004). Finally, chromatin immunoprecipitation and reporter assays have shown that 
NANOG is responsible for the activation of its partner, SALL4, and vice versa, 
probably as a NANOG-SALL4 heterodimer (Wu et al. 2006). A simple diagram of 







Figure 3-1. Known regulatory interactions of pluripotency transcription factors. The 
arrows symbolize transcription activation. Block arrows and letters represent well-studied 
interactions, whereas thin arrows and letters, interactions supported by limited evidence. The 
formation of heterodimers between pluripotency factors is not taken into account for this 
model.(Catena et al. 2004; Rodda et al. 2005; Okumura-Nakanishi et al. 2005; Loh et al. 
2006; Wu et al. 2006). 
 
3.1.3. The pluripotency transcription factor OCT4 
 OCT4 was first discovered by Schöler et al. (1989a; 1989b) as an octamer 
motif-binding activity present in progenitor germ cells, oocytes, ES cells and 
embryonic carcinoma (EC) cells . This binding activity was lost upon in vitro 
differentiation of ES and EC cells. Reporters under the control of an octamer motif-
containing promoter were active in ES cells and became silenced as these cells 
differentiated . This reporter was specifically expressed in the inner cell mass (ICM) 
of the mouse blastocyst. These experiments were establishing what is now widely 
known: OCT4 is an octamer motif-binding transcription factor that is present in the 
oocyte, ICM and germ cells and its expression is lost as the cells differentiate. 
 The Oct4 gene (ENSMUSG00000024406, Figure 3-2) is approximately 5Kb 
long, has 5 exons and encodes a protein of 376 amino acids. The first thorough 







Figure 3-2. Structure of the Oct4 gene and its upstream region. An alternative start site 
has been reported 63 bp downstream of the indicated start site. The longer transcript version 
is used for position numbering with reference to the transcription start site. The position of 
the CpG dinucleotides is shown. UTR: untranslated region. The map has been based in 
deletion analyses (Yeom et al. 1996) and the conservation of the regions between mouse, 
human and cow (Nordhoff et al. 2001). 
 
 
by Yeom et al.  (1996) and it identified a promoter (P), a proximal (PE) and a distal 
enhancer (DE). By introducing  deletion constructs in mouse embryos, the authors 
showed that the promoter region is sufficient for reporter expression, the DE is 
necessary for expression in the ICM (and ES cells) and the germ cell lineage, while 
the PE is important for activation of the reporter in the post-implantation epiblast (as 
well as in embryonal carcinoma, EC, cells). This discrete role of the two enhancers 
suggests there must be a molecular “switch from distal to proximal enhancer activity 
around implantation” (Ovitt and Schoeler 1998). 
 In more detail, the promoter, which is approximately 60bp from the 
transcription start site, contains a putative Sp1/3 recognition site and a retinoic acid 
response element (RARE)-like sequence that partially overlap. It has been shown 
that the Sp1/3 element is occupied in undifferentiated ES and EC cells, but the 
occupancy is lost upon in vitro differentiation (Minucci et al. 1996). Furthermore, the 
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same study showed that an intact Sp1/3 site is necessary for the transcriptional 
activation of a reporter with the Oct4 promoter. It is interesting that Nanog has also 
been reported to contain functional Sp1/3 binding sites in its promoter (Wu and Yao 
2006). Nevertheless, in another study (Schoorlemmer et al. 1994), deletion of Sp1 
had no effect in Oct4 expression indicating functional overlap with Sp3 or some 
other GC-box binding transcription factor.  
 The GC-box binding orphan nuclear receptor SF1 has also been implicated in 
the activation of Oct4 in EC cells through binding to the promoter at the RARE 
element (Barnea and Bergman 2000) and Fuhrmann et al. (2001) showed that 
displacement of SF1 by GCNF is necessary for Oct4 repression. The interaction of 
GCNF with the Oct4 promoter in vivo was confirmed by immunoprecipitation of the 
Oct4 promoter with an anti-GCNF antibody shortly after RA-induced differentiation 
of ES and EC cells  (Gu et al. 2005b). The same study showed that GCNF-/- ES cells 
failed to downregulate Oct4, Nanog, Sox2 and other pluripotency markers upon 
induction of differentiation with RA, suggesting a more general role of GCNF in the 
regulation of pluripotency transcription factors. Except from the factors discussed 
here, many hormone receptors have been shown to bind the Oct4 RARE in vitro and 
to exert some influence in the expression of reporter constructs containing the RARE 
element. These results however, are contradictory to the results of other researchers 
and there is no in vivo evidence for their support. 
 Much less is known about the factors that bind and regulate the activity of the 
two enhancers, both of which contain conserved RARE-like elements (Nordhoff et 
al. 2001). Chromatin immunoprecipitation with anti-LRH-1 antibody can precipitate 
the PE in ES cells (Gu et al. 2005a). Moreover, in concordance with the observation 
that the PE is important for maintaining Oct4 expression at the epiblast stage, the 
same authors show that disruption of LRH-1 has no effect on Oct4 expression at the 
inner cell mass (ICM), but causes dramatic reduction of its expression after 
implantation. They also show that there may be some functional overlap with the 
closely related receptor SF-1 and suggest a role of LRH-1 on promoter activation. 
 NANOG binds the entire region that spans the two enhancers, while OCT4 
binds to the DE (Loh et al. 2006) but nothing is yet known about the functional 
significance of these interactions. 
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 Interestingly, downregulation of DICER with siRNAs reduced the mRNA 
levels of Oct4, as well as Nanog and Sox2 by about a half, giving rise to the 
argument that transcription of these pluripotency factors may also be regulated by 
RNA interference (Cui et al. 2007). 
3.1.4.  Epigenetic regulation of Oct4 
 Five years ago it was discovered that at least four CpG dinucleotides in the 5’ 
upstream region of Oct4 quickly gain methylation after implantation (Gidekel and 
Bergman 2002). The same sites were unmethylated in EC cells and methylated in the 
trophoblast, pointing to some epigenetic regulation of Oct4 expression. It was later 
shown that indeed Oct4 can be reactivated in trophoblast and fibroblast cells after 
treatment with 5-aza-2’-deoxycytidine and trichostatin A (Hattori et al. 2004).  
Thorough methylation analysis showed that the Oct4 promoter region is 
unmethylated in the cells where the gene is expressed and methylated where it is not. 
Furthermore, the active promoter is associated with H3 acetylation and this 
modification is lost in the silenced gene. Interestingly, H4 acetylation levels do not 
change.  
 The question was obvious, is methylation regulating Oct4 expression or is it a 
secondary modification? Sato et al. (2006) investigated how the Oct4 mRNA levels 
compare with the methylation levels in selected regions of P, PE and DE. They found 
that Oct4 levels seemed to be well into decline before methylation appeared. Further 
investigation showed that the Oct4 repressor GCNF co-immunoprecipitates with 
DNMT3a and DNMT3b and that GCNF and DNMT3a overexpression cause Oct4 
promoter hypermethylation. Detailed analysis of the methylation levels at the 
promoter (Gu et al. 2006) showed that embryos without a functional GCNF can not 
methylate the Sp1/3- RARE region of the promoter, although the methylation of the 
rest of the promoter is comparable to the wild-type, and causes the ectopic 
expression of the gene. They also showed that GCNF sequentially recruits MBD3 
and MBD2 (in this order) to suppress transcription. As expected from the 
specificities of MBD2 and MBD3, GCNF and MBD3 binding is indifferent to 
methylation, whereas MBD2 requires methylation for binding to the Oct4. However, 
the need for DNA methyltransferases for the downregulation of Oct4 remains 
controversial; Gu et al. showed that DNMT3a/b -/- ES cells fail to methylate the 
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promoter of Oct4 upon differentiation although the gene can be downregulated. On 
the other hand, Jackson et al. (2004) observed the opposite: DNMT3a/b -/- cells can 
not downregulate Oct4. The main difference between these two observations was the 
strategy followed for the differenciation of ES cells and the downregulation of Oct4. 
While Jackson et al. (2004) differentiated the cells by simple LIF removal, Gu et al. 
(2006) differentiated the ES cells by LIF removal and addition of retinoic acid (RA). 
Another difference between the two approaches is that Jackson et al. (2004) 
emphasise that the mutant cell lina was of advanced passage number, something that 
they had previously shown to affect the global DNA methylation levels in these cells. 
Gu et al. (2006) on the other hand do not mention the passage number of the cells 
they used. An interesting observation made by Feldman et al. (2006) that the Oct4 
promoter in DNMT1-/- fibroblasts appears to be less methylated than in wild-type, 
indicating that DNMT1 could also be an important player.  
 Regarding the histone modifications associated with the active and idle Oct4 
promoter, Sato et al.  (2006) showed that silencing is accompanied by a reduction in 
the levels of the active chromatin modifications acetylH3K9/14 and trimethylH3K4 
but no significant alteration in trimethylH3K9 or trimethylH3K27. They observed a 
reduction at dimethylH3K9. However, Feldman et al. (2006) disagreed as they saw 
an increase in di- and tri-methylH3K9 levels at the promoter and it was initiated 
before the onset of transcriptional repression. They investigated this further and 
found that the H3K9 methyltransferase G9a is responsible for this modification. 
They hypothesised that methylation of H3K9 is needed for DNMT3 binding to the 
promoter and long-term silencing of Oct4 but not for repression initiation. The link 
between the G9a-driven and the GCNF-induced silencing of Oct4 still remains to be 
discovered. 
3.1.5. Aims 
 Despite the recent intensive research on Oct4 regulation there are still many 
questions that remain unanswered. The aim of this study was to investigate how and 
why DNA methylation is established at the Oct4 upstream region. In more detail, the 
exact time when DNA methylation first appears with regards to the transcriptional 
status of the gene, as well as the pattern with which it is established was investigated. 
Appreciating that most of the previous studies on Oct4 methylation were either of 
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low resolution or focused on the promoter of the gene, the entire upstream region 
with all three regulatory elements was examined on each CpG position during the 
course of the gene’s downregulation. It was expected that, given the previous 
knowledge of the important upstream regions that are occupied at different 
differentiation stages, as well as the transcription factors that bind to the different 
regulatory elements, such a study would make clearer what the molecular trigger that 
leads to DNA methylation at this locus is. Finally, in order to achieve this goal, an 
appropriate differentiation model system is established for the investigation of Oct4 
downregulation.  
3.2. Establishment of the in vitro  di fferentiat ion 
system  
 In vitro differentiation of ES cells into embryoid bodies (EB) is a technique 
that models the events of early development and is the first step in many protocols 
for directed differentiation of ES cells into specific cell types. Leahy et al. (1999) 
have shown that all the main cell lineages are present in EBs and the timing of their 
appearance matches closely that of the early embryo. During EB formation, the cells 
initially aggregate into compact masses. Later, through a program of apoptosis and 
cell contact-mediated interactions very similar to those that take place during in vivo 
differentiation, they form a cavity that bears similarities to egg cylinder-stage 
embryos (Choi et al. 2005). 
 In vitro differentiation of ES cells has the obvious advantage that the time, 
cost and ethical issues associated with harvesting embryos are overcome. Moreover, 
it allows the easy production of large quantities of differentiated material, which 
furthermore can be of much purer cell lineage than in the embryo. On the other hand, 
in this system, the environmental differentiation stimuli that are present in vivo are 
missing; there is no maternal environment or embryonic trophectoderm, which in 
turn means that not all the events of early development can be recapitulated in vitro. 
Finally, it should not be forgotten that the starting point of differentiation is not the 
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inner cell mass (ICM) but ES cells, which, although are derived from it, are not 
equivalent to it. Dispite its drawbacks, in vitro differentiation of ES cells has been 
judged to be appropriate for the investigation of the mechanism of Oct4 
downregulation. Oct4 is active in ES cells as it is in the ICM and silenced in EBs like 
in the differentiated embryo. The lack of maternal signals or trophectoderm does not 
appear to influence this process. Assuming realistically that there is only one 
mechanism for Oct4 silencing, in vitro differentiation of ES cells provides a good 
system for the purposes of this research work.  
 There are two common methods to induce differentiation of ES cells. The 
simplest way is to remove LIF and allow the cells to grow in suspension. This 
method relies on blocking the LIF-STAT3 pathway that promotes pluripotency. The 
alternative method requires the addition of RA too. RA is an activator of 
morphogenesis, development, and cell differentiation through the activation of 
retinoid receptors.  Both methods have been applied in the past for varied 
differentiation periods in the investigation of the Oct4 regulatory mechanism, making 
it difficult to combine the information from different laboratories. Here the two 
methods are interrogated in terms of their potential for silencing and methylation of 
Oct4. 
3.2.1. RA-induced differentiation of ES cells is the most 
efficient method for Oct4 silencing 
 E14 ES cells were differentiated by removal of LIF for three, seven, fourteen 
and twenty one days (EB3, EB7, EB14 and EB21). Alternatively, RA was added to 
the medium after three days of LIF removal and the differentiation continued for 
another two and four days (RA2 and RA4). Northern hybridisation of RNA extracted 
from each differentiation stage (Figure 3-3) showed that Oct4 down-regulation was 
quicker and more efficient after RA treatment. Three days after LIF removal the 
Oct4 levels had dropped by 20% and then stayed almost stable even after twenty one 
days of differentiation (samples EB3-EB21). At this stage the embryoid bodies were 
not looking healthy and the cells were dying. In the RA samples by contrast, the Oct4 
levels went down to 50% after only two days after addition of RA. 
 Next, the degree of DNA methylation in the Oct4 promoter at each stage of 
differentiation in these samples was analysed (Figure 3-4). DNA extracted from tail  
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Figure 3-3. Expression analysis of Oct4 during differentiation by LIF removal or 
addition of RA. E14 ES cells (ES) were allowed to differentiate in vitro by LIF removal for 3, 
7, 14 and 21 days (EB3, EB7, EB14 and EB21), or, after 3 days of LIF removal, RA was 
added to the medium to a final concentration of 1µM for 2 and 4 days (RA2 and RA4). The 
top panel shows hybridisation against a probe for the entire last exon of Oct4 and the bottom 
panel shows the control hybridization against S26. The numbers below the picture indicate 
the Oct4 signal at each stage as a fraction of the signal in ES cells, after correction for equal 
loading. 
 
tips was also analysed as a control of the natural methylation levels of DNA 
methylation at the Oct4 promoter in finally differentiated cells. As expected, ES cells 
do not have any methylation, while methylation at the terminally differentiated tail 
cells is very high, reaching 45% (Figure 3-4, A). Differentiation by removal of LIF 
does induce some methylation establishment at the promoter but the process appears 
to be again very slow and inefficient and the methylation after twenty one days does 
not exceed 13% (Figure 3-4, B). On the other hand, addition of RA to the 
differentiation medium accelerates the methylation process and makes it more 
efficient; only four days after addition of RA (seven days without LIF) the 
cellsachieve 29% methylation (Figure 3-4, C).  Interestingly, methylation is not 
gained gradually after RA addition. The promoter remains unmethylated for the first 
two days and then, within the next two days (approximately two cell duplications), 
methylation appears.  
 Because of these results, all the subsequent in vitro differentiation 
experiments were conducted with the RA method.  
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Figure 3-4. Methylation analysis of the promoter region of Oct4 during differentiation 
by LIF removal or addition of RA. The region from -200 to +100 (+55) (left to right for each 
cell type) with respect to the transcriptional start site is analysed. Methylated and non-
methylated CpGs are denoted by filled and empty circles respectively. The calculated 
percentage methylation is shown next to the data. (A) Methylation analysis of the Oct4 
promoter in pluripotent ES cells and terminally differentiated cells from the tail tip. (B) 
Methylation analysis during the course of in vitro differentiation of ES cells to embryoid 
bodies by LIF removal. (C) Methylation analysis during the course in vitro differentiation of 
E14 ES cells to embryoid bodies by addition of RA (after three days of LIF removal).  
3.2.2. The RA-induced in vitro differentiation is 
reproducibly recreating events of early development 
 Before proceeding with examining the epigenetic regulation of Oct4, the 
reproducibility of the chosen differentiation program needed to be verified. Two sets 
of RA-induced embryoid bodies were produced from E14 ES cells (I and II) and 






Figure 3-5. Expression of developmental markers during the course of in vitro 
differentiation of E14 ES cells. Two sets of embryoid bodies (I and II) were produced from 
E14 ES cells by removal of LIF for three days (EB3) and then addition of RA to the medium 
for the indicated number of days (RA2 to RA6). + : reverse transcribed RNA,  – : mock-
reverse transcribed RNA. Whenever a marker could not be detected in the embryoid bodies, 
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a positive control (+ve) was included to verify the reaction worked. A water negative control 
was included in all reactions. (Continues in next page)  
 
Figure 3-5 (Continued) M is the molecular weight marker. (A) Endodermal markers: 
transthyretin (TRA), SRY-box containing gene 17 (Sox17), transferring (TTR), hepatic 
nuclear factor 4 alpha (Hnfα), albumin (Alb). (B) Mesodermal markers: foetal liver kinase 1 
(Flk-1), homeobox protein NK-2 homolog E (Nkx2.5). (C) Ectodermal markers: fibroblast 
growth factor 5 (Fgf5), SRY-box containing gene 1 (Sox1), homeo box msh-like 3 (Msx3). 
(D) Stem cell marker: RNA exonuclease 1 homolog (Rex1). (E) Loading control: 
glycerinaldehyde-3-phosphate dehydrogenase (Gapdh). 
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 In both sets a variety of endodermal markers (Figure 3-5, A) was induced but 
not the hepatic marker Hnfα or the visceral endoderm marker albumin. None of the 
mesodermal markers (Figure 3-5, B) tested could be detected, while the primitive 
ectodermal marker (Figure 3-5, C) Fgf 5 could be detected since early. Other 
ectodermal markers that are typical of the neurectoderm (Sox1 and Msx3) could also 
be detected, but at later stages of differentiation. Finally, the ES cell marker Rex1 
(Figure 3-5, D) was downregulated as expected although in varying degrees, which 
indicates the persistence of some ES cells despite the differentiating environment and 
is to some degree expected. These results show that three days of LIF removal and 
then addition of RA can successfully differentiate ES cells towards different cell 
lineages in a reproducible way. 
3.3. DNA methylat ion of Oct4  during in vi tro 
differentiation and i ts effect in the gene’s 
expression 
3.3.1. There are distinct methylation patterns in the 
different regulatory elements of Oct4 
 Methylation at the promoter of Oct4 has been linked with its transcriptional 
status. Nevertheless, until very recently there was no detailed information on the 
establishment of the methylation pattern and how it correlates with transcription. 
Appreciating this gap in our knowledge, the methylation pattern of the Oct4 5’ 
upstream region as it is being established during in vitro differentiation of E14 ES 
cells was analysed. Figure 3-6 shows the time course of Oct4 downregulation during 
the in vitro differentiation program used.  
 The results of the detailed bisulfite analysis of the entire Oct4 upstream 
region as well as small part of the gene itself are shown in Figure 3-7. As Feldman et 




Figure 3-6. RT-qPCR expression analysis of Oct4 in differentiating E14 ES cells. This is 
the average of five experiments. The error bars are the standard error of the mean for each 
differentiation point. The Oct4 levels were normalised against gapdh and are represented 
here as fractions of the levels in ES cells. 
 
methylation-sensitive PCR analysis, establishment of methylation appears to happen 
after the downregulation of transcription. In consequence, in EB3 Oct4 levels are 
already decreased by half (Figure 3-6) but there is no sign of methylation in any of 
the examined regions (Figure 3-7). Methylation appears to start soon after RA2, 
when the mRNA levels of the gene have almost reached their minimum.  
 What has not been published previously is a thorough bisulfite analysis along 
the Oct4 upstream region that includes all regulatory regions and all non-functional 
DNA. This information, taken together with the known distinct regulatory functions 
of the DE, PE and P in Oct4 expression, could provide invaluable information on 
whether methylation is specific to the regions that play a role in the gene’s 
expression in ES cells, or happens indiscriminately throughout the region. 
 In order to perform the analysis in each individual regulatory and non-
regulatory element, the entire region was divided into seven segments as shown in 
Figure 3-7. Segment A contained the DE, segment C the PE, segment B was the 
region between the two enhancers and segment was E the region between the 
promoter and the PE. Finally, the promoter was subdivided into two segments; 
segment G contained the first few CpGs of the transcribed region and the Sp1/3-




Figure 3-7. Bisulfite analysis of the entire upstream region of Oct4 during in vitro 
differentiation of E14 ES cells. The arrowheads show the positions and direction of the 
primers used for walking across the region. A, B, C, D, E, F and G refer to the segments 
used for the statistical analysis in Figure 3-8. The positions of the regulatory elements in 
reference to the transcription start site are shown. DE, distal enhancer; PE, proximal 
enhancer; P, promoter; G, gene. Filled circles represent methylated CpGs and empty ones 
non-methylated CpGs.  
 
shown to include any transcription factor binding sites. The methylation frequency in 
each of these segments was calculated for RA4 and RA6 (Figure 3-8). These two 
differentiation points were selected for the analysis to represent the initiation and 
advanced stage of de novo methylation respectively. These methylation frequencies 

































































Figure 3-8. Methylation frequency for each element of the Oct4 upstream region in the 
course of in vitro differentiation of E14 ES cells. The methylation frequency was 
calculated for RA4 (A) and RA6 (B) from the bisulfite data in Figure 3-7. The frequencies 
were calculated as number of methyl-CpGs over the total number of CpGs in each segment. 
The data were analysed pairwise with the Wilcoxon two sample rank test, * p≤0.05 and ** 
p≤0.01. The error bars show the standard error of the mean as calculated for the among 
clone variation per segment. 
 
the methylation is non-uniform among the examined segments. Comparable results 
were obtained with the Kolmogorov-Smirnov test. 
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 At the initiation of de novo methylation (Figure 3-8, A), the PE, which has a 
role in Oct4 expression in the epiblast and has been shown to lose LRH-1 occupancy 
when repressed, appeared to be preferentially methylated in comparison to the DE 
and the Sp1/3-RARE containing segments. The first CpG upstream of the 
transcription start position (Figure 3-7) was virtually devoid of methylation, 
something that has also been observed by Gu et al. (2006). Methylation between 
consecutive elements did not show a significant variation, indicating that methylation 
might be established in specific regions and then “leak” sideways. As the 
establishment of the methylation pattern progressed (Figure 3-8, B) methylation 
increased throughout the upstream region of Oct4. However, the DE and the Sp1/3-
RARE containing segments (A and G) continued to have very low methylation 
levels. At this stage, the F fragment of the promoter region also had significantly 
higher methylation levels than the more upstream G fragment and the DE. The 
fragments that do not contain any regulatory regions appeared to be following the 
methylation pattern of their surroundings.  
3.3.2. DNMT3a is the main de novo DNA 
metyltransferase present at the time Oct4 methylation is 
being established 
 Although it is now generally accepted that DNA methylation at the promoter 
of Oct4 appears after downregulation of the gene, there has been some controversy 
regarding the role of DNMT3a and b. Experiments with DNMT3a/b -/- cells have 
been contradictory (Jackson et al. 2004; Feldman et al. 2006; Watanabe et al. 2002). 
In order to explore the importance of the DNA methylatransferases for the 
downregulation of Oct4 in the present system, the efficiency of Oct4  downregulation 
in differentiating DNMT3a/b -/- and DNMT1 -/- ES cells (passage number 20 at the 
beginning of in vitro differentiation) was investigated (Figure 3-9). The 
downregulation of Oct4 in these cells was indistinguishable from the wild-type 
(Figure 3-6), indicating that DNMTs ‒like DNA methylation‒ are dispensable for the 
gene’s silencing.  
 Despite the fact that DNMTs seem to be dispensable for Oct4 
downregulation, de novo methylation does take place in wild-type cells and there is 
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substantial evidence that GCNF and G9a recruit de novo DNA methyltransferases 
albeit indirectly. It is not clear though whether the recruitment involves DNMT3a, 
DNMT3b or both. Watanabe et al. (2002) have shown that the levels of DNMT3a 
and b change during embryonic development. In order to investigate whether the 
DNMT3a and b levels remain constant during the in vitro differentiation program, 
the mRNA level in each stage were measured by RT-qPCR (Figure 3-10). Both the 
DNMT3 enzymes start with similar mRNA levels relative to gapdh in ES cells. 
Nevertheless the level of DNMT3b falls by about 90% and by stage RA4 it is 
significantly lower than DNMT3a. This means that at the time when methylation of 
the Oct4 upstream region takes place, the main DNA methyltranferase present to 
carry out the de novo methylation is DNMT3a.  
  
 
Figure 3-9. RT-qPCR expression analysis of Oct4 in differentiating DNMT3a/b -/- (A) 
and DNMT1 -/- (B) ES cells.  The mRNA levels were normalised against gapdh and are 




Figure 3-10. RT-qPCR analysis of DNMT3a and DNMT3b in differentiating E14 ES cells. 
This is the average of three experiments.The mRNA levels were normalised against gapdh 
and are shown here relative to the DNMT3a level in ES cells. The bars are the standard 
error of the mean for each differentiation point. Stars indicate significantly (p≤0.05) lower 
levels of DNMT3b in comparison to DNMT3a (paired Student’s t-test). 
3.4. Histone modification changes of the Oct4 
distal  enhancer during di f ferentiation 
 Since methylation levels of the distal enhancer were comparable to those of 
the promoter (Figure 3-7), it was further investigated if this similarity extends to the 
histone modification changes. The promoter has been shown to lose H3K4 
methylation and H3 acetylation (Feldman et al. 2006), while H4 acetylation is 
reduced throughout the upstream region during differentiation (McCool et al. 2007). 
Analysis of the DE (Figure 3-11) showed that H3 acetylation was highly enriched 
after differentiation and H4 acetylation appeared depleted. The level of 
trimethylH3K4, which is typical of active chromatin regions ‒like H3 and H4 
acetylation‒ did not show any change between the pluripotent and differentiated cells 
although it has been shown to decrease at the promoter. The same result has been 








































































Figure 3-11. Chromatin immunoprecipitation of histone modifications in the DE 
element of Oct4 before (ES) and after (RA6) differentiation of E14 cells. The 
immunoprecipitated DNA was PCR amplified for 30, 35 and 40 cycles (A). (B) Quantification 
of the PCRs shown in (A) relative to input (i.e. the signal from the ChIPed samples divided 
by the signal of input times ten). 
 
 As for the “repressive” chromatin modifications, trimethylH4K20 was 
observed to increase at the distal enhancer in the silenced gene. This is probably 
related to the decrease in H4 acetylation as the two modifications have been shown 
to be mutually excusive (Sarg et al. 2004) . On the other hand, the polycomb-related 
trimethylH3K27 did not show any changes. The latter does not come as a surprise 
since Aoto et al. (2006) have shown that this modification is enriched only at 
terminally differentiated, not proliferating, in vitro generated neurons and not their 
precursors. Dimethyl H3K9 levels do not seem to change but there is a large 
enrichment in trimethyl H3K9 as observed by Feldman et al. (2006) for the 
promoter.  All in all, in comparison to the histone modification changes studied at the 
promoter, trimethylH3K9 enrichment and acetylH4 depletion seem to be shared with 
the distal enhancer. 
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3.5. The effect of G9a on Oct4  methylat ion. 
 Feldman et al. (2006) have shown that the histone methyltransferase, G9a is 
recruited at the promoter of Oct4 and is responsible for the enrichment of 
trimethylH3K9 after differentiation. TrimethylH3K9 subsequently attracts the de 
novo DNA methyltransferases to the region. The observation that trimethylH3K9 
levels also increase in the DE raises the possibility that G9a is also recruited to the 
DE. The effect that G9a depletion has directly on the methylation patterns in the 
silenced promoter, or any other element in the Oct4 upstream regulatory region, was 
not investigated. For this reason, detailed bisulfite analysis of the Oct4 upstream 
region was also conducted for the G9a -/- 2-3 ES cells. The goal of this analysis was 
to investigate the direct effect of G9a on the establishment of DNA methylation 
throughout the upstream region of Oct4.  
 These cell lines are from a different genetic background (C57BL/6) than the 
E14 ES cells already analysed (129/Ola) and for this reason it was first examined 
whether the genetic background affects the ES cell response to in vitro differentiation 
conditions. 
3.5.1. ES cells of different genetic background follow a 
different differentiation program after induction with RA 
 Wild-type COL4 ES cells (C57BL/6) were induced to differentiate by 
removal of LIF for three days and then addition of RA as described (section 3.2.1). 
The analysis of the differentiation process was performed with various differentiation 
markers as before (section 3.2.2) and is shown in Figure 3-12. Although there are 
many similarities in the expression of the various developmental markers with the 
E14 ES cells (Figure 3-5) there are also some striking differences. The most 
prominent difference is the expression of the mesodermal markers in this cell line 
(Figure 3-12, B), something that was not observed on E14 cells. Although the 
endodermal and ectodermal markers TTR and Msx3 respectively are not expressed in 
this cell line, the other markers of these lineages however show very similar  
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Figure 3-12. Expression of developmental markers during the course of in vitro 
differentiation of COL4 ES cells. + : reverse transcribed RNA,  – : mock-reverse 
transcribed RNA, +ve: positive control. M is the molecular weight marker. (A) Endodermal 
markers. (B) Mesodermal markers. (C) Ectodermal markers. (D) Stem cell marker. (E) 
Loading control. Refer to Figure 3-5 for details. 
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expression patterns to the E14 ES cells. Surprisingly, despite the successful 
upregulation of various differentiation markers, the ES cells marker Rex1 (Figure 
3-12, D) is not downregulated.  
 In summary, the ES cell lines of the two genetic backgrounds show 
differences in the direction they differentiate to in the presence of RA. The 129/Ola 
cell line shows inability to differentiate towards mesodermal lineages, whereas the 
C57BL/6 cells can. Moreover, although both cell lines expressed ectodermal 
markers, the precise markers detected varied between cell lines indicating that 
different ectodermal directions were followed. Finally, the C57BL/6 cells showed 
complete inability to downregulate the ES cell marker Rex 1 in the given 
differentiation time.  
3.5.2. ES cells of different genetic backgrounds show 
differences in the establishment of methylation 
 Having shown that the wild-type ES cells of different genetic background do not 
behave identically under differentiation conditions, the wild-type methylation patterns 
were re-analysed in differentiating COL4 ES cells. The results of these analyses are 
shown in Figure 3-13 (B) and Figure 3-14. There is variation in the establishment of 
methylation in the two different genetic backgrounds; E14 ES cells (Figure 3-7) 
accumulate some methylation in the DE at the end of the differentiation program, 
while COL4 fail to gain any methylation at this region (p=0.05). Methylation levels of 
the two wild-type cell lines at the other regions examined show no difference. 
3.5.3. G9a -/- ES cells fail  to establish distinct 
methylation patterns in the regulatory elements of Oct4 
 Examination of the effect that the absence of G9a has on the establishment of 
methylation at the Oct4 upstream regulatory region revealed that the mechanism is 
indeed impaired throughout the upstream region and not only at the promoter (Figure 
3-13C and Figure 3-14). Initially, in RA4, methylation in G9a -/- ES cells increased, 
and the methylation pattern was indistinguishable to the wild-type cells. The 
establishment of DNA methylation in the Oct4 upstream region appeared to start 




Figure 3-13. Bisulfite analysis of the DE, PE and P of Oct4 during in vitro 
differentiation of COL4 and 2-3 ES cells. (A) Map of the upstream Oct4 region. The 
arrowheads show the positions and direction of the primers used. A, C, F and G refer to the 
segments used for the statistical analysis in Figure 3-14. DE, distal enhancer; PE, proximal 
enhancer; P, promoter; G, gene. (B) Wild-type COL4 ES cells. (C) G9a -/- 2-3 ES cells. Filled 




























































Figure 3-14. Methylation frequency for the DE, PE and P elements of the Oct4 
upstream region in the course of in vitro differentiation of G9a -/- 2-3 ES cells and their 
wild-type controls (COL4). The methylation frequency was calculated for RA4 (A) and RA6 
(B) from the bisulfite data in Figure 3-13. The frequencies were calculated as number of 
methyl-CpGs over the total number of CpGs in each segment. The data were analysed 
pairwise with the Wilcoxon two sample rank test, * p≤0.5 and ** p≤0.1. The error bars show 
the standard error of the mean as calculated for the among clone variation per segment. 
 
however failed to continue as it did in the wild-type COL4 cells. By the end of the 
differentiation protocol, there was a statistically significant difference in the 
methylation level of the PE (segment C) between the G9a -/- and wild-type ES cells. 
Examination of the promoter region (segments F and G), revealed that methylation 
there was also very low. It would appear from this study that initiation of methylation 
is unaffected in the G9a -/- ES cells and the methylation levels at the PE have 
correctly risen by RA4. However, establishment of high methylation levels at the PE 
‒and to a less extent to the DE and P‒ at a later stage is much impaired. This 
difference has been missed in the previous studies. 
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3.5.4. Oct4 mRNA downregulation is not impeded by the 
absence of G9a 
 It has been reported that Oct4 downregulation is not affected in the short term 
by the absence of G9a (Feldman et al. 2006). Examination of whether this is the case 
in this differentiation system confirmed that G9a -/- cells downregulate Oct4 



































































Figure 3-15. Expression analysis of Oct4 in COL4  (A) and 2-3 (B) ES cells using RT-
qPCR. Each plot shows the average of three experiments. The error bars are the standard 
error of the mean for each differentiation point. The Oct4 levels were normalised against 
gapdh and are represented here as fractions of the levels in ES cells. * p≤0.05 and ** p≤0.01 
(Student’s t-test). (A)  Wild-type COL4 ES cells. The asterisks indicate significant difference 
from the equivalent differentiation stage of E14 ES cells (Figure 3-16). (B) G9a -/- 2-3 ES 
cells. The asterisks indicate significant difference from the equivalent differentiation stage of  




interesting that the wild-type COL4 ES cells show inability to completely shut down 
the gene, at least to the levels of the E14 cell line (Figure 3-15, B). This observation 
could explain the previously observed failure to downregulate Rex1 in this cell line 
(Figure 3-12), as Oct4 is this gene’s direct activator (Ben-Shushan et al. 1998) 
3.6. Nanog  levels mirror Oct4  transcript ion 
f luctuations in di fferent cell  l ines 
 The observation that Oct4 downregulation follows different patterns in the 
different cell lines examined (E14, COL4 and 2-3) raises questions about the reason 
for such a variation. The methylation analyses have shown that there are different 
methylation patterns at the three regulatory elements of Oct4 in these cell lines. This 
however, can not explain this difference since in all cases methylation appears 
second. An explanation could come from the effect of some transcription factor. As a 
possible candidate, the expression pattern of Nanog in these cell lines is examined. 
Nanog is successfully downregulated, as expected, in the differentiating E14 and 2-3 
ES cells that can also downregulate Oct4 expression to basal levels (Figure 3-16, A). 
In contrast, COL4 cells that were unable to completely shut down Oct4, fail to 
downregulate Nanog (Figure 3-16, B). This poses the egg and hen paradox: is failure 
to repress Oct4 causing Nanog levels to rise or Nanog is not repressed because Oct4 
is still present? The answer is probably both, and this is a forceful demonstration of 




























































































Figure 3-16. Expression analysis of nanog in COL4 and 2-3 ES cells using RT-qPCR.  
The error bars are the standard error of the mean for each differentiation point. The Oct4 
levels were normalised against gapdh and are represented here as fractions of the levels in 
ES cells. The asterisks indicate significant difference from the mRNA levels in the ES cells of 
the same cell line.* p≤0.05 and ** p≤0.01 (Student’s t-test). (A)  Wild-type E14 ES cells. The 
average of five experiments is shown. (B)  Wild-type COL4 ES cells. The average of three 
experiments is shown and the asterisks indicate significant difference from the E14 ES cells.  
(C) G9a -/- 2-3 ES cells. The average of three experiments is shown and the asterisks 
indicate significant difference from the COL4 ES cells. 
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3.7. Discussion 
 Oct4 is the best studied pluripotency transcription factor with respect to its 
regulation. Intense research in the last years provides evidence for a regulation that 
involves a complex network of activators, suppressors, feedback loops and 
epigenetic changes that act on the promoter and the two enhancers of the gene. 
Although many of these players are known, many mediators of interactions still 
remain to be discovered. More importantly, the orchestration of all the factors at the 
gene’s three regulatory elements in order to stop transcription as a response to the 
differentiation stimulus is still unknown. Finally, most emphasis until now has been 
given to the promoter region and our knowledge about the events that take place on 
the two enhancers is very limited. This study investigated the link between 
transcriptional repression and methylation of the gene’s entire regulatory region. 
Assesment of the in vitro differentiation protocol as a means to downregulate 
Oct4 
 In vivo, Oct4 is silenced in the trophoblast and as the epiblast differentiates 
into the three main cell lineages. Assuming that there is only one mechanism for the 
gene’s downregulation, in vitro differentiation of ES cells into embryoid bodies has 
been used for its study (Sato et al. 2006; Gu et al. 2006; Feldman et al. 2006 and this 
study). In all the previous studies, ES cell differentiation was induced by 
simultaneous removal of LIF and addition of RA. In the present study LIF was first 
removed for three days and then RA was added to the medium for another six days. 
Comparison of the timing of the gene’s expression and methylation between the 
present and previous studies is difficult as there appears to be variation between 
different laboratories; expression of Oct4 is reported to reach its minimum after 
between two and six days of differentiation, while DNA methylation seems to first 
appear after between one and six days. Despite the variability, the results of the 
present study fall within the time ranges described in the previous reports; expression 
of Oct4 reaches its minimum two days after addition of RA, while DNA methylation 
first appears four days after addition of RA. What is more important, in all the 
studies, DNA methylation appears after the gene is downregulated.  
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 It should be noted that in the present study (Figure 3-6) as well as in other 
reports (Sato et al. 2006; Gu et al. 2006), Oct4 expression in the EBs, as assessed by 
RT-PCR, never reaches zero but there is always some residual, very low expression 
of the gene. This could be attributed to the presence of a small, resistant population 
of ES cells that are not differentiated. Such an assumption is supported by the 
residual expression of Rex1 (Figure 3-5, D) and nanog (Figure 3-16, A) too. 
Alternatively to this hypothesis, Oct4 expression in all cells could approach zero 
asymptotically. If this is the case, then Figure 3-6 shows the kinetics of Oct4 
downregulation. The simplest way to test experimentally which of the two 
hypotheses is correct, whould be to stain the EBs of various differentiation stages 
with antibodies against Oct4 and/or some other ES cell marker such as SSEA-1. If 
the first hypothesis of the presence of a residual population of ES cells is correct, 
then an increasing population of cells should be negative for the staining at each 
differentiation stage but Oct4-positive cells should persist. If on the other hand, Oct4 
downregulation happens gradually in all the cells, the intensity of the staining in each 
cell should decrease in each differentiation stage. Similarily, EGFP or luciferase 
expression, driven by the Oct4 regulatory elements in differentiating ES cells could 
be used to monitor the kinetics by which the gene is downregulated. 
Patterns of methylation establishment in Oct4 
 It has recently been reported that the downregulation of Oct4 does not depend 
on DNA methylation although methylation does invariably appear at a later stage 
(Feldman et al. 2006; Gu et al. 2006; Sato et al. 2006). The present results support 
this observation and further show that there seems to be a “DNA methylation wave” 
that does not extend uniformly along the gene’s upstream region, but it rather 
happens preferentially at some elements and not others (Figure 3-17). In more detail, 
methylation is first detected at the proximal enhancer. As differentiation proceeds, 
DNA methylation seems to increase and also spread towards the promoter and the 
distal enhancer.  
 There are two possible explanations for the observed pattern of methylation 
establishment at the Oct4 upstream region; methylation is targeted first to the 
proximal enhancer through specific recruitment of DNMT3s, or the proximal 
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Figure 3-17. Schematic diagram of the methylation establishment pattern at the Oct4 
upstream region. The diagram models the observed methylation levels at each element of 
the Oct4 upstream region with time, after induction of differentiation. DE, distal enhancer; 
PE, proximal enhancer; P, promoter (segment G, Figure 3-7 and Figure 3-13) 
 
factors. A definitive answer to the question of which of the two mechanisms is 
responsible for the observed pattern of methylation establishment would come from 
ChIP mapping of DNMT3s along the Oct4 upstream region. In the absence of such 
data, the current study together with previous footprinting analyses of the regulatory 
elements, favour the passive mechanism of methylation establishment at the 
proximal enhancer. In more detail, no suppressors are known to bind to the proximal 
enhancer and in vivo footprinting has shown that this region is protected in 
undifferentiated EC and ES cells but the occupancy is lost upon treatment with RA 
(Minucci et al. 1996; Okazawa et al. 1991). The promoter on the other hand, is 
resistant to methylation only in part; the portion of the promoter that resists 
methylation is the same that contains recognition elements for the repressor GCNF 
and the activator SF-1 and has been shown to be protected in both undifferentiated 
and differentiated EC cells (Pikarsky et al. 1994). The central CpG of the potential 
Sp1 binding site, in particular, remains virtually free of methylation in this (Figure 
3-7and Figure 3-13) and other studies (Gu et al. 2006). The rest of the promoter, 
where no transcription factors are known to bind, is not protected in footprinting 
assays and it gains significant levels of methylation, comparable to those of the 
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proximal enhancer. The footprinting data, together with the sharp, significant drop of 
DNA methylation levels between these two adjacent regions of the promoter (Figure 
3-8) testify for a mechanism in which protection by transcription factor binding 
impedes DNA methylation establishment. Such a mechanism has been reported 
before for the mouse Aprt gene in which Sp1 binding is protecting the gene’s CpG 
island from methylation (Brandeis et al. 1994; Macleod et al. 1994; Mummaneni et 
al. 1998). In an analogous manner, lack of protection by transcription factor binding 
at the proximal enhancer, would make this element vulnerable to the action of DNA 
methyltransferases that have been recruited at the promoter. These data support the 
hypothesis that methylation at the proximal enhancer and the non-regulatory 
sequences that surround it, is not targeted but rather happens where the opportunity 
arises, as transcription factors are removed and a region becomes exposed. As it will 
be discussed extensively later, DNMT3 recruitment to the promoter could have a 
function that is not mediated by de novo DNA methylation. 
 If this is indeed the case, then the question arises: why is methylation first 
established at the proximal enhancer and not throughout the central part of the Oct4 
upstream region (segments B through E, Figure 3-7)? The distal enhancer, but not the 
proximal enhancer, is involved in Oct4 expression in ES cells (Yeom et al. 1996). 
Like at the promoter region, a significant delay in methylation was also observed in 
the distanl enhancer (Figure 3-7). Moreover, after induction of repression, similar 
changes in the levels of H3K9 methylation and H4 acetylation were observed for the 
distal enhancer (Figure 3-11) as for the promoter (Feldman et al. 2006). Finally, low 
resolution analysis of the histone modifications in ES cells in the 40 Kb region 
surrounding Oct4, gives evidence that H3/4 acetylation, H3K4 methylation and 
H3S10 phosphorylation marks are shared between the promoter and distal enhancer 
but not the promoter and the proximal enhancer (Aoto et al. 2006). These data 
suggest that the same factors are acting on the promoter and distant enhancer ‒but 
not on the proximal enhancer‒ despite the fact that the two elements are separated by 
more than 2Kb. A simple model of enhancer action from a distance is DNA bending 
and formation of a loop that brings the enhancer closer to the gene (Li et al. 2006b). 
In the Oct4 upstream region, this would mean that the distal enhancer and the 
promoter are brought in close proximity, excluding the proximal enhancer from the 
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regulation of the gene’s transcription in ES cells. This in turn would explain why the 
proximal enhancer acquires methylation first, as this element is located midway 
between the promoter and the distal enhancer (approximately 1Kb from each), thus 
has the biggest distance from the regions that are occupied by transcription factors 
and potentially protected from DNA methylation. 
Evidence for DNMT3a specificity on Oct4 
 According to the expression profile of DNMT3a and b during the course of 
differentiation (Figure 3-10), the main de novo DNA methyltransferase present at the 
time of methylation establishment in the upstream region of Oct4 is DNMT3a. This 
suggests that DNMT3a alone could be responsible for the de novo methylation of 
Oct4. More support for this comes from experiments in which HP1β, a known 
partner of DNMT3a, and DNMT3a itself were immunoprecipitated on the Oct4 
promoter (Feldman et al. 2006). Furthermore, co-transfection of GCNF and 
DNMT3a caused methylation of the Oct4 promoter in ES cells (Sato et al. 2006). 
Nevertheless, GCNF co-immunoprecipitates with both DNMT3a and b in vitro (Sato 
et al. 2006) and there are no published negative immunoprecipitation results that 
show clearly that DNMT3b can not be found at Oct4 .The absence of such 
information may be due to the low levels of DNMT3b. The observation that 
DNMT3a operates in a distributive fashion while DNMT3b is processive (Gowher 
and Jeltsch 2002; 2001) agrees with DNMT3a being the main DNA 
methyltransferase acting on Oct4; the processive DNMT3b does not allow 
intermediate, partially-methylated products to populate, while the distributive 
DNMT3a does. It was the latter situation that was observed in Oct4 (Figure 3-7 and 
Figure 3-13). It has also been shown that DNMT3a is very inefficient in methylating 
DNA assembled in nucleosomes and it has much greater activity on naked DNA 
(Takeshima et al. 2006). This, in turn, re-enforces the idea that exposed DNA 
becomes methylated during silencing of Oct4. The specificity of DNMT3a on Oct4 
could be tested more directly by examining this region’s methylation levels in ES 
cells that were differentiated in the absence of either DNMT3a or DNMT3b. If 
DNMT3a is indeed specific for Oct4, then methylation should not be established in 
its absence and not affected by the absence of DNMT3b. 
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Significance of DNA methylation establishment at Oct4 
 It is hard to imagine that, if de novo DNA methyltransferases are recruited to 
the promoter in the course of Oct4 silencing as the experimental evidence suggest, 
the cell would invest energy in such interactions if there were no need for them at the 
locus. Nevertheless, expression analysis of Oct4 in differentiating DNMT3a/b -/- ES 
cells here (Figure 3-9) and elsewhere (Gu et al. 2006) has shown that the gene can be 
successfully silenced even in the absence of DNMT3s. On the other hand Jackson et 
al. (2004) have observed that Oct4 silencing is impeded in these cells. In the latter 
study, the null cells used were of advanced passage number and were severely 
hypomethylated, while in this study, the cells were of relatively low passage number 
and were expected to maintain some level of DNA methylation. It cannot be 
excluded that the difference between the two studies is because of secondary effects 
of the global levels of DNA methylation.Alternatively, the decisive difference 
between these two opposite observations could be the in vitro differentiation protocol 
used. In this study, as well as in the study by Gu et al. (2006), differentiation was 
induced with RA, while Jackson et al. (2004) differentiated with simple LIF removal. 
As seen in Figure 3-3 and Figure 3-4 there is a significant delay on Oct4 
downregulation and methylation when RA is not included in the differentiation 
protocol. This delay is also apparent in the necessary for downregulation timescale in 
the wild-type cells in the work of  Jackson et al. (2004) that lasted several weeks and 
that of Gu et al. (2006) that did not exceed six days. There is no reason to believe 
that there are fundamental differences in the mechanism that silences Oct4 between 
the two differentiation protocols. A slowing down of the silencing cascade is a 
simpler explanation. It is therefore possible that the two opposing results are actually 
part of one whole story; the slow differentiation protocol points to a delay in Oct4 
downregulation in the absence of DNMT3s and the fast RA-induced differentiation 
shows that downregulation of Oct4 is not terminally impeded. In other words 
DNMT3s and DNA methylation could be acting to enhance the suppressive effects 
of other factors on Oct4.  
 In the present study, evidence that shows delayed downregulation of Oct4 
comes from the observations in G9a -/- ES cells. EB3-stage embryoid bodies of these 
cells have significantly higher levels of Oct4 than their wild-type counterparts 
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(Figure 3-15) although the final gene shut-down is not affected. Feldman et al. 
(2006) have suggested that G9a acts on the Oct4 promoter by recruiting DNMT3s in 
order to permanently silence the downregulated gene. However, the present results 
do not support this. G9a -/- ES cells could initiate methylation at the proximal 
enhancer, exactly like the wild type cells, but could not establish the final 
methylation pattern (Figure 3-13). According to the present study, G9a has a role in 
accelerating the gene’s downregulation, probably by stabilising or enhancing the 
DNMT3 interaction with the locus. 
 The conclusions of Feldman et al.  (2006) were drawn from the fact that 
differentiated ES cells lacking DNMT3a and b or G9a can re-revert to the pluripotent 
state ‒as assessed by Oct4 expression‒, whereas their wild-type counterparts can not. 
This experiment however does not control for the possibility that the assay could just 
be selecting for non-differentiated cells that are still expressing Oct4 at the time of 
switching to the LIF-supplemented medium. The present analysis suggests that such 
a resistant population of ES cells that remains undifferentiated under differentiation 
conditions exists, even in wild-type cells (Rex1 expression, Figure 3-5 and Figure 
3-12, residual Oct4 expression, Figure 3-6 and Figure 3-15). According to this 
explanation and in combination with the hypothesis of delayed downregulation stated 
above, DNMT3a/b -/- and G9a -/- ES cells would have delayed Oct4 shutdown. At 
the time of switching medium, more cells would be still expressing Oct4 in 
comparison with the wild-type cells.  When replated under conditions that support 
pluripotency, there would be more cells in the KO cell lines that had not yet silenced 
the gene than in the wild-type cell line and these cells would thrive and give 
colonies. In other words, the cells were never differentiated and always expressed 
Oct4. One way to test this scenario would be to sort the differentiated ES cells 
according to an ES-specific surface antigen, such as SSEA-1, before replating. More 
directly, the number of cells that express Oct4 could be determined in a 
subpopulation of the differentiated cells at the time of switching and this number 
could be later used to normalise the number of Oct4-expressing colonies obtained.  
Reconstruction of the protein-protein interactions during Oct4 repression 
 There are two suppressive mechanisms that are associated with DNMT3s, 
DNA methylation and association with histone deacetylases (HDACs). Interaction 
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with HDACs has been shown to be the only means of regulation of PC12 
differentiation by DNMT3b (Bai et al. 2005). The DNMT3a/b -/- cell line used in 
this and the other experiments is a catalytic knock-out of the DNA 
methylatransferase activity in both enzymes (Okano et al. 1999). Since the 
aminoterminal cysteine-rich (Fuks et al. 2001) and ATRX-like (Bachman et al. 
2001) domains of DNMT3s are interacting with the HDACs independently of the 
catalytic carboxyterminal domain of the protein, there is no reason to assume that the 
HDAC association in this cell line is in anyway affected. It is therefore likely that the 
HDAC interactions of DNMT3s are not impaired in the DNMT3a/b -/- ES cells and 
HDACs can be recruited at the Oct4 promoter through their interaction with 
DNMT3s even in the absence of de novo methylation.  
 Gu et al. (2006) have shown that MBD3 is recruited to Oct4 by GCNF 
regardless of methylation, while MBD2 is also recruited in a methylation-dependent 
manner later. This methylation-dependent interaction with MBD2 could be the key to 
the explanation of a delayed downregulation of Oct4 in the absence of DNMT3s. In 
the same study, Gu et al. (2006)  have shown that MBD3 is the main repressor of 
Oct4. Along this line, Kaji et al. (2007) have shown that MBD3 -/- embryos have 
ectopic expression of Oct4 at the postimplantation stage. MBD2 and 3 are both 
transcriptional repressors. They are both known to associate with the Mi-2/NuRD 
complex and the HDACs in it (Zhang et al. 1999). At Oct4, MBD3 is recruited first 
to the locus, and its accompanying NuRD histone remodelling complex could be 
sufficient for a slow but successful downregulation, while de novo methylation and 
MBD2-related repression could be intensifying the silencing, fine-tuning the initial 
effect.  
 Experiments to test this suggested line of interactions that could lead to Oct4 
repression could include sequential immunoprecipitation of MBD3 or MBD2 and 
components of the NuRD complex in DNMT3a/b -/- differentiating ES cells. If the 
path of interactions proposed here is correct, then MBD3 but not MBD2 should co-
immunoprecipitate with NuRD on the Oct4 promoter. Moreover, if the association of 
MBD3 with the NuRD complex is disrupted, silencing would be impossible. 
Directed mutagenesis of the MBD3 region that is responsible for MBD3 association 
with the NuRD complex would show if this is true.  
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“Accelerated repression” of Oct4 
 The discussion above puts forward a model of an “accelerated repression” for 
Oct4 (Figure 3-18). According to this model, environmental factors prime the gene 
for silencing through recruitment of GCNF that displaces the activator SF-1 or LRH-
1. GCNF in turn, recruits MBD3 in order to silence the gene. MBD3 is recruited in 
the context of the NuRD complex (Zhang et al. 1999) that has histone deacetylase 
activity. This recruitment is enough for the downregulation of the gene but at a slow 
rate imposed by the heterochromatinisation of the locus. HDAC1, which is part of 
the NuRD complex, is also a partner of DNMT3a (Fuks et al. 2001) and could be 
responsible for its recruitment at the locus. The newly established DNA methylation 
of the exposed regions stabilises MBD2 localisation to the locus. This model does 
not make any prediction as to whether MBD2 replaces MBD3 in the NuRD complex 
or the two complexes coexist, at least transiently, at the promoter of the gene. 
Recruitment of the MBD2 suppressor intensifies and accelerates the initial 
repression. HDAC activity on the other hand recruits G9a which methylates the 
deacetylated H3. G9a can interact with DNMT3a, recruiting more methyltransferase 
activity to the region. More methylated DNA allows for stronger MBD2 binding and 
so on. In other words, the downregulation of Oct4 is happening in waves of repressor 
recruitment, each wave enforcing the effects of the previous by either recruiting more 
repressors and/or recruiting more of the same. Whether these factors need to be 
constantly bound to the gene or the chromatin modification changes are enough to 
sustain permanent silencing is not known. This model assumes that RNA polymerase 
II is inhibited by heterochromatinisation and inaccessibility of the locus. 
 There are a few testable predictions of the “accelerated repression” model. 
The role of HDACs in accelerating downregulation through their participation in 
many repressive complexes is central in this model. If the domain of MBD2 that is 
responsible for HDAC interactions is disrupted, then the downregulation should be 
slow. Another line of experiments could be based on the prediction that a similar 
delay in downregulation of the gene should be observed in the absence of either 
DNMT3s, or MBD2. By repeating the differentiation program in MBD2-/- and 
DNMT3a/b -/- ES cells, but with much more time course points, e.g. every 12 hours, 





















































Figure 3-18. Model of accelerated repression of Oct4. (A) In the presence transcription 
factors the gene is active. Once there is a stimulus to initiate repression, these factors are 
replaced by GCNF that is loaded with the repressor MBD3. In the absence of other 
interactions, transcription continues. (B) The repression starts because MBD3 has been 
recruited with the NuRD complex that contains HDACs and chromatin remodelers that make 
the chromatin environment hostile to transcription. This downregulation is slow but enough to 
lead to the complete repression on the gene. (C) The histone deacetylases of the NuRD 
complex can form a complex with DNMT3a, recruiting it to the locus. DNA methylation of 
unprotected regions stabilises MBD2 binding to the locus. MBD2 can also interact with 
histone deacetylases that in turn attract DNMT3a and the cascade escalates causing quick 
downregulation of the gene. Although the model has been depicted with the distal enhancer 
and the promoter forming a loop, this is not important for its validity. Empty circles are CpGs 
and filled circles are methyl-CpGs. Finally, all the protein-protein interactions are considered 
reversible, following the rules of equilibrium dynamics. 
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is indeed the case. It would be interesting to repeat the above experiment in a cell 
line that is deficient of only DNMT3a and see if DNMT3b can substitute for its 
action. Finally, the model predicts that there is a stoichiometric increase in HDACs 
and MBD2 as the gene downregulation proceeds. Carefully controlled chromatin 
immunoprecipitation experiments should be able to test for such an increase. 
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4. Investigation of methylation in 
mouse CpG islands 
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4.1. CpG islands in the mammalian genome 
4.1.1. Discovery and definition of CpG islands 
 In the early eighties it was known that vertebrate genomes have high CpG 
methylation levels and that the mammalian genome is generally depleted of CpG 
dinucleotides, most probably due to the hypermutability of methylcytosines (Bird 
1980; Duncan and Miller 1980). Naveh-Many and Cedar (1982) and Cooper et al. 
(1983) independently showed that despite the overall high methylation, there is a 
fraction in the vertebrate genome that is virtually methylation-free. More detailed 
analysis of some of these methylation-free genomic fragments (Bird et al. 1985) 
demonstrated that they are also GC-rich in comparison to the rest of the genome and 
have increased  observed versus expected frequency of CpGs (o/e). Regions of high 
o/e in the genome had been already recognised as being preferentially found in the 5’ 
regions of genes (McClelland and Ivarie 1982). Bird (1986) finally identified the 5’-
associated CpG-rich regions with the unmethylated “CpG-rich islands”. The first 
formal definition of CpG islands came from Gardiner-Garden and Frommer (1987) 
that defined them as a “200-bp (or longer) stretch of DNA with a GC content of 50% 
and an o/e in excess of 0.6”. 
4.1.2. Distribution of CpG islands in the genome 
 The genomes of mouse and human are reported to contain about 15,500 and 
27,000 CpG islands respectively, distributed on the chromosomes with an average 
density of 5-10 CpG islands/ Mb (Mouse Genome Sequencing Consortium 2002). 
The only exception to this rule is human chromosome 19, which is extremely CpG 
island-rich and has approximately 45 CpG islands/ Mb. The distribution of CpG 
islands on the chromosomes is not uniform  and they appear to colocalise with what 
are known as G bands (Craig and Bickmore 1994). Since the human and mouse 
genomes are estimated to contain around 22,000 genes, it would appear ―at least for 
human― that CpG islands are in excess in comparison to genes. Moreover, it has 
long been known that not all genes are associated with CpG islands. In more detail, it 
is estimated that around 50% of the mouse genes and 56% of the human genes 
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associate with a CpG island (Antequera and Bird 1993). This leaves an estimate of 
34% and 55% of all CpG islands in mouse and human respectively to be intergenic. 
The high number of intergenic CpG islands in humans is enough to explain the 
difference between human and mouse regarding the total number of CpG islands. 
 CpG islands in the 5’ region of human genes are often flanked by Alu 
elements that also have a GC-rich DNA sequence (Kang et al. 2006). By applying 
the CpG island criteria of Gardiner-Garden and Frommer (1987) on human 
chromosomes 21 and 22, Takai and Jones (2002) found that about half of the 
identified CpG islands had recognisable Alu motifs. This proportion was four times 
smaller when more stringent CpG island selection criteria (500 nt, 55% GC and 0.65 
o/e) were applied and the new CpG island criteria were suggested as more accurate. 
 According to data on human chromosomes 21 and 22, 17.4% of the CpG 
islands are located in the 5’ region of a gene (Takai and Jones 2002). CpG islands 
that lie at the 5’ of genes can begin outside of the transcribed region, or within the 
first exon, but most of them extend well into the gene (Gardiner-Garden and 
Frommer 1987). CpG islands in the 5’ are not depleted for TATA boxes and, as 
expected from their sequence composition and they often contain GC-boxes 
(Gardiner-Garden and Frommer 1987).  
 Using the genome sequence of mouse and human, it has been shown that 
CpG islands are preferentially, but not exclusively, present in the promoters of 
housekeeping genes (Yamashita et al. 2005; Saxonov et al. 2006). This has been 
associated with the negative effect that DNA methylation has on transcription and 
the need for housekeeping genes to be constitutively expressed. Robinson et al. 
(2004) explored the possible functions of CpG islands that appear to be present in 
tissue-specific genes. They compared CpG island-associated and non-CpG island-
associated genes with respect to the gene ontology (GO) terms accompanying them 
and their relative abundance in embryonic expressed sequence tag (EST) libraries. 
They made the interesting observation that many of the tissue-specific genes that are 
associated with CpG islands are important during development. Finally, earlier work 
on a limited number of genes with CpG island promoters and various expression 
patterns indicated that the CpG islands of tissue-specific genes tend to be at the lower 
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end of the o/e spectrum for CpG islands (Edwards 1990). The same result was later 
confirmed for genes that have a role in development (Ponger et al. 2001). 
 13% of CpG islands (Takai and Jones 2002) are associated with exons, and a 
remaining small fraction appears to be at the 3’ of genes (Gardiner-Garden and 
Frommer 1987). Because base composition in the exons is important for carrying the 
genetic information, it has been hypothesised that CpG-rich exonic sequences may 
be selected because of their coding potential for arginine (CGN and AG(A/G)). This 
scenario relies on the accepted fact that selection acts against mutations that would 
have deleterious effects on the encoded proteins. In the case of arginine, selection 
would act against mutated CpGs, which in turn would lead to the maintenance of the 
o/e of the region. Gardiner-Garden and Frommer (1987) tested this hypothesis in a 
big variety of exon-associated CpG islands in a variety of vertebrates. They 
calculated the o/e of these regions with and without the arginine codons and they 
found that the high o/e content of them could not be attributed solely to codon usage 
for most of the genes. 
 A more generalised theory trying to explain the presence of CpG islands in 
the gene body is the isochore theory. According to this theory, housekeeping genes 
are embedded in GC-rich regions and this is reflected in the base composition of 
their wobble third codon position that is not under strict selection. Analysis of the 
base composition in the gene body of housekeeping and tissue-specific genes has 
been contradictory (Pesole et al. 1999; Goncalves et al. 2000; Duret and Galtier 
2000; Ponger et al. 2001). Other analyses suggest that the isochore theory might be 
true for human but not mouse (Vinogradov 2003). 
 There is very little research on the 3’ CpG islands. Shabalina et al. (2003) 
have shown that GC-rich 3’ untranslated regions (UTR) tend to be conserved 
between human and mouse and they suggested that the base composition might be 
important for their function during transcription. However, they did not specifically 
examine CpG islands in these positions. In another report, comparative analysis of  
the non-coding regions of homologous mouse and human genes showed high 
conservation at their 3’UTRs  (Jareborg et al. 1999). A CpG island was associated 
with the 3’ UTR of 10% of the mouse and 35% of the human genes. Much more 
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experimentation and analysis is required in order to understand the role of 3’ CpG 
islands. 
4.1.3. Methylation status of CpG islands 
 Because of the history of their discovery, CpG islands are typically thought of 
as devoid of methylation. This assumption was evident in the construction of the first 
comprehensive CpG island library by selecting genomic sequences mainly on the 
basis of them being free of methylation (Cross et al. 1994). Examples such as 
imprinted genes, X-linked CpG islands and aberrantly methylated cancer cells show 
however that there is no evidence that CpG islands are intrinsically 
“unmethylatable”. Indeed, there is a long line of evidence for the presence of 
methylated CpG islands in the mammalian genome.  
Tissue-specific CpG island methylation patterns 
 The first genome-wide approaches for the investigation of CpG island 
methylation were based on a methylation-sensitive restriction digestion protocol, 
namely restriction landmark genome scanning (RLGS). RLGS experiments showed 
that, at least in mouse, there is a dynamic methylation profile characteristic of the 
cell type. Comparison of the methylation profile in a variety of mouse tissues showed 
that approximately 5.6% of the CpG islands show differential, tissue-specific 
methylation patterns (Song et al. 2005). Importantly, although there appeared to be 
an overall methylation signature for each tissue, the methylation status of each of 
these loci could be shared among more than one tissues.  
 The fact that all the different tissues arise from the differentiation of a single 
fertilised oocyte, makes it obvious that these different methylation patterns have to 
be brought about during development. RLGS experiments that were testing this 
programmed CpG island methylation hypothesis showed that, indeed, there is a 
characteristic methylation profile that changes between ES cells, trophoblast cells, 
embryonic germ cells, embryoid bodies, the foetus and somatic tissues (Shiota et al. 
2002; Kremenskoy et al. 2003). Perhaps the most important discovery of these 
analyses is that, although the total number of methylated loci increases with 
differentiation as expected, there is not a general trend for increasing methylation in 
each locus, but the locus  can become methylated or lose methylation to give rise to 
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the tissue-specific methylation pattern.  Finally, it appears that the earlier stages of 
differentiation are the time point in which most of the tissue-specific methylation 
reprogramming events happen. This is supported by the fact that during 
differentiation, the differentially methylated loci were approximately 16%  of the 
total (Shiota et al. 2002) as opposed to only 5.6% when adult tissues were compared 
(Song et al. 2005). Additionally, RLGS comparison of the final stages of brain 
development (Kawai et al. 1993) showed that only 1.7% of the CpG islands were 
differentially methylated in this later developmental stage to give rise to the adult 
brain. 
 Comparison of the methylation status of CpG islands in various healthy 
human tissues has showed that, like in mice, there is a tissue-specific pattern of CpG 
island methylation and some of these differentially methylated CpG islands are 
shared between different tissues (Eckhardt et al. 2006 and R. Illingworth, personal 
communication). Interestingly, in most of the studies, CpG island methylation seems 
to be restricted to those regions that are in the lower spectrum of o/e values, 
something that probably is due to increased mutation rates of methylated CpGs (Fang 
et al. 2006; Bock et al. 2006; Weber et al. 2007). Additionally, Weber et al. (2007) 
have shown that methylation of CpG island promoters correlates well with lack of 
transcription, especially in the CpG islands with the highest o/e values. However, in 
this study, methylation was also detected in active promoters with low o/e. Detailed 
methylation profiling of human chromosomes 6, 20 and 21 has shown that CpG 
islands located at gene promoters are more resistant to methylation (Eckhardt et al. 
2006) ; 12.1% of the CpG islands that were associated with the 5’ of genes were 
methylated,  in contrast to 23.4% of non-5’ associated CpG islands.  
 An interesting case of tissue-specific CpG island methylation in human is that 
of the ψSLC6A8 pseudogene. The 5’ CpG island of the normal SLC6A8 gene in this 
case is free of methylation, but that of the pseudogene is methylated in all the studied 
tissues except from testes (Grunau et al. 2000). This is possibly a mechanism 
employed by the cell to restrict transcription of the non-functional gene that can 
probably respond to the same transcription factors as the normal gene. 
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CpG island methylation patterns in sperm 
 A specific case of tissue-specific CpG island methylation is that of sperm. 
The reason for this separation from the other tissues is the hereditary potential of 
these cells. It has been postulated that sperm (as well as oocytes, which are much 
more difficult to study) should have lower global levels of DNA methylation because 
any spontaneous deleterious mutation of methylcytosines could be transmitted to the 
offspring. Moreover, many consider germ cells as being totipotent (although another 
school of thought supports they are highly differentiated) and their expression 
potential therefore needs to be free of the transcription constraints imposed by 
methylation. Perhaps surprisingly, human sperm appears to have significant CpG 
island methylation, although, in overall, it is lower than that of somatic tissues 
(Weber et al. 2007). As in somatic tissues, the CpG islands in the higher end of o/e 
values have the least representation in the methylated fraction. Importantly, 
germline-specific genes were depleted from the methylated fraction of CpG islands. 
However, the majority of methylation in testes is found in non-CpG island and 
repetitive sequences (Oakes et al. 2007b). 
CpG island methylation and ageing  
 It has been postulated for some time that CpG island methylation increases 
with age, something that has been related to the aberrant methylation phenotype of 
cancer cells (Ting et al. 2006). However, the experimental evidence to support this 
hypothesis is fragmental. Of the recent experimental data, a study on monozygotic 
twins has shown that although the siblings were epigenetically indistinguishable in 
the beginning of their life, they accumulated DNA methylation as they aged (Fraga et 
al. 2005). This study however did not examine specifically CpG islands. Another 
study showed that the CpG islands associated with the CSX and SOX10 human genes 
gain methylation with age (Chu et al. 2007). The authors could explain this tendency 
with a mathematical model in which random methylation errors accumulated during 
repeated mitotic cell divisions. On the opposite side, the study from Eckhardt et al. 
(2006) did not reveal any significant differences in the global DNA methylation 
levels when different age groups were compared. The effect that ageing could have 
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on the methylation landscape of the genome is a very interesting concept with many 
applications in medicine that should be more systematically investigated. 
4.1.4. Dynamic evolution of CpG islands 
 What is causing the existence of CpG islands in vertebrate genomes? The 
answer to this question is not known but speculations can be made. DNA 
methylation is associated with cytosine loss through mutation (Bird 1980; Duncan 
and Miller 1980). This relationship between cytosine methylation and cytosine 
depletion is evident in the genomes of invertebrates that do not have DNA 
methylation and have a high frequency of the CpG dinucleotide, as well as in the 
observation that CpG islands of lower o/e are more often found methylated than 
those of high o/e. According to this, it would be perhaps more appropriate to view 
CpG islands not as regions with increased CpG frequency, but rather as regions in 
the CpG-depleted genome where the CpG frequency approaches the theoretically 
expected. Following this line of thought, the theoretically expected base composition 
of the genome should have been present in an ancestral organism, before the 
appearance of DNA methylation in the genome in its present form. If this is true, 
then the presence of CpG islands could be linked to an ancestral tendency of these 
regions to avoid methylation which is evident until today.  
 By studying the presence of methylation in the different categories of 
eukaryotes (Figure 4-1) one can see that DNA methylation is present in organisms as 
diverse as plants, protists, and chordates. It would appear that being a eukaryote goes 
together with having DNA methylation and its absence from the genome of certain 
eukaryotes is acquired at a later stage, independently. If this is the case, then some 
traces of CpG depletion (which is the biological footprint of CpG methylation) 
should be present today in these organisms. Indeed, the genome of D. melanogaster 
that does not have DNA methylation has an average o/e of approximately 0.7 and not 
1, as it would be expected if there were no bias (Jabbari and Bernardi 2004). 
Interestingly, both the genomes of D. melanogaster as well as that of S. cerevisiae  
show CpG peaks around the promoters of genes which resemble the CpG islands of 
vertebrates (Shimizu et al. 1997). It could be hypothesised that the biological force 







































Figure 4-1. Schematic phylogenetic relationships of various eukaryotes and the 
occurrence of CpG islands. The key to the colour-codes is shown below the figure. A 
mosaic methylation pattern is smaller regions of CpG depleted DNA embedded in a CpG-
rich genome. In these cases, the CpG depleted regions colocalise with dense methylation. 
Representative organisms in each category are shown in parentheses. The list of organisms 
is by no means extensive. There is no information about the CpG distribution in the genome 
of protists. Neurospora has DNA methylation in specific sequences that tend to be CpG-
depleted. (Pollack et al. 1991; Tweedie et al. 1997; Shimizu et al. 1997; Regev et al. 1998; 
Simmen et al. 1999; Varriale and Bernardi 2006a; 2006b and “The tree of life web project”) 
 
organisms diverged from the common ancestor and was frozen as soon as 
methylation vanished from these genomes. 
 What could be the benefit of resisting methylation in an otherwise globally 
methylated genome? As discussed thoroughly in the introduction, DNA methylation 
seems to be refractory to transcription. Perhaps, in order to ensure transcription of 
certain genes, the cell developed a mechanism to prevent methylation in these 
promoters. This is supported by the fact that the majority of housekeeping genes is 
associated with a CpG island in the promoter region (Yamashita et al. 2005; Saxonov 
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et al. 2006), and that a big proportion of CpG islands is located at the 5’ of genes 
(Gardiner-Garden and Frommer 1987; Takai and Jones 2002). Moreover, analysis of 
promoter-associated CpG islands in mouse, human and dog has shown that 
orthologous genes in these organisms tend to maintain their association with CpG 
islands (Jiang et al. 2007). Given all the evidence, transcription regulation could be a 
reason that certain genomic regions remained methylation-free and gave rise to 
today’s CpG islands. 
 The above hypothesis however, does not provide any explanation about the 
presence of CpG islands in non-regulatory and intergenic regions. It has been 
proposed that CpG islands serve as origins of replication (ORIs) (Delgado et al. 
1998; Antequera and Bird 1999). This theory has been put forward in order to 
explain the absence of methylation in CpG islands and is based on observations on 
CpG islands that are associated with 5’ of genes. Gomez and Antequera (1999) have 
shown that in S. pombe replication firing does not depend on transcription and ORIs 
can be found at intergenic regions. There is no reason, to my knowledge, that the 
model of ORI-associated CpG islands can not be expanded to include non-promoter 
CpG islands.   
 As illustrated in Figure 4-1, not all the organisms that have DNA methylation 
have the same pattern of CpG depletion. Organisms like C. intestinalis have mosaic 
methylation of CpG-depleted and methylated “islands” in an otherwise CpG-rich and 
unmethylated genome (Simmen et al. 1999). This raises the possibility that a 
different mechanism is in action for the formation of the CpG pattern in the genomes 
of invertebrates. Based on the observation that DNA methylation and CpG depletion 
is targeted to the gene body in C. intestinalis, it has been suggested that methylation 
in the gene body could be preventing aberrant transcription from cryptic promoters 
(Suzuki et al. 2007). This could be an alternative mechanism that regulated the CpG 
distribution that is characteristic of all the other deuterostomes except from 
mammals, birds, reptiles, amphibians and fish. A. thaliana seems to both have CpG 
islands and show transcription-related gene body methylation (Zilberman et al. 
2007). There is no reason to exclude the possibility that these two putative 
mechanisms of formation of CpG-rich regions acted in parallel for the formation of 
the CpG patterns observed in today’s organisms. 
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4.1.5.  Remaining questions 
 The existence of CpG islands and their methylation characteristics in 
mammals and other organisms pose a series of biologically important questions. First 
of all, what has been the force that led to their formation? Related is the question of 
why some organisms have evolved to harbour DNA methylation and others not? 
What determines whether a CpG island will be methylated and what is the cellular 
mechanism that ensures it will remain methylation-free? What is the role of CpG 
islands that are not located at promoters? Is CpG island methylation determining the 
developmental fate of a cell? 
 The goal of this study was to identify for the first time the CpG island 
methylation patterns in the mouse brain and to investigate to which extent these 
patterns are being established during development. In more detail, the CpG islands in 
the mouse genome were computationally identified and their sequences were used 
for the preparation of a mouse CpG island tilling microarray. Hybridisation to the 
CpG island microarray was then used for the identification of the CpG islands that 
are methylated in brain, which had been isolated using an affinity purification 
technology. Additionally, the same methodology was used for the identification of 
CpG islands that become de novo methylated during in vitro differentiation of ES 
cells and the results were compared to the CpG island methylation in brain. The 
implications of the results on the establishment of the CpG island methylation during 
development in mouse are discussed. 
4.2. Identi f ication of the CpG islands in the 
mouse genome 
 For the purposes of constructing a CpG island microarray for this study, the 
CpG islands of mouse were computationally identified. This was done by using the 
more relaxed 0.6 o/e and 50% GC thresholds as the CpG islands of mouse are less 
CpG-rich than the human ones (Matsuo et al. 1993). To avoid however 
contamination with low complexity sequences, the genome sequence was first 
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masked and the repetitive and low complexity sequences were discarded before 
filtering for CpG islands. Furthermore, to improve the specificity of the screen, the 
minimum length requirement was 500 nucleotides. This method returned sequences 
that a priori do not include repetitive or low complexity elements and have the 
typical characteristics of CpG islands (Figure 4-2).  
 The original purpose for the identification of the CpG islands of mouse had 
been the construction of a microarray that was intended to be used in conjunction 
with affinity purified CpG islands. As it will be explained more thoroughly later 
(section 4.3.3), the fragmentation of the genome for the purification of the CpG 
islands had been performed by means of Mse I restriction digestion. This dictated 
that the algorithm for the identification of the CpG islands was applied on an in silico 
Mse I-digested genome. In order to reassemble possibly fragmented CpG islands, 
neighbouring Mse I fragments that passed the CpG island selection criteria were 
grouped together if they were separated by less than 200 bp and/or they spanned a 
region equal or less than 2,500 nucleotides. After this, the total number of CpG 
islands present on the array was calculated to be 20,755. 
4.2.1. Distribution of CpG islands in the mouse genome 
 24.7% of the CpG islands are intergenic. The distribution of the CpG islands 
on the chromosomes shows a strong positive correlation with their gene content 
(Pearson’s correlation: 0.9, p=1.85 10
-8
, Figure 4-3). The only exception is 
chromosome X that shows fewer CpG islands than expected by its gene content. Of 
the gene-associated CpG islands, 67.34% (50.71% of all the CpG islands) are at the 
5’, 6.3% (4.75% of all the CpG islands) are at the 3’ and 30.88% (23.25% of all the 
CpG islands) are intragenic. A simplified diagram that shows the distribution of CpG 
islands relative to the transcription start site is shown in Figure 4-4. 
 The number of genes that are associated with the CpG islands (in any position 
relatively to the transcription start site) is 62.87% of the total (NCBI build 34). If 
only the 5’ CpG islands are taken into account, then the percentage of genes that are 
associated with a CpG island is 51.72%. This number is very close to the one 




Figure 4-2. Histograms of GC-richness and o/e of the Mse I fragments on the 
microarray. (A) Distribution of the Mse I fragments according to their GC content. The 
vertical red line shows the 0.5 threshold of the CpG island definition. (B) Distribution of the 
Mse I fragments according to their o/e value. The o/e was calculated along 200 nucleotide 
windows. The vertical red line shows the 0.6 threshold of the CpG island definition. 
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Figure 4-3. Scatter plot of the number of CpG islands against the number of genes in 
each chromosome. The regression line is also shown. The Pearson’s correlation and the 
confidence value for the two variables being positively correlated is shown at the top left. 







Figure 4-4. Simplified diagram of the distribution of CpG islands relative to the 
transcription start site. The vertical bars show the frequency of CpG islands in intergenic 
regions, 5’, intragenic regions and 3’ (left to right). A cartoon of the respective regions is 
shown at the bottom. The thin line represents intergenic regions and the box genes. The 
arrow shows the transcription start site, yellow boxes show 5’ and 3’ untranslated regions 
and the pale blue box the translated region (introns and exons).  
 138 
 
 The information on the CpG island distribution in the mouse genome and 
their association with genes is shown in Table 4-1. 
 An interesting observation can be made when the number of CpG islands per 
gene region is calculated. In total, there appear to be on average 1.061 CpG islands 
per gene which are distributed as follows: there are 0.82 CpG islands per 5’, 
approximately one CpG island per intragenic region and 1.3 CpG islands per 3’. The 
overlap of one CpG island with the 5’ of more than one genes was further 
investigated. 10% of all the 5’-associated CpG islands were shared between two 
genes, and in almost all of these cases, the genes were of opposite orientation. Such 










































































 The number of CpG islands in each gene region divided with the total number of gene-
associated CpG islands (5’, Intragenic and 3’). 
2
 The number of CpG island-associated genes in each category (5’, Intragenic and 3’) as a 
fraction of the total number of CpG island-associated genes calculated by substracting the 
intergenic CpG islands from the total. 
3
 The number of CpG island-associated genes in each category (5’, Intragenic and 3’) as a 
fraction of the total number of genes predicted in NCBI Build 34 (i.e. 24741 genes).  
4
 Not applicable. 
5 
This number is smaller than the sum of the rows above because of the cases of CpG 
islands mapping in more than one gene regions. 
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4.2.2. Functional annotation of the genes that are 
associated with CpG islands in mouse 
 The genes that were associated with the CpG islands were compared against 
the NCBI gene library using the PANTHER interface (http://www.pantherdb.org). 
The probability that a specific class of genes is enriched in the library was corrected 
for multiple testing with the Bonferroni algorithm. The gene classes identified as 
being preferentially associated with CpG islands can be seen in Table 4-2 and 
include development, metabolism and protein synthesis, cell cycle, signalling, 
transport, cell structure as well as some genes that are important for neuronal 
activity. The terms “cell cycle”, “metabolism”, “developmental processes”, “protein 
transport”, “protein modification”, “cell communication”, “transport”, “death” 
 
Table 4-2. Gene ontology categories that are significantly enriched in CpG island-
associated genes. 
 GO term 
No. of genes in 
NCBI 




 P value 
Developmental 
processes 
2385 1040 664.79 6.25 10
 -44
 




















131 82 36.51 1.20 10
 -8
 






























Table 4-2. (Continued) 
 GO term 
No. of genes in 
NCBI 




















608 240 169.47 4.45 10
 -6
 
Lipid, fatty acid 
and steroid 
metabolism 















148 71 41.25 2.24 10
 -3
 
DNA metabolism 327 137 91.15 5.80 10
 -4
 


















































1687 645 470.23 3.74 10
 -13
 
Cell cycle control 425 203 118.46 1.05 10
 -10
 
Mitosis 374 152 104.25 8.70 10
 -4
 



















Table 4-2. (Continued) 
 GO term 
No. of genes in 
NCBI 




 P value 
Signal 
transduction 
















































233 105 64.95 5.43 10
 -4
 
Transport 1455 547 405.56 1.26 10
 -10
 



































284 117 79.16 5.50 10
 -3
 
Cell structure and 
motility 
1128 459 314.42 1.14 10
 -13
 


















and “signal transduction” have also been shown to be preferentially associated with 
CpG islands in independent studies in mouse and human (Yamashita et al. 2005; 
Saxonov et al. 2006). 
 The developmental and housekeeping functions of the CpG island-associated 
genes vastly outnumber the rest. An association of CpG islands with housekeeping 
genes was noticed since early, but it is only recently that a role in development has 
started to be recognised. The preferential association of CpG islands with genes 
involved in signalling has not been reported before and is very interesting as this 
function is largely cell-type dependent. Another highly specialised role of genes that 
are associated with CpG islands is a role in neuronal function. Further detailed 
investigation of the genes that consist these functional groups could provide more 
insight into their significance.  
4.3. MBD-affini ty puri f ication (MAP) of 
methylated CpG islands 
 MAP relies on the affinity of the MBD domain for methyl-CpGs and is based 
on the protocol of Cross et al. (1994). Briefly, total genomic DNA is digested with 
Mse I (TTAA) that preferentially cuts outside CpG island sequences. Then, 
methylated CpG islands are purified using an MBD domain affinity purification 
column. The purified DNA is finally hybridised to a microarray that contains 
sequences representing all the CpG islands. The hybridisation signal is interpreted in 
terms of enrichment or depletion of any given CpG island relative to the initial, total 
DNA. 
4.3.1. Murine CpG island microarray 
 At the time this work was carried out there was no commercially available 
microarray, specific for mouse CpG islands. The CpG islands in the mouse genome 
were identified as described in section 4.2 and were flanked by Mse I recognition 
sites (TTAA). The 26,687 Mse I fragments that passed the CpG island criteria were 
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used for the construction of the oligonucleotide microarray. Each fragment was 
represented on the array by an average number of 14.4 50-mer probes that were tiled 
in 48-nucleotide intervals. The total number of probes on the array was 385,215. 
4.3.2. Purification of the MBD protein and packing of 
the column 
 The MBD protein was expressed and purified as described in the Materials 
and Methods. The expected molecular weight of the MBD protein is 10.4 KDa and 
the process of the purification was monitored with SDS-PAGE (Figure 4-5). The 
purified protein was analysed with EMSA to confirm that its methyl-DNA binding 
activity was not compromised (Figure 4-6). Next, the purified, recombinant protein 
was bound to nickel beads and packed into a column. The efficiency of the binding 
to the beads was evaluated with SDS-PAGE (Figure 4-7).  
 
 
Figure 4-5. SDS-PAGE monitoring of the MBD purification process. A representative 
example is shown. Lane 1, 1:10
-5
 v/v of uninduced bacterial culture; Lane 2, 1:10
-5
 v/v of 
bacterial culture induced for recombinant protein expression for 2 hours with IPTG; Lane 3, 
1:10
-5
 v/v of bacterial lysate; Lanes 4 and 5, 1:600 v/v of first and second elution of the 
purified protein. The arrowhead shows the band that corresponds to the MBD protein. 
 
 
4.3.3. Preparation of the DNA 
 Genomic DNA was digested with Mse I (TTAA). This was the chosen 
method for the fragmentation of the genomic DNA since Mse I recognises sequences 
outside CpG islands more frequently and is less likely to destroy them (Cross et al. 






Figure 4-6. EMSA of the purified MBD protein. The methyl-binding activities of two 
independent protein preparations are shown. Increasing amounts of the MBD protein were 
incubated with either the unmethylated or the in vitro methylated CG11 radiolabelled probe in 
the presence of 1µg of the non-specific competitor poly-dAdT. Controls with the CxxC protein 




Figure 4-7. SDS-PAGE evaluation of the binding efficiency of the purified MBD protein 
to Ni-NTA sepharose beads. A representative example is shown. Lane 1, 1:750 v/v of the 
unbound protein; Lanes 2-4, increasing volumes of protein that is bound to the Ni-NTA 
sepharose beads. The arrowhead shows the band that corresponds to the MBD protein. 
 
dephosphorylated. The dephosphorylation was tested for completeness by incubating  
the sample with T4 ligase for one hour and resolving the DNA with agarose 
electrophoresis (Figure 4-8, A).  Next, the adaptors were ligated to the DNA and the 






Figure 4-8. Quality controls during the preparation of the genomic DNA for MAP. 
Representative examples are shown. (A) Assesment of the dephosporylation reaction. 
Genomic DNA, that had been digested with Mse I, was dephosphorylated (CIP) and then 
self-ligated (T4). Positive and negative controls without dephosphorylation and/or ligation are 
included. The self-ligated dephosphorylated sample is indistinguishable from the non-ligated 
one. (B) Evaluation of the adaptor ligation efficiency. Increasing amounts of adaptor-ligated 
template were PCR amplified.  
 
4.3.4. Affinity chromatography 
 The methylated CpG island fraction of the prepared DNA samples was 
affinity-purified with the MBD-column. A representative example is shown in Figure 
4-9. In this example the source of the DNA was of male karyotype, thus the X-linked 
CpG islands ―such as that of the HPRT gene― are present as only one 
unmethylated copy per cell. The only exception is the CpG island of Xist that is 
expected to be methylated in the active X chromosome. Furthermore, the typical 
CpG island of the Ccne gene is unmethylated and the imprinted region of the Igf2r 
gene is present as both methylated (imprinted) and unmethylated DNA. 
The sample was injected into the column and the unbound DNA was washed with 
0.1 M salt (absorbance peak between 0 and 6 ml, Figure 4-9, A). Then, the 
stringency of the elution was gradually increased by increasing the salt concentration 
from 0.1 to a final 1M. The progress of the elution was monitored by PCR with the 
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diagnostic primers for the Ccne, Xist, HPRT and Igf2r CpG islands. PCR 
amplification of the Ccne and HPRT CpG islands showed that the non-specifically 
bound, unmethylated DNA eluted at salt concentrations between 0.25 and 0.8 M with 
a peak at 0.5 M (elution volumes 12, 36 and 24 ml respectively). The 
elution of the specifically bound, methylated Xist CpG island on the other hand 
started at 0.4 M and continued after the final 1 M salt concentration was reached 
(elution volumes 18 and 48 ml respectively). The elution peak for the methylated 
Xist was at 0.8 M (39 ml). Finally the Igf2r differentially methylated CpG island had, 
as expected, two elution peaks; the unmethylated allele peaked at 0.5 M (24 ml) 
together with the other unmethylated CpG islands, while the methylated allele 
peaked at 0.8 M (39 ml) together with Xist. The elution profile of total DNA during 
the run (absorption at 260 nm) was used to evaluate if the peaks observed after PCR 
amplification were specific. As it can be seen at the plot (Figure 4-9, A, top) the 
DNA elution during the run was continuous and the observed peaks did not 
correspond to elution of bulk DNA from the column at the given salt concentrations.  
 During the first separation, the elution spectra of the unmethylated and 
methylated CpG islands overlapped. In order to obtain pure, methylated CpG islands, 
the fractions from the first elution that contained  mainly methylated DNA and only 
the tails of the unmethylated peak (33 to 48 ml in this example) were pooled and 
passed through the column for a second time (Figure 4-9, B). The second elution was 
performed in two steps. The first step consisted of a non-specific elution of the 
contaminating unmethylated CpG islands at low salt concentrations (elution 
volumes12-19 ml and 0.6-0.8 M salt). The second step included a gradual increase 
from the lowest salt concentration that eluted only methylated CpG islands (0.8M) to 
the maximum concentration of 1 M and then a long wash at the highest salt 
concentration. The two steps were separated by a long wash at the highest 
concentration that elutes unmethylated but not the bulk of methylated CpG islands  
(19-33 ml, 0.8 M). As the PCR analysis of the fractions showed (Figure 4-9, B,  
bottom) this second affinity purification separated perfectly the methylated CpG 
islands. These fractions that contained pure, methylated CpG islands were pooled 






Figure 4-9. Illustration of the MAP procedure. (A) First round of affinity purification of 
methylated CpG islands. The elution profile of DNA, as measured by arbitrary absorbance 
(260 nm) units during the run is shown on top. The corresponding salt (NaCl) concentration 
at each point of the purification process is plotted over the elution profile chromatogram. A 
sample from each fraction was PCR amplified and the PCR product is shown below the 
corresponding fraction of the elution profile. The amplified CpG island and the methylation 
status of the two alleles are shown on the right of each PCR . (B) Second round of affinity 
purification of methylated CpG islands. As for (A). 
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4.4. Qual ity control  of brain MAP and pre-
processing of brain data  
  The brains of three mice, either female or male, were pooled together and the 
DNA was prepared as described previously (section 4.1 of this chapter and Materials 
and Methods). The DNA samples were PCR amplified with a primer specific to the 
adaptors and hybridised to the custom-made CpG island oligonucleotide arrays. The 
methyl-CpG island enriched fractions after MAP were hybridised against the input 
DNA of each sample for the elimination of possible bias during the preparation of 
the DNA or during the hybridisation. This process was repeated three times for each 
sex, so in total the DNA from nine female and nine male mice was hybridised on six 
microarrays, three for each sex. 
4.4.1. The microarray data show methylation of CpG 
islands on the inactive X chromosome  
 To verify that the hybridisation worked and that the post-hybridisation, 
normalisation process had not introduced unacceptable biases to the results, the 
signal ratio of enriched versus input DNA of all the “female” arrays was plotted 
against that of the “male” arrays (Figure 4-10). In such comparisons, the higher the 
values in each axis, the higher the enrichment of the particular CpG island relative to 
the input. The two sources of DNA are not expected to have any major differences in 
their methylation patterns except for those of the inactive X chromosome. Indeed, the 
signal ratios generally aligned on the diagonal of the plot, showing equal enrichment 
in both sources. The only difference between female- and male-derived DNA was a 
“spike” towards higher values in the female axis. Further analysis showed that this 
“spike” consisted entirely of probes specific for the X chromosome (Figure 4-10, A). 
It would not be unreasonable to assume that this “spike” correctly showed the 
increased methylation levels in the CpG islands of the inactive X chromosome in 
females. As a control, the signal ratio of the spots that corresponded to chromosome 
16 were plotted (Figure 4-10, B) and they all aligned on the diagonal with the bulk of 
the autosomal CpG islands, as expected.  
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Figure 4-10. Female versus male scatter plots of the microarray data. The logarithm to 
base 2 of the MAP-enriched versus input signal ratio for each probe of the female and male 
samples is plotted on the X- and Y-axis respectively. The probes that correspond to CpG 
islands of the X chromosome are plotted in red (A) and those that correspond to 
chromosome 16 are plotted in green (B). 
 150 
4.4.2. Calculation of the signal threshold for enriched 
Mse I fragments 
 There are technical issues that prevent direct estimation of the absolute 
enrichment levels from normalised microarray data. This means that a normalised 
logarithm of signal ratio (henceforth referred to as the M value) equal to one does not 
necessarily mean two-fold enrichment. A threshold of the normalised microarray 
data that signified enrichment of the particular genomic fragment is therefore needed. 
Second, as described previously (section 4.3.1), every Mse I fragment was 
represented on the array by many, tiled oligonucleotides. As a consequence of that, 
the enrichment of each fragment was described by multiple M values, one for each 
oligonucleotide. In some cases the M values for one Mse I fragment were very 
similar, but in others they were distributed over a larger range of values. Because of 
the preparation method of the DNA however, local intensity peaks within one Mse I 
fragment were not expected even if the local concentration of methylcytosines within 
the fragment varied. This meant that a summarisation method was needed for the 
microarray data of each CpG island, which would reflect its enrichment in the 
sample. 
  Quantitative real-time PCR (qPCR) was employed to find the threshold at 
which an Mse I genomic fragment could be considered as enriched. In more detail, 
twenty-four fragments were chosen from the array so that they represented a variety 
of M values (Figure 4-11). Specific primers were designed for each Mse I fragment 
and qPCR was performed in triplicate on equal amounts of MAP-enriched and input 
DNA for each primer pair. The pooled DNA from six female and three male brains 
was used in each PCR. By using equal amounts of DNA and not relying on the 
overall concentration of DNA in the input and MAP-enriched samples, problems 
associated with DNA recovery efficiency and amplification efficiency were 
minimised.  
 The ratio of the MAP-enriched versus input sample of each Mse I fragment 
tested, as determined by qPCR, showed a very good positive correlation with its 
mean M value from the microarray (Pearson’s correlation 0.77, p=1.86 10-5) (Figure 





Figure 4-11. Distribution of the M values of the 24 Mse I fragments used for the 
calculation of the signal threshold. The M values are the normalised logarithm to base 
two of the signal ratio of the MAP-enriched DNA versus input. The distribution of the M 
values of each Mse I fragment is shown as a boxplot in which the bottom and top of the box 
are the first and third quartiles and the horizontal line inside the box shows the median. The 
whiskers in each plot extend to the most extreme data point which is no more than 1.5 times 
the interquartile range from the box and the outliers of the distribution are shown with dashes 





Figure 4-12. Calculation of the signal threshold for enriched CpG islands.  (A) 
Correlation plot of the relative enrichment of each CpG island as calculated by qPCR and 
microarray hybridisation. The calculated Pearson’s correlation of the data and the confidence 
value (p) is given on the top of the plot. (B) Plots used for the calculation of the threshold. 
The logarithms of the MAP/ Input values as calculated by qPCR were plotted in ascending 
order and the boundary between enriched and non-enriched CpG islands was drawn 
(dashed vertical line). The error bars show the technical variation. Next, the minimum M 
value that excluded all the points on the left of the boundary was found (horizontal red line) 
and was used as the threshold. 
 
were plotted in ascending order and the fragment that showed the lowest positive 
enrichment value was determined (fragment Br4-3, Figure 4-12, B). This fragment 
was then used for the determination of the threshold M value. In more detail, the 
mean M values of the 24 fragments were plotted in the same ascending order as 
determined by qPCR. The fragments that were placed left of fragment Br4-3 were all 
considered as having M values that represent no enrichment and the lowest M value 
that excluded all of them from the sample was determined. According to this analysis 
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the threshold mean M value for the enriched CpG islands was 0.6 (1.5 fold) and it 
excluded all the CpG islands that were not enriched according to the qPCR (false 
positives) and only 2 (14%) of the enriched ones (false negatives). This meant that 
the threshold of M=0.6 was stringent in that it produced a low percentage of false 
negatives but did not allow for false positives. Moreover, when the distribution of the 
mean M values of all the Mse I fragments on the array was plotted (Figure 4-13), 
there were two distinct peaks. The peak at the left consisted of unenriched fragments 
of low M values and the peak at the right of the fragments with higher M values that 
are enriched after MAP. Importantly, a mean M value of 0.6 lays just before the peak 




Figure 4-13. Distribution of the mean M values of all the Mse I fragments on the 
microarray after hybridisation with brain DNA. The x axis shows the mean M value and 
the y axis shows the number of Mse I fragments. The dashed vertical line shows mean M 
value equal to 0.6.  
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 To further validate the use of the M=0.6 threshold, the M value distributions 
together with the mean M value of Mse I fragments of known methylation status 
were plotted (Figure 4-14). The Mse I fragments that consisted the differentially 
methylated regions (DMRs) of Xist and various imprinted CpG islands were used as 
positive controls (Figure 4-14, A). As expected, the range of M values for these  
 
 
Figure 4-14. Application of the M=0.6 threshold on Mse I fragments that contain CpG 
islands of known methylation status. (A) M value distribution of methylated CpG islands. 
The mean M values of all the CpG islands are greater than 0.6. (B) M value distribution of 
unmethylated CpG islands. The mean M values of all the CpG islands are smaller than 0.6. 
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fragments was clearly shifted in comparison to the M values of all the probes on the  
array.  Moreover, in all cases, the mean M value was above the threshold of 0.6. A 
similar analysis was performed for the CpG islands of housekeeping genes (Figure 
4-14, B). These genes are expected to be free of methylation and therefore depleted 
in the sample. The distribution of the M values of the fragments that corresponded to 
these CpG islands was not noticeably different from that of the entire array. 
Importantly, a few of them appeared to have mean and median M values above zero. 
Application of the M=0.6 threshold on their mean M values however, successfully 
removed them from the group of enriched CpG Mse I fragments.   
  Finally, analysis of the CpG island of Ddx4 (Figure 4-15) agreed with the 
previous report that it is densely methylated in brain (Song et al. 2005). During MAP, 
this CpG island was eluting with the methylated fraction of genomic DNA. Moreover, 
in the array data its average M value was 1.64, well above the M=0.6 threshold and 
comparable with those of Xist and Peg10 (2.5 and 1.88 respectively). 
   
 
Figure 4-15. Enrichment of the known methylated CpG island of Ddx4. (A) In the second 
elution during MAP, Ddx4 eluted in the methylated fractions together with Xist and Peg10. 
(B) The distribution and mean M values of Ddx4 are above the 0.6 threshold and comparable 
to those of Xist and Peg10. 
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4.4.3. Methylation analysis of enriched Mse I fragments 
 Before proceeding with global analysis of the methylation status of CpG 
islands in mouse brain it was necessary to verify that the subset of Mse I fragments 
that passed the M=0.6 threshold were indeed significantly methylated. In other 
words, there is no information on how the enrichment of each fragment after MAP 
relative to the input correlates with its degree of methylation. Or, how methylated is 
a genomic fragment that has a mean M value of 0.6 and what, for instance, is the 
difference with a fragment that has a mean M value of 4? 
 To gain an understanding of how the mean M values correlated with the 
degree of methylation, regions of three genes were chosen to be analysed in detail by 
bisulfite genomic sequencing. These regions corresponded to the CpG islands of the 
genes Celsr1, Celsr2 and Celsr3. These genes are all very CpG-rich and are 
represented on the array by many sequences/Mse I fragments, derived from both the 
promoter/first exon, as well as from regions of the gene body (Figure 4-16). As it can  
 
 
Figure 4-16. Diagram of the Celsr regions that are present on the array. In each case 
the gene structure is shown on top with a 5’ to 3’ prime orientation, starting from the first 
exon. Empty boxes represent exons. The vertical lines underneath the gene cartoon 
correspond to the positions of CpGs. The numbered blue boxes at the bottom indicate the 
regions that are present on the array. The left and right ends of each of these boxes signify 
Mse I positions. The filled black boxes at the bottom right represent a length of 1 Kb. 
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be seen in Figure 4-17, according to the microarray data the different regions of these 
genes showed different enrichments. 
 The mean M values of all the fragments of Celsr1, except for the one derived 
from the 5’ end, were above the threshold (Figure 4-17, A). According to this, 
fragments 2, 3, 4, 5 and 6 should all be methylated.  However, it was obvious that the 
intensity of the hybridisation was not equally high for all the methylated fragments. 
The mean M value of fragment 3 for example was twice that of fragment 2. Bisulfite 
genomic sequencing showed that this difference between the two mean M values had 
a biological meaning (Figure 4-18, A). It looks like fragment 2 is largely 
unmethylated and that the densely methylated last few CpGs were responsible for 
carrying it to the enriched fraction during MAP. Fragment 3 on the other hand, gave 
the impression of being more uniformly methylated. It appears that the local high 
concentration of methylcytosines at the 3’ end of fragment 2 was responsible for 
raising the mean M value of the fragment above the threshold. The low overall 
methylation however was reflected in the relatively low mean M value.  It is 
interesting to observe that the transition from unmethylated to methylated happened 
sharply, within the 139 bp (8 CpGs) that separated amplicons 3-1 and 3-2. 
 According to the M=0.6 threshold, all the Mse I fragments that map on the 
Celsr 2 gene were enriched and therefore methylated (Figure 4-17, B). Methylation 
analysis of fragment 5, which had a mean M value equal to 1.88, confirmed that it 
was densely methylated (Figure 4-18B). Fragments 6 and 7 were marginally above 
the M=0.6 threshold (mean M values 0.61 and 0.66 respectively). It was interesting 
to investigate if in these cases the M=0.6 threshold was correct in including these 
fragments in the methylated CpG island pool. Genomic bisulfite sequencing of a 
random region of fragment 6 showed dense methylation, validating the use of the 
M=0.6 threshold (Figure 4-18, B). 
 Finally, none of the fragments that mapped on the Celsr 3 gene passed the 
M=0.6 threshold (Figure 4-17, C). Fragment 2 however was very close to it, with a 
mean M value of 0.54. Bisulfite genomic sequencing showed that it was correct not 
to include this fragment  in the pool of methylated CpG islands as methylation in it 





Figure 4-17. M value distributions of the different Mse I fragments/regions of Celsr 1 
(A), Celsr 2 (B) and Celsr 3 (C). The relative positions of the Mse I fragments/regions in the 
genes are shown in Figure 4-16. The fragment 6 of Celsr 1 and the fragments 1 and 2 of 
Celsr 2 are omitted because their M values were of low confidence (i.e. had high q values).  
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Figure 4-18. Bisulfite genomic sequencing of various CpG island regions. (A) Celsr 1, 
(B) Celsr 2, (C) Celsr 3. Close-up of Figure 4-16. The green boxes show the regions that 
were analysed. Filled circles are methylated CpGs and empty circles unmethylated CpGs. 
 
 In conclusion, bisulfite analysis of several fragments with various M values 
confirmed that the use of the M=0.6 threshold could be applied for the identification 
of methylated CpG islands in this experiment. Fragments with mean M values 
marginally above the threshold were methylated and fragments with mean M values 
slightly below the threshold were not. Dense but local methylation in a fragment is 
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enough to raise the mean M value above the threshold. On the other hand, fragments 
with sporadic, low methylation are not included in the pool of methylated DNA. 
4.5. Global trends of methylated CpG islands in 
mouse brains 
4.5.1. CpG density of methylated CpG islands 
 Similar analyses of human methylated CpG islands have shown that CpG 
islands of medium CpG density are preferentially methylated. In order to examine if 
this is the case in mouse too, all the Mse I fragments that passed the M=0.6 threshold 
were selected and their o/e was calculated. The means, medians and standard 
deviations of the o/e in both the total and the methylated fragments are shown in 
Table 4-3. The actual distribution of the o/e values in the enriched CpG islands in 
comparison to the original distribution of all the fragments is shown in Figure 4-19.   
In order to asses if a certain class of sequences becomes preferentially methylated in 
brain, three statistical tests were performed; the t-test interrogates the difference of  
the means, the Wilcoxon test interrogates the difference of the medians and the 
Kolmogorov-Smirnov (KS) test examines differences in  the shape of the 
distributions. 
 By examining Figure 4-19 one can notice that the distribution of the 
methylated fragments is not symmetrical; there is a sharp rise at low values, a local 
peak at around 0.8 and a slow fading at higher values. The distribution of the entire  
 
Table 4-3. Measures of central tendency of the o/e values in the total and methylated 
Mse I fragments. 
 All Methylated 
Mean 0.775 0.896 
Median 0.929 0.940 




Figure 4-19. Histogram of the o/e of the methylated Mse I fragments. Grey bars are 
used for the histogram of the methylated fragments and white for that of all the fragments. 
The o/e was calculated along 200 nucleotide windows. The vertical red line shows the 0.6 
threshold of the CpG island definition. 
 
set of fragments on the other hand is symmetrical with a peak at around 1. In other 
words, it appears from the distribution plot that the methylated CpG islands tend to 
have lower o/e values than the entire set of CpG islands. Such a conclusion is  
supported by the KS test (p value <2.2 10
-16
). On the other hand, the mean and 
themedian of the o/e values (Table 4-3) show that the methylated CpG islands are 
enriched for high CpG content (p values of t-test and Wilcoxon test <2.2 10
-16
). 
Given these conflicting results, it is difficult to draw conclusions about a general 
tendency of the methylated CpG islands regarding their CpG content. 
4.5.2. Distribution of methylated CpG islands in the 
genome 
 In order to analyse the global distribution of the methylated CpG islands, the 
CpG islands that were located on the X chromosome were excluded from the 
analysis. The reason for this was that the presence of the inactive X chromosome in 
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the sample could interfere with the interpretation of the global patterns of CpG island 
methylation. 
 18.38% of the CpG islands were methylated in brain. This corresponds to 
42.77% of all the CpG island-associated genes. The observed methylation patterns 
according to the genomic location of the CpG island are shown in Table 4-4. It was 
next examined whether there was a tendency for more than one region to become 
methylated together in the same gene, or whether methylation was happening 
independently. Of the 2385 genes that containing CpG islands in both the 5’ and the 
gene body, 11.9% showed methylation in both regions. Of the 215 genes that 
contained CpG islands in both 3’ and the gene body, 10.23% showed methylation in 
both regions. Finally, of the 438 genes that had CpG islands in both the 5’ and 3’ 
regions, 7.53% showed methylation. There were no genes that had CpG islands in all  
 
Table 4-4. Distribution of the autosomal CpG islands that are methylated in brain in 


























































 The percentage of methylated autosomal CpG islands relative to the total autosomal CpG 
islands per location.  
2
 The percentage of methylated autosomal CpG islands per genomic region relative to all the 
methylated autosomal CpG islands. 
3
 The number of genes that are associated with the methylated autosomal CpG islands 
relative to all the genes that are associated with CpG islands in the indicated location.  
4
 Not applicable. 
5 
This number is smaller than the sum of the rows above because of the cases of CpG 
islands mapping in more than one gene locations. 
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three regions. It seems like the different regions of the gene are in principle acquiring 
methylation independently from each other. 
 It was previously shown that 1065 CpG islands (1047 if only the autosomes 
are considered) overlap with the 5’ regions of two genes with opposite orientations in 
the genome (section 4.2). This introduces the interesting possibility  
that the two genes share a common regulatory mechanism and the presence of a CpG 
island in these cases might have a special significance. In order to investigate this 
scenario, the methylation status of these CpG islands was examined. 145 of these 
CpG islands (13.8%) were methylated. When this number is compared to the total 
fraction of 5’CpG islands that become methylated (15.63%, Table 4-4), it seems like 
there is no particular tendency of this category of 5’ CpG islands to be methylated 
more or less often than the rest. 
4.5.3. Gene ontology of the methylated genes 
 In order to identify general methylation trends of the genes that are associated 
with CpG island genes in brain, gene ontology analysis was performed. The genes 
that were associated with methylated CpG islands were compared against all the 
CpG island-associated genes using the PANTHER interface (Thomas et al. 2003; Mi 
et al. 2005, http://www.pantherdb.org) and Bonferroni correction for multiple 
testing. The results of this analysis are shown in Table 4-5.  
 It becomes immediately evident that the genes that play a direct role in 
development and were seen to be preferentially associated with CpG islands, are also 
showing preferential methylation. Moreover, genes that participate in the cadherin 
and Wnt signalling pathways that also have a role in development are also 
preferentially methylated. The Celsr genes, whose methylation pattern was analysed 
in detail in section 4.4.3, belong to the cadherin superfamily. The significance of 
methylation in the CpG islands of genes involved in cell structure and 
communication and the cytoskeleton is not immediately obvious and could involve 
tissue-specific methylation events. 
  The distribution of methylated CpG islands in the different gene regions is 
important for the interpretation of the methylation data. It is generally considered that 
methylation at the 5’end of a gene is related to transcriptional inactivity, something 
that is not as widely accepted for the gene body and 3’ regions. Moreover, it has been 
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Table 4-5. Gene ontology classification of the genes that are associated with 
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suggested that gene body methylation might be specific to housekeeping genes 
(Suzuki et al. 2007). In order to examine the existence of any such trend, the same 
analysis was performed separately for the 5’, 3’ and gene body-associated CpG 
islands. 
 It is expected that methylated CpG islands at the 5’ will associate with genes 
that are not important for brain function. Indeed, as Table 4-6 shows, this is generally 
the case. However, it appears that the categories of genes that are preferentially 
associated with 5’ CpG island methylation are not as diverse as the highly specialised 
brain function would indicate. In particular chemosensory genes and genes that are 
specific for the nasal cavity (olfaction and pheromone response) are the main 
categories of the methyl-CpG island-associated genes. G protein signalling is also 
very important for these functions. Receptors were a class of genes that was 
significantly correlated with CpG islands (Table 4-2). It is possible that the presence 
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Table 4-6. Gene ontology classification of the genes that are associated with 
methylated CpG islands at their 5’. 
GO term 
No. of genes 
with CpGi 
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 M.F., molecular function, 
2 
B.P., biological process 
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of CpG islands in these genes in particular has some special physiological meaning.  
 When the gene ontologies of genes that contain methylated CpG islands in 
their gene body are compared (Table 4-7) with those of the 5’ CpG islands, it was 
surprising to notice that roughly the same functions are associated with methylation 
in both regions. Namely, receptor activity, signal transduction, sensory and 
chemosensory perception and olfaction are all enriched in this class of CpG islands.  
 Finally, despite the high occurrence of methylation in the 3’ CpG islands 





Table 4-7. Gene ontology classification of the genes that are associated with 
methylated CpG islands at their gene body. 
GO term 
No. of genes 
with CpGi 
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4.6. Detection of CpG island methylat ion 
establishment during development 
 In order to investigate further the relationship of CpG island methylation with 
development, the MAP methodology was used for the comparison of the CpG island 
methylation status between ES cells and embryoid bodies, their in vitro differentiated 
derivatives. The embryoid bodies were obtained from wild-type ES cells (E14) by 
LIF removal for three days, followed by addition of retinoic acid for ten days 
(RA10). DNA samples from the ES cells and the embryoid bodies were prepared, 
affinity purified and hybridised on the CpG island microarrays against input DNA as 
described (section 4.3).  The results presented here are the sum of three independent 
differentiation experiments. 
4.6.1. Validation of the microarray data 
 The microarrays were normalised as described in Materials and methods. 
Comparison of the M values (normalised logarithm of the signal ratio between the 
MAP-enriched sample and input DNA) between experiments showed the 
reproducibility was poor (Figure 4-20). This prohibited genome-wide analysis of 
these microarray data in a way similar to that applied in the brain data (section 4.4). 
The low reproducibility most probably indicated the presence of noise at the arrays 
due to low overall methylation levels in these cells in combination with PCR 
amplification as it will be discussed in more detail later. 
 In order to investigate whether the results from the probes that showed the 
least variation would allow extraction of any data from these arrays, the M values of 
Mse I fragments of known methylation status were plotted (Figure 4-21). In more 
detail, the M values of imprinted CpG islands as well as the differentially methylated 
region of Xist were plotted for both the ES and the RA10 samples. The ES cell line 
used in this experiment was of male karyotype and, like imprinted genes, Xist was 
expected to be methylated and show high M value. As it can be seen in Figure 4-21, 
in all cases, the distribution of M values of these genomic regions is shifted in 
comparison to the M values for the bulk of CpG islands present on the array. In 
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conclusion, these control CpG islands are correctly and reliably identified as being 
methylated by the microarray results. 
 
-6         -4         -2          0           2         4          6 -6       -4         -2        0          2         4         6
-6        -4         -2         0          2         4          6 -6       -4        -2         0         2        4         6











































































































































































































































A                                                    D
B                                                   E
C                                                    F
 
Figure 4-20. Scatterplots of the M values between replicates. The three ES arrays (Array 
ESA to ESC) and the three RA10 arrays (Array RA10A to RA10C) are compared. The x and 
y axes show the M values in the respective array. Probes that exhibit similar behaviour in 
both experiments lay near the diagonal. (A to C) Comparison of the microarrays that were 
hybridised with ES cell samples. (D to F) Comparison of the microarrays that were 




Figure 4-21. Distribution of the M values that were acquired for genomic regions that 
are expected to be methylated in ES cells and embryoid bodies (RA10). 
 
 Having confirmed that ‒at least for some of the Mse I fragments‒ the 
microarray data appeared to be trustworthy, the most consistently enriched Mse I 
fragments were identified. In more detail, each Mse I fragment was represented on 
the microarray by multiple oligos. Because the DNA preparation method during 
MAP involves fragmentation by Mse I digestion, the oligos derived from the same 
Mse I fragment should show comparable hybridisation signals. This was used for the 
identification of the Mse I fragments that were reliably enriched in the RA10 
samples. The fragments that had an M value below or equal to 0 at the ES sample 
and above or equal to 2 at the RA10 sample in at least 90% of their associated 
oligonucleotides on the array, were selected as being potentially highly enriched. 
This process identified 24 Mse I fragments as being highly enriched in the embryoid 
bodies but not in ES cells (Table 4-8).  
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Table 4-8. CpG islands that are enriched in the RA10 MAP-purified samples, as 























































































































































0.12 0.93 Zfx Intron 1 9 
1
According to NCBI build 34, 
2
Mean M values in the indicated experiment, 
3
 Associated gene 
and location of the fragment relative to it, 
4
Total number of exons in the associated gene 
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 The enrichment of a random subgroup of these fragments was confirmed with 
qPCR (Figure 4-22). The qPCR was performed on equal volumes of MAP-purified 
DNA from ES cells and RA10. Enrichment in the RA10 samples was confirmed for 
eight of the twelve fragments tested with qPCR. These results, together with the 
previous verification that the MAP-enriched fragments are methylated (sections 4.3 
and 4.4), are a good indication that the majority of the fragments in Table 4-8 are de 
novo methylated during differentiation of ES cells. However, further verification 
with bisulfite sequencing will be needed for the definitive confirmation of the 



















Fragment ID  
Figure 4-22. qPCR verification of the microarray data. The fragment IDs correspond to 
those of Table 4-8. The y axis represents the calculated ratio of the fragment in the affinity-
purified DNA from embryoid bodies (RA10) relative to the affinity-purified DNA from ES cells. 
The red dashed line shows a ratio of 1 (no enrichment). 
 
4.6.2. Methylation pattern of the de novo methylated 
fragments in brain 
 Fragments that appeared to be enriched in the embryoid bodies were further 
investigated in terms of their methylation pattern in brain. Nine out of fifteen 
fragments that appear to become de novo methylated in embryoid bodies were also 




Table 4-9. Annotation of genes associated with Mse I fragments/CpG islands that 



















 Zfa General N Unclassified 
Dev7-1 2.58 Ascl3 Olfactory epithelium Y Transcription 
regulation 
Dev10-1 0.99 4930505D03Rik Distinct/not brain Y Unclassified 
Dev10-3 1.31 Pde7b Olfactory epithelium Y Signal 
transduction 
Dev12-1 0.49 Npas3 General Y Transcription 
regulation 
Dev2-1 1.03 A330102K23Rik General N Apoptosis 
Dev4-1 1.81 Hpcal4 Brain  N Vision 

















Hsdl1 Distinct/ brain N Steroid 
metabolism 
Dev11-1 -0.96 Plekhm1 General Y Unclassified 
Dev11-2 2.14 Kcnh6 Distinct/not brain Y Signal 
transduction 
Dev14-2 -0.89 Ptgdr Dorsal root ganglia Y Signal 
transduction 











Cluap1 Distinct/brain Y Unclassified 
Bold letters indicate that the microarray result has been confirmed by qPCR (Figure 4-22).  
1 
The IDs correspond to the Mse I fragments in Table 4-8. 
2 
Mean M value of the Mse I fragment in the brain microarray experiment. 
3 
Position of the Mse I fragment relative to the associated gene.  
4 
The expression pattern information has been acquired from the SymAtlas database 
(http://symatlas.gnf.org). Tissue-specific expression is indicated by the tissue in which the 
gene is expressed. Broader expression is characterised as “General” if there is no tissue 
preference and “Distinct” if there is a distinct expression pattern in different tissues. If 
expression is “Distinct” the expression status of the gene in the brain is especially 
mentioned. 
5 
Y/N, the expression pattern of the associated gene agrees or disagrees, respectively, with 
the methylation status of the CpG island in the brain. 
6 
The biological process terms were acquired from the PANTHER database 
(http://www.pantherdb.org). 
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 In order to understand better these methylation patterns, the function of the 
genes that are associated with these fragments was explored. The gene ontology 
characterisation of the genes was acquired from the PANTHER database (Thomas et 
al. 2003; Mi et al. 2005, http://www.pantherdb.org). A few of these genes are 
involved in signal transduction and the list also includes transcription factors, genes 
involved in metabolism and apoptosis as well as genes associated with vision and 
skeletal development (Table 4-9). However, there did not appear to be a general 
trend for the genes that are associated with the de novo methylated fragments 
regarding their function.  
 Next, the genes were analysed in terms of their expression pattern in different 
tissues. The expression data were acquired from the SymAtlas expression microarray 
database (Su et al. 2002 , http://symatlas.gnf.org). A gene was considered to be 
expressed in a tissue if its signal was reported to be equal or more than thirty times 
the array median. As it can be seen in Table 4-9, the genes showed a variety of 
expression patterns, from tissue-specific to general expression in all the examined 
tissues. Importantly, the expression of a gene in brain seemed to correlate well with 
absence of methylation in its associated CpG island. This was true for all the genes 
that were associated with CpG islands at their 5’ end. The methylation status of CpG 
islands at the 3’ UTR as well as the gene body was not predicting as well the genes’ 
expression in brain, although it did show some consistency with expression 
(methylation of six out of nine intergenic CpG islands was in accordance to the 
gene’s transcription status). 
4.7. Discussion 
 CpG islands are discrete regions of the genome because of two 
characteristics, their unusual CpG frequency and the fact that most commonly, 
although not always, they are free of methylation. Their high CpG content is 
generally attributed to the absence of methylation, the mechanism however that  
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keeps them free of methylation or the reason that this happens is not known. The 
observation that they are often found in housekeeping promoters seems to provide 
some biological meaning to their existence. The situation however becomes more 
complicated with the acknowledgment that CpG islands are not refractory to 
methylation, they are not confined to promoters and they are also found associated 
with tissue-specific genes.  
 The present study is the first high-throughput detailed analysis of CpG island 
methylation in mouse regardless of the location of the CpG islands in the genome. 
There are two main reasons that such analysis has not been conducted until now. 
Until very recently, the (almost) complete genome sequence of the mouse was not 
available. It is of course impossible to embark on any genome-wide CpG island 
scavenging without the genomic sequence. Additionally, an affinity purification 
technology of methylcytosines has not been available until recently. By taking 
advantage of the recent technical breakthroughs, the characteristics and methylation 
patterns of CpG islands in mouse brain were investigated and CpG islands that are 
potentially becoming methylated during in vitro differentiation of   cells were 
identified. 
Distribution of CpG islands in the genome 
 The number of CpG islands identified in this study is 20,755. This number is 
well below the 27,000 CpG islands estimated in the human genome (Mouse Genome 
Sequencing Consortium) and agrees with previous calculations that predicted CpG 
island depletion in mouse (Antequera and Bird 1993). However, the presently 
calculated number of mouse CpG islands is much higher than the estimate from the 
Mouse Genome Sequencing Consortium (2002), that reported 15,500 CpG islands. 
 The possibility that repetitive sequences could have contaminated the island 
population can be reasonably excluded as the genome had been repeat-masked before 
applying the CpG island algorithm. Moreover Ponger et al. (2001) had shown that 
contamination of the CpG island sequences with repetitive sequences is considerably 
reduced if, like in the present study, a window of 500 nucleotides is used.  
 It is possible that the present number is an overestimation because CpG 
islands were identified after in silico Mse I digestion of the genome. Mouse CpG 
islands are known to be less CpG and GC-rich which raises the possibility that Mse I 
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recognition sites (TTAA) are contained within them. This possibility was appreciated 
and the CpG islands were reassembled according to the distance and the overall 
length of the neighbouring Mse I fragments (section 4.2). It is possible that the 
reassembly had been incomplete. Calculation however of the GC content and the o/e 
ratio of the identified CpG islands provides support that the genomic regions had 
been correctly selected (Figure 4-2). Moreover, the agreement of some of the present 
results with other investigations as well the positive correlation of the CpG island 
content with the gene content in the chromosomes (Figure 4-3) supports the present 
estimation of the mouse CpG island number. Finally, some, partial, explanation to 
the discrepancy in the number of CpG islands could come from the fact that a later 
genome assembly used for the estimation of CpG islands in this study than the one 
that was used for the 15,500 estimate. As GC-regions are more difficult to sequence, 
this study might have included important CpG island genomic regions that were not 
available at the time of the previous calculation.  
 Half of the identified CpG islands are at the 5’ region of genes, most of the 
remaining are equally divided in intragenic and intergenic regions and a small 
proportion lays at the 3’ of genes. Previous analysis of the CpG islands in human 
chromosomes 21 and 22 (Takai and Jones 2002) showed that only17.4% of the CpG 
islands were located in 5’ regions. The most important reason for the difference 
between the two studies appears to be a different approach in determining what 
consists 5’ regions. In the present study known and predicted genes were included in 
the calculations, while Takai and Jones (2002) included only known genes. By doing 
so they identified an excess of 75% of CpG islands that could not be classified 
anywhere relatively to the transcription start site. In this study, the intergenic CpG 
islands were only 24.7% of the total. These numbers make it obvious that the 
inclusion of predicted genes in this study can account for the difference in 5’-
associated CpG islands.  
 The number of genes (predicted and characterised) associated with the CpG 
islands that were identified is approximately 63% of the total (NCBI build 34). As 
predicted if the main functional role of CpG islands was transcriptional regulation, 
the majority of the CpG island-associated genes include them in their promoter 
regions (Table 4-1). This corresponds to approximately 52% of all the mouse genes, 
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which agrees with the number previously calculated (46.9%, Antequera and Bird 
1993). A significant proportion of the CpG island-associated genes contains them in 
the gene body. About half of these genes also have a separate CpG island region 
identified in their 5’. Finally, a very small percentage of genes have a CpG island 
only at their 3’. 
Sequence composition of methylated CpG islands in mouse  
 Previous studies have demonstrated that methylated CpG islands tend to be at 
the lower end of the o/e range (Fang et al. 2006; Bock et al. 2006; Weber et al. 
2007). In the present study, the mean, median and shape of the distribution of the o/e 
values of the methylated CpG islands were compared with those from the entire set 
of CpG islands in order to identify any trends in the sequence composition of the 
methylated CpG islands in mouse. Statistical analysis produced contradictory results 
and no conclusion could be drawn regarding the CpG density of methylated CpG 
islands (section 4.5.1).   
 One explanation to the unclear CpG frequency character of the methylated 
CpG islands could come from the shape of their distribution (Figure 4-19). Due to 
skewing of the distribution, although there appears to be a local peak at lower o/e 
‒and this is supported by the KS test‒ the bulk of the methylated CpG islands lays 
within higher CpG values. The results of the t-test and Wilcoxon test are supportive 
of the latter. It is almost as if there are two forces determining the CpG content of 
methylated CpG islands; one that causes the preferential methylation of CpG islands 
with a specific, lower than the bulk average CpG content and another that supports 
the methylation of a broader range of CpG islands of higher values. 
 As the purification of these CpG islands was based on their interaction with 
the MBD domain of MeCP2, which has been shown to have specificity for a single 
CpG (Klose et al. 2005), it is unlikely that the methodology had introduced bias in 
the selection of methylated CpG-islands. It is not impossible that in the mouse, 
methylation shows less preference for CpG-depleted CpG islands. Previous reports 
have shown that the mouse genome is more CpG-depleted than the human, 
presumably through mutation of methylcytosines (Matsuo et al. 1993). One can 
imagine that the process of mutation of methylated CpG islands may be close to 
equilibrium in this organism, in which the remaining CpG density of the CpG islands 
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is important for their function. If this is true, then it means that the function of CpG 
islands ‒whatever this might be‒ relies on a critical CpG density and could give 
clues for deciphering the role of CpG islands in the genome. Without further analysis 
however, it is impossible to draw any definite conclusions about the CpG density of 
methylated CpG islands in mouse from the present results. 
Patterns of CpG island methylation in mouse brain 
 18.38% of all the identified CpG islands were found methylated in brain. This 
number compares very well to the report by Shiota et al. (2002) that calculated 16% 
of  the CpG islands in mouse as being methylated in somatic tissues in comparison to 
stem and germ cells. Methylated CpG islands showed preference for genes that are 
involved in development, cell structure and communication. The importance of CpG 
island-associated genes in development has been implied before (Robinson et al. 
2004) and the present data confirm this association.  
 Similarly to the results of Eckhardt et al. (2006), 15.63% of  the 5’ CpG 
islands were methylated in mouse brain. This corresponds to methylation of 34.72% 
of the genes with a 5’ CpG island, or around 18% of all the genes in the genome 
(Table 4-4). The possibility that CpG island methylation is a specific transcriptional 
regulatory mechanism was explored further by analyzing the gene functions that 
were preferentially associated with methylated 5’ CpG islands (Table 4-6). The 
genes that were identified to preferentially have a methylated CpG island at their 5’ 
were typical of sensory receptors and are not expected to be important for neuronal 
function. Moreover, the neuron-specific genes that were identified to preferentially 
contain CpG islands (Table 4-2) were not enriched in the methylated CpG island 
fraction. It would be interesting to see if neuron-specific genes acquire methylation 
in non-neuronal tissues. If this is the case then these results are in accordance with a 
transcriptional role of CpG island methylation. 
 Although an important 23.32% of 3’ CpG island-associated genes were 
methylated (Table 4-4), these genes were not enriched for any particular function. It 
is possible that CpG island methylation in these regions has no biological 
significance and only follows the methylation pattern of the rest of the genome. 
Alternatively, these CpG islands could be functionally related with some other gene. 
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Of course there is also a possibility that the role of these CpG islands is not related to 
the function of the gene but is more general. 
 Finally, it should be noted that intergenic CpG islands were methylated with 
almost the same frequency as 5’ CpG islands (Table 4-4). It is possible, although not 
probable, that the robust gene prediction algorithms have missed approximately 
5,000 genes that are present in what is today considered as intergenic regions. A 
more reasonable explanation however, would be that these regions only follow the 
methylation pattern of their surroundings. Spreading of DNA methylation has been 
suggested as a mechanism of methylation establishment in the genome (Turker 2002) 
and is supported by the phenomenon of position effect variegation in mice. Support 
for this assumption however, should come from experimental data. One way to test 
the assumption of DNA methylation spreading in intergenic regions would be to 
target foreign DNA with high CpG-density e.g.  Drosophila genomic DNA, in 
intergenomic regions of mouse that are known to be euchromatic or heterochromatic. 
If the assumption is correct, then the CpG island-like sequence should acquire the 
methylation characteristics of its surroundings. Furthermore, direct methylation 
analysis of the non-CpG island genomic regions that are surrounding the intergenic 
CpG islands should be consistent with the methylation status of the latter, as 
determined in the present study. 
Characterisation of de novo methylated CpG islands in differentiated ES cells 
 When the DNA from ES cells and embryoid bodies that was prepared with 
the MAP methodology, was hybridised to the CpG island microarrays, the results 
showed big variation between experiments. This prevented the genome-wide analysis 
of de novo methylated CpG islands. There are two possible reasons that might have 
caused variation between experiments. First, the ES cells had stayed in culture for 
different lengths of time before differentiation and this could have led to the 
appearance of aberrant methylation. Such a tendency for cells in culture to acquire 
DNA methylation has been described before (Antequera et al. 1990). However, the 
fact that these ES cells are routinely used for the production of transgenic ES cells in 
the laboratory testifies against such an explanation. Moreover, if different 
methylation patterns had been established during culturing of the ES cells, then the 
same patterns would be present in the embryoid bodies derived from them. However, 
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the observed variation between experiments had not improved when the pairs of ES 
cells and their differentiation derivatives were analysed together during 
normalisation of the data.  
 A more likely explanation for the experimental variation is that ES cells and 
embryoid bodies have very little methylation in comparison to adult tissues and the 
detected signal at the microarrays was mainly due to background hybridisation. Such 
a problem had been encountered before when the MAP methodology was applied for 
the purification of methylated CpG islands from sperm (R. Illingworth, personal 
communication). According to the model of methylation establishment during 
development (Shiota et al. 2002; Kremenskoy et al. 2003), ES cells that represent 
very early stages of development ‒as well as sperm‒ should have less methylation 
than adult tissues. If this is the case, then PCR amplification of the MAP-purified 
DNA before microarray hybridisation could be introducing noise to the data, making 
their interpretation difficult. Ways to avoid amplification of noise would be T7 RNA 
polymerase-mediated amplification (Liu et al. 2003) or using sufficient starting 
material so that amplification would not be required prior to labelling. Furthermore, 
verification of the microarray results by qPCR on DNA that has not been previously 
amplified would be a reliable test of whether the fragments are truly enriched after 
MAP. The MAP method itself has been shown to be reliable on purifying methylated 
DNA (Figure 4-10, Figure 4-14, Figure 4-15, Figure 4-18). All these taken together 
make it most probable that the majority of the CpG islands that were selected as 
being preferentially enriched in the embryoid bodies are indeed methylated (Figure 
4-22, Table 4-8). 
A transcription-driven mechanism for the determination of CpG island 
methylation could be acting during development  
 Out of the 5,883 genes in the mouse genome that fall under the umbrella of 
development-related, 2,771 have CpG islands (47.1%) (Table 4-2) and more than a 
quarter of these is methylated in brain (Table 4-5). On the other end, the other big 
class of CpG island-associated genes are genes with a maintenance or housekeeping 
function. According to the present analysis, this category alone makes up 
approximately 80% of all the CpG island-associated genes. As anticipated, these 
genes were not preferentially methylated. The observation that such a high 
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proportion of CpG island-associated genes has housekeeping functions, could be the 
explanation to why CpG islands were discovered through absence of methylation. 
The implication of this is that the CpG island DNA sequence could have no intrinsic 
tendency to be devoid of methylation. Instead, like in almost all examined promoters, 
it is the transcriptional status of the associated gene that determines the presence or 
absence of methylation at it. 
 An active role of transcriptional regulation on the methylation status of CpG 
islands can be seen by comparing housekeeping and developmental genes. These two 
main categories of CpG island-associated genes show opposite behaviours in brain 
regarding methylation; housekeeping genes seem to avoid methylation, while 
developmental genes preferentially acquire it (Table 4-5). This could be explained in 
terms of transcriptional regulation; both these classes of genes are of great 
importance for multicellular organisms, the housekeeping genes for cell survival and 
the developmental genes for organism survival. However, the demand for 
housekeeping genes is constant, while developmental genes become redundant after 
differentiation and body patterning has been completed. This could be determining 
their different fates regarding methylation.  
 Moreover, there was a group of CpG islands that appeared to become de novo 
methylated when pluripotent ES cells were induced to differentiate (Table 4-8). In 
vitro differentiation of ES cells is reported to mimic the events during early 
development and leads to the formation of the main cell lineages of the organism 
(Leahy et al. 1999; Choi et al. 2005 and present study, chapter 3). It can be 
reasonably assumed that these CpG islands are methylated in at least some of the in 
vitro derived cell lineages. Furthermore, identification of the methylation status of 
the same CpG islands in brain (Table 4-9), showed that ‒at least for the 5’-associated 
CpG islands‒ there was a direct correlation of the transcriptional status of the 
associated gene in brain with absence of methylation. These taken together, 
strengthen the relationship of CpG island methylation with absence of transcription 
and provide strong evidence for a developmental program for the establishment 
ofCpG island methylation.  
 The present study showed that CpG island methylation occurs throughout the 
mouse genome with similar frequencies, regardless of the position relative to the 
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transcription start site of a gene (Table 4-4). When the genes that are associated with 
intragenic CpG island methylation in brain were specifically analysed (Table 4-7), 
the gene ontology categories were very similar to the ones of the methylated 5’ CpG 
island genes (receptor activity, signal transduction, sensory and chemosensory 
perception and olfaction). This can not be readily explained by concurrent 
methylation of the 5’ and gene body, as analysis showed that, of all the genes that 
have CpG islands in both these regions, only approximately 10% show methylation 
in both (section 4.5.2). On the other hand, there was a distinct, although not absolute, 
correlation of the methylation status of the intergenic CpG islands in brain with the 
transcription status of their associated gene in the same tissue (Table 4-9). Moreover, 
CpG island methylation was established during in vitro differentiation of ES cells 
regardless of their location in the genome (Table 4-8). These data suggest that CpG 
island methylation in mouse is related with the transcription status of the associated 
genes regardless of their position relative to the associated gene.  
 Given the evidence from the present study, one can imagine a CpG island 
methylation process in which, as the initial totipotent zygote becomes more 
differentiated and the cell lineages committed, CpG island methylation serves as a 
special mechanism to irrevocably silence genes that are not anymore needed in the 
emerging cell lineage. This would lead to the methylation of only a group of the CpG 
islands that are associated with these genes in each tissue. Comparative methylation 
analyses of CpG islands in many adult tissues have shown that, indeed, although 
much of the methylation pattern is shared, there are also differences according to the 
cell type (Shiota et al. 2002; Kremenskoy et al. 2003; R. Illingworth, personal 
communication). Moreover, similar analysis of different regions and developmental 
stages of brain showed only small differences in CpG island methylation (1.7%) 
(Kawai et al. 1993). 
 The proposed scenario could be experimentally tested by examining the 
methylation status of CpG islands in many different adult cell types. These CpG 
islands could be the ones identified in this study as being de novo methylated in 
embryoid bodies (Table 4-8) as well as others that are associated with developmental 
genes. In a process analogous to the phylogenetic analysis of organisms, the most 
closely related cell types should have more similar methylation patterns than the ones 
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that diverged earlier in development. If the hypothesis is correct, then the tree 
produced by comparing the methylation status of CpG islands in the different tissues 
should be able to reproduce the known developmental relationships of the tested cell 
types.  
Conclusions 
 The aim of this study was to provide a detailed account of the methylation 
status of CpG islands in mouse regardless of their position in the genome. In order to 
achieve this, the CpG islands in the mouse genome were identified by applying a 
novel CpG island prediction algorithm. It was found that half of the mouse CpG 
islands sit on the 5’ prime end of genes, approximately 5% on the 3’ prime end and 
approximately 23% are intragenic. The remaining 25% of the CpG islands are not 
associated with genes. The two main classes of the CpG island-associated genes were 
housekeeping and developmental, while two other interesting gene categories that 
were over-repressented in the CpG island-associated genes were olfactory and 
neuronal. Next, the methylated CpG islands from brain genomic DNA were purified 
by an affinity method and characterised. A total of 18.38% of the CpG islands were 
found to be methylated in brain the majority of which were located on 5’ prime and 
intragenic regions. Developmental and olfactory genes were over-represented in the 
group of methylated CpG island-associated genes. Application of the same 
methodology showed that there is de novo methylation of CpG islands during in vitro 
differentiation of ES cells. Unfortunatelly, experimental limitations prohibited the 
global identification of the CpG islands that become methylated after the in vitro 
differentiation of ES cells. The experiment however provided a list of CpG islands 
that become methylated and it was shown that transcriptional inertia is most probably 
associated with them. Finally, all the data taken together, point to a developmental 





 The aim of this study has been to investigate how DNA methylation patterns 
are established during mouse development. Oct4 has been used as a specific example 
of a developmentally regulated gene that becomes de novo methylated as it is 
transcriptionally repressed. The experiments described in the previous pages 
confirmed the previous finding that DNA methylation is dispensable and comes after 
the gene’s initial downregulation. It has been further demonstrated that establishment 
of DNA methylation at the upstream region of Oct4 starts at the proximal enhancer, 
which is dispensable for the gene’s expression in ES cells (Yeom et al. 1996; Gu et 
al. 2005a), and is not targeted at the promoter as previously thought (Gidekel and 
Bergman 2002; Gu et al. 2006; Feldman et al. 2006). DNA methylation then spreads 
outwards, towards the distal enhancer and the promoter. Importantly, it has been 
shown that G9a does not function to recruit DNA methylation at the promoter of 
Oct4, as previously assumed (Feldman et al. 2006), but has a role in methylation 
spreading.  
 Perhaps the most important question that arises from these findings is 
whether the establishment of the DNA methylation pattern is active or passive. One 
experiment to test this would be to delete the proximal enhancer, from which DNA 
methylation is initiated. There are two main possible outcomes from such an 
experiment where the proximal enhancer of Oct4 is deleted; methylation can be 
completely abolished from the upstream region of Oct4, or methylation will be 
established as normal, initiating from the new “middle region” between promoter and 
enhancer. The first case would be an indication that DNA methylation is targeted to 
the proximal enhancer, while the second would provide evidence of a more passive 
way for methylation establishment. Chromatin immunoprecipitation of the DNMT3s 
in the entire wild-type upstream region would strengthen the results; high abundance 
of DNMT3s at the proximal enhancer would be supporting the active methylation 
model, while more diffuse localisation would provide support for a passive 
methylation establishment. 
 In any case, elucidating the mechanism by which the DNA methylation 
pattern is established in the upstream region of Oct4 consists an important finding. 
The only other case were the way that the DNA methylation pattern is established is 
known, is that of Aprt (Macleod et al. 1994; Mummaneni et al. 1998). At this gene, 
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transcription factor binding prevents methylation of the bound upstream region, 
presumably through steric hindrance of the DNMT3s. It is important that through 
Oct4 and other systems of inducible DNA methylation we obtain more information 
on the molecular cascade that leads to the specific methylation patterns we observe in 
the genome. In this way we would perhaps be able to put forward a more generalised 
model of DNA methylation establishment, understand better the function of DNA 
methylation in the mammalian genome and, eventually, understand better the ay that 
the cell works. 
 Moreover, given evidence from this and other studies, a model was proposed 
to explain the observed de novo methylation pattern as well as the dispensability of 
DNA methylation for this gene’s silencing. According to this model, DNA 
methylation acts as an anchor for transcription repressors that may be recruited 
through other mechanisms. Stabilisation of the orchestrated recruitment of repressors 
and chromatin remodelling complexes to the promoter leads to timely and efficient 
silencing. This model can explain why establishment of methylation at this gene 
would be important in vivo, during the coordinated differentiation of a multicellular 
organism, but dispensable for its transcriptional repression in cultured cells. 
However, as discussed in Chapter 3, this model needs to be experimentally tested in 
more detail. 
 For the investigation of genome-wide methylation patterns in mouse CpG 
islands, the CpG islands in the mouse genome were first identified by using a novel 
prediction algorithm. The results showed that half of the CpG islands are situated at 
the 5’ end of genes, while the rest are almost equally divided between intergenic and 
intragenic regions. Only a very small proportion of CpG islands lies at the 3’ of 
genes. Previous studies have indicated an association of CpG islands with 
housekeeping (Yamashita et al. 2005; Saxonov et al. 2006) and developmental genes 
(Robinson et al. 2004). Gene ontology analysis of the genes that are associated with 
the identified CpG islands in this study agreed with the previous reports, and also 
identified genes that are important for neuronal activity as being preferentially 
associated with CpG islands.  
 For the detection of methylated CpG islands, an affinity purification method 
was applied in conjunction with microarray hybridisation. Various control 
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experiments throughout the purification and hybridisation process have verified that 
this method is reliable in identifying methylated CpG islands. According to this 
analysis, approximately 43% of all the CpG island-associated genes are methylated 
in mouse brain. The bulk of these genes has developmental or tissue-specific 
functions. This is in accordance with a role of CpG island methylation in 
transcription, as well as the existence of a developmental program for CpG island 
methylation establishment.  
 The possibility that the CpG island methylation patterns are established 
during development was futher investigated by applying the same methodology on in 
vitro differentiated embryonic stem cells. Unfortunately, this approach failed to give 
information about the genome-wide pattern of CpG island methylation 
establishment. This was probably because the methylation levels achieved in the 
given time scale were very low and amplification of the material resulted in an 
increase of the noise-to-signal ratio. However, candidates for de novo methylated 
CpG islands were identified. When the methylation status of these CpG islands and 
the expression of their associated genes in brain was analysed, there was a very good 
correlation of the presence of methylation with transcriptional repression. Having 
established an in vitro model of early development where these CpG islands become 
de novo methylated, it will be very interesting to see whether and how methylation in 
these regions correlates temporally with transcription repression. If the mechanism of 
DNA methylation establishment in Oct4 is widespread and acts on CpG islands, then 
it would be expected that methylation in these cases will follow the gene’s 
repression. Moreover, this system provides a significant number of candidates for the 
study of the induced methylation of CpG islands. As outlined above, elucidation of 
the mechanism that leads to DNA methylation and the molecular events that 
surround it can provide invaluable knowledge on the function of the mammalian 
genome.   
 According to the detected methylation pattern of CpG islands in brain, almost 
equal proportions of the intergenic and 5’-associated CpG islands were found to be 
methylated. Taking into account the discovery that, in the case of Oct4, an element 
that lies more that 1 Kb upstream from the transcriptional start site ‒and not the 
immediate 5’ region of the gene‒ preferentially becomes methylated, it is possible 
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that the intergenic methylated CpG islands have a role in the regulation of a gene 
from a distance. The possibility however, that these intergenic CpG islands only 
follow the methylation pattern of their surroundings cannot be excluded. 
 The evidence for a developmental program of DNA methylation 
establishment has accumulated in the recent years. The possibility that CpG islands 
and non-CpG island sequences acquire methylation through a similar mechanism can 
not be excluded. Moreover, it becomes clear that although DNA methylation is 
associated with transcriptional inertia, it does not appear to be indispensable for gene 
repression. Perhaps this is why certain organisms have managed to eliminated it from 
their genome. Further studies on specific examples of DNA methylation 
establishment, as well as genome-wide analyses of DNA methylation in different 
tissues and developmental stages, coupled with expression analysis of the associated 
genes, will shed more light on the impact that DNA methylation has in mammals.  
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Electronic resources 
BiQ Analyser    http://biq-analyzer.bioinf.mpi-sb.mpg.de/ 
Bioconductor    http://biq-analyzer.bioinf.mpi-sb.mpg.de/ 
PANTHER, classification system http://www.pantherdb.org/ 
Tree of life web project  http://www.tolweb.org/tree/  
Symatlas    http://symatlas.gnf.org/SymAtlas/ 
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